Pyrrolidinyl and pyrrolinyl ethylamine compounds as kappa agonists

ABSTRACT

A compound of the following formula:  
                 
 
     and the salts thereof wherein A is hydrogen, halo, hydroxy, or the like; the broken line represents an optional double bond with proviso that if the broken line is a double bond, then A is absent; Ar 1  is optionally substituted phenyl or the like; Ar 2  is aryl or heteroaryl selected from phenyl, napththyl, pyridyl, and the like, the aryl or heteroaryl being optionally substituted; R 1  is hydrogen, hydroxy, C 1 -C 4  alkyl, or the like; and R 2  and R 3  are independently selected from optionally substituted C 1 -C 7  alkyl, C 3 -C 6  cycloalkyl, C 2 -C 6  alkenyl, C 2 -C 6  alkynyl, and the like or R 2  and R 3 , together with the nitrogen atom to which they are attached, form an optionally substituted pyrrolidine, piperidine or morpholine ring. These compounds are useful as kappa agonists.

TECHNICAL FIELD

[0001] This invention relates to novel pyrrolidinyl and pyrrolinylethylamine compounds and their pharmaceutically acceptable salts, and topharmaceutical compositions containing them. The pharmaceutically activecompounds of this invention can be used as a selective kappa-receptoragonist.

BACKGROUND ART

[0002] Opioid analgesics such as morphine are therapeutically useful,but their usage is strictly limited because of their side effects suchas drug dependency and abuse. Thus, analgesics with high usefulness andreduced tendency to cause drug dependency are desired. Considerablepharmacological and biochemical studies have been carried out todiscover the opioid peptides and opioid receptors, and the discovery ofthe subtype of opioid receptor such as mu (μ), delta (δ), kappa (κ) in avariety of species, including human, has made a beginning towardscreating new analgesics. As it is thought that opioid analgesics such asmorphine act as a mu-receptor agonist, separating the action based on akappa-receptor agonist from the action based on mu-receptor agonist hasbeen investigated. Recently kappa-selective agonists (kappa-agonists)have been reported from the above viewpoint for example, EMD-61753: ABarber et al., Br. J Pharmacol., Vol. 113, pp. 1317-1327, 1994. Some ofthem actually have been studied in clinical trials (Med Res. Rev., Vol.12, p. 525, 1992).

[0003] European Patent No. EP 0254545 B1 discloses a variety ofethylenediamine compounds. European Patent No. EP 0483580 A2 discloses avariety of pyrrolidine compounds as analgesics. InternationalPublication WO 96/30339 discloses a wide variety of pyrrolidinylhydroxamic acid compounds as selective kappa-receptor agonists.

BRIEF DISCLOSURE OF THE INVENTION

[0004] The present invention provides a compound of the followingformula:

[0005] and the salts thereof, wherein

[0006] A is hydrogen, halo, hydroxy, C₁-C₆ (preferably C₁-C₄) alkyl,halo C₁-C₆ (preferably C₁-C₄) alkyl, C₁-C₆ (preferably C₁-C₄) alkoxy,halo C₁-C₆ (preferably C₁-C₄) alkoxy, oxo, OY wherein Y is a hydroxyprotecting group, or absent;

[0007] the broken line represents an optional double bond with provisothat if the broken line is a double bond, then A is absent;

[0008] Ar¹ is phenyl optionally substituted by one or more (preferablyone to two) substituents selected from halo, hydroxy, C₁-C₄ alkyl, C₁-C₄alkoxy, C₁-C₄ alkoxy-C₁-C₄ alkoxy, CF₃, carboxy-C₁-C₄ alkoxy and C₁-C₄alkoxy-carbonyl-C₁-C₄ alkoxy;

[0009] Ar² is aryl or heteroaryl selected from phenyl, naphthyl,pyridyl, thienyl, furyl pyrrolyl and pyrimidyl, the aryl or heteroarylbeing optionally substituted by one or more (preferably one to two)substituents selected from halo, hydroxy, amino, nitro, carboxy, C₁-C₄alkyl, C₁-C₄ alkoxy, C₁-C₄ alkylamino, di C₁-C₄ alkylamino, halo C₁-C₄alkyl, C₁-C₄ alkylthio and sulfonyl methyl;

[0010] R¹ is hydrogen, hydroxy, C₁-C₄ alkyl, C₁-C₄ alkoxy or OY whereinY is a hydroxy protecting group; and

[0011] R² and R³ are independently selected from hydrogen, hydroxy,C₁-C₇ alkyl optionally substituted by one or more (preferably one tofive) hydroxy or halo, C₃-C₆ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl,C₁-C₇ (preferably C₁-C₅) alkoxy, phenyl optionally substituted by halo(preferably substituted by one or two halogen atoms), phenyl C₁-C₇(preferably C₁-C₅) alkyl, halo substituted phenyl C₁-C₇ alkyl, and(CH₂)nX—R⁴ wherein n is one or two, X is O, NH or S and R⁴ is C₁-C₃alkyl, or when Ar² is phenyl, —Ar²—C(═O)—N(R²)— is a phthalimide groupand R³ is C₁-C₇ alkyl, or

[0012] R² and R³, together with the nitrogen atom to which they areattached, form a pyrrolidine, piperidine or morpholine ring, optionallysubstituted by C₁-C₃ alkyl or halo.

[0013] When Ar² is phenyl, R² ³N—C(═O)— is preferably at the meta orpara position on the phenyl ring with respect to2-A-pyrrolydinyl)-1-Ar¹-ethyl-N(R¹)—. When oxo is selected as “A” group,it is apparent that the oxygen atom should be attached to thepyrrolidinyl group through a double bond.

[0014] The pyrrolidinyl and pyrrolynyl ethylamine compounds of thepresent invention of formula (I) exhibit good kappa-receptor agonistactivity, and thus are useful as an analgesic, anesthetic,anti-inflammatory or neuroprotective agent, and also useful in thetreatment of arthritis, stroke or functional bowel disease such asabdominal pain, for the treatment of a mammalian subject, especially ahuman subject. Specifically, these compounds are useful as an analgesicfor acute and chronic pain. Especially, these compounds are useful as ananalgesic at central nervous system in the mammalian subject. Also,these compounds are useful as an analgesic for peripheral mediatedinflammatory pain caused, for example by burns (induced by a contactwith heat, acid or the other agents), scald (induced by a contact by hotliquid or steam), rheumatism or the like, in the said subject.

[0015] Accordingly, the present invention provides a pharmaceuticalcomposition, which is useful as an analgesic, anesthetic,anti-inflammatory or neuroprotective agent, and also useful in thetreatment of the above-mentioned diseases, which comprises atherapeutically effective amount of the compound of the formula (I), anda pharmaceutically inert carrier.

[0016] The present invention also provides a method for the treatment ofa medical condition for which agonist activity toward opioidkappa-receptor is needed, in a mammalian subject, which comprisesadministering to said subject a therapeutically effective amount of thecompound of the formula (I).

DETAILED DISCLOSURE OF THE INVENTION

[0017] In this specification, the team “hydroxy protecting group” meansa functional group to protect a hydroxy group against undesirablereactions during synthetic procedures, including, but not limited tobenzyl, benzoyl, methoxymethyl, tetrahydropyranyl and trialkylsilyl.

[0018] The term “C₁-C₆ alkyl” is used herein means a straight orbranched alkyl including but not limited to methyl, ethyl, n-propyl,iso-propyl, n-butyl, sec-butyl, tert-butyl and the like.

[0019] The term “C₁-C₆ alkoxy” is used herein to mean a straight orbranched —OR (R is C₁-C₆ alkyl) including, but not limited to, methoxy,ethoxy, propoxy, isopropoxy, n-butoxy, iso-butoxy, tert-butoxy and thelike.

[0020] The term “halo” means F, Cl, Br or I, preferably F or Cl.

[0021] The term “halo C₁-C₆ alkyl” means a straight or branched,halo-substituted alkyl of 1 to 6 carbon atoms including, but not limitedto methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl andtert-butyl, substituted by 1 to 13 (preferably one to five) halogenatoms.

[0022] The term “halo C₁-C₆ alkoxy” means C₁-C₆ alkoxy substituted by 1to 13 (preferably one to three) halogen atoms.

[0023] The term “halo substituted phenyl C₁-C₇ alkyl” means C₁-C₇ alkylhaving a phenyl group attached to its terminal carbon atom, the phenylgroup being substituted by one to five (preferably one to two) halogenatoms.

[0024] A preferred group of compounds of this invention includes thecompounds of the formula (I) wherein

[0025] A is hydrogen, halo, hydroxy, oxo or OY, or if the broken line isa double bond then A is absent;

[0026] Ar¹ is phenyl optionally substituted by one to three substituentsselected from halo, hydroxy, C₁-C₄ alkoxy, carboxy C₁-C₄ alkoxy andC₁-C₄ alkoxy-carbonyl-C₁-C₄ alkoxy;

[0027] Ar² is phenyl, pyridyl or thienyl, optionally substituted by oneto two halo or C₁-C₄ alkoxy,

[0028] R¹ is hydrogen, hydroxy or C₁-C₄ alkyl; and.

[0029] R² and R³ are independently selected from hydrogen, C₁-C₇ alkyloptionally substitute by one or more hydroxy or halo, C₃-C₆ (preferablyC₃-C₄) cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ (preferably C₂-C₃) alkynyl,C₁-C₄ alkoxy phenyl and halo substituted phenyl C₁-C₇ alkyl, when Ar² is—Ar²—C(═O)—N(R²)— is a phthalimide group and R³ is C₁-C₇ alkyl, or

[0030] R² and R³, together with the nitrogen atom to which they areattached, form a pyrrolidine or morpholine ring.

[0031] A more preferred group of this invention includes the compoundsof the formula (I) wherein

[0032] A is hydrogen, fluorine, chlorine, hydroxy or OY wherein Y ismethoxymethyl or tetrahydropyranyl; or is the broken fine is a doublebond this A is absent or;

[0033] Ar¹ is phenyl optionally substituted by chlorine, hydroxy,methoxy or carboxymethoxy;

[0034] Ar² is phenyl, pyridyl or thienyl, optionally substituted bychlorine, fluorine or methoxy;

[0035] R¹ is C₁-C₄ alkyl;

[0036] R² is C₁-C₇ (preferably C₁-C₁) alkyl optionally substituted byhydroxy or fluorine, C₂-C₆ (preferably C₂-C₃) alkenyl, halo substitutedphenylmethyl or phenyl; and

[0037] R³ is hydrogen or methyl; or

[0038] R² and R³, together with the nitrogen atom to which they areattached, form a pyrrolidine or morpholine ring.

[0039] A more preferred group of this invention includes the compoundsof the formula (I) wherein

[0040] A is hydroxy, fluorine or chlorine; or if the broken line is adouble bond, then A is absent; Ar¹ is phenyl optionally substituted bycarboxymethoxy; Ar² is phenyl optionally substituted by methoxy orpyridyl; R¹ is C₁-C₄ alkyl; R² is C₁-C₇ alkyl optionally substitute byhydroxy; and R³ is hydrogen.

[0041] Preferred individual compounds are:

[0042]4-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-propylbenzamide;

[0043]4-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-2-methoxy-N′-propylbenzamide;

[0044]6-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-propylnicotinamide;

[0045]4-{N-[1-(S)-(3-carboxymethoxyphenyl)-2-(3-(S)-hydroxypyrrolidin-1-yl)-ethyl]-N-methylamino}-N′-propylbenzamide;

[0046]4-{N-[2-(3-(S)-fluoropyrrolidin-1-yl)1-(S)-phenylethyl]-N-methylamino}-N′-propylbenzamide;

[0047]4-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-(2-(S)-hydroxypropyl)benzamide;

[0048]5-{N-[2-(3-(S)-fluoropyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-propylpicolinamide;

[0049]4-{N-methylamino-N-[2-(3-pyrrolin-1-yl)-1-(S)-phenylethyl]}-N′-propylbenzamide;and

[0050]4-{N-[2-(3-(S)-chloropyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-(2-(S)-hydroxypropyl)benzamide.

[0051] Other preferred individual compounds are:

[0052]4-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-isopropylbenzamide;

[0053]3-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-propylbenzamide;

[0054]2-chloro-4-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-propylbenzamide;

[0055]4-{N-[2-(3(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-3-methoxy-N′-propylbenzamide;

[0056]3-chloro-4-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-propylbenzamide;

[0057]4-{N-[1-(S)-(3-hydroxyphenyl)-2-(3-(S)-hydroxypyrrolidin-1-yl)-ethyl]-N-methylamino}-N′-propylbenzamide;

[0058]4-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-(3-methyl)-ethyl]-N-methylamino}-N′-propylbenzamide;

[0059]4-{N-[1-(S)-phenyl-2-(pyrrolidin-1-yl)ethyl]-N-methylamino}-N′-propylbenzamide;

[0060]4-{N-[1-(S)(3-chlorophenyl)-2-(3-(S)-hydroxypyrrolidin-1-yl)-ethyl]-N-methylamino}-N′-propylbenzamide;

[0061]4-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(R)-phenylethyl]-N-methylamino}-N′-propylbenzamide;

[0062]4-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-pyrrolidinebenzamide;

[0063]4-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]N-methylamino}-morpholinebenzamide;

[0064]4-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-(2-(R)hydroxypropyl)benzamide;

[0065]4-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-isobutylbenzamide;

[0066]4-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-allylbenzamide;

[0067]4-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-(3,3,3,-trifluoropropyl)benzamide;

[0068]3-fluoro-4-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-propylbenzamide;

[0069]4-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-(2,2,3,3,3,-pentafluoropropyl)benzamide;

[0070]4-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino)}-N′-tert-amylbenzamide;

[0071]5-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-propylpicolinamide;

[0072]4-{N-[2-(3-(S)-fluoropyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino{-N′-(2-(S)-hydroxypropyl)benzamide;

[0073]2-chloro-4-{N-[2-(3-(S)-fluoropyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino-}-N′-propylbenzamide;and

[0074]4-{N-[2-(3-(S)-chloropyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-propylbenzamide.

[0075] Other preferred compounds are:

[0076]4-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-methylbenzamide;

[0077]4-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-ethylbenzamide;

[0078]4-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-butylbenzamide;

[0079]4-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-pentylbenzamide;

[0080]4-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-phenylbenzamide;

[0081]4-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-(2-chlorobenzyl)benzamide;

[0082]4-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′,N′-dimethylbenzamide;

[0083]4-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-methyl-N′-propylbenzamide;

[0084]5-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-propyl-2-thiophenecarboxamide;

[0085]4-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]amino}-N′-propylbenzamide;

[0086]4-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-propylphthalimide;

[0087]4-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-ethoxybenzamide;

[0088]4-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-(3-hydroxypropyl)benzamide;

[0089]4-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-cyclopropylbenzamide;

[0090]4-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-(S)-sec-butylbenzamide;

[0091]4-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-(R)-sec-butylbenzamide;

[0092]4-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-propargylbenzamide;

[0093]4-{N-[1-(R)-(3-carboxymethoxyphenyl)-2-(3-(S)-hydroxypyrrolidin-1-yl)-ethyl]-N-methylamino}-N′-propylbenzamide;

[0094]4-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-tert-butylbenzamide;

[0095]4-{N-hydroxy-N-[2-3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]amino}-N′-propylbenzamide;

[0096]4-{N-[2-(3-(S)-fluoropyrrolidin-1-yl)-1-(S)-phenylethyl]-N-hydroxyamino}-N′-propylbenzamide;

[0097] 4-{N-[2-(3-(R)-fluoropyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-propylbenzamide;

[0098]4-{N-[2-3-(S)-fluoropyrrolidin-1-yl)-1-(R)-phenylethyl]-N-methylamino}-N′-propylbenzamide;

[0099]4-{N-[2-(3-(S)-chloropyrrolidin-1-yl)-1-(S)phenylethyl]-N-methylamino}-N′-(2-(R)-hydroxypropyl)benzamide;and

[0100]4-{N-[2-(3-oxopyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-propylbenzamide.

[0101] Further, the present invention provides a compound of thefollowing formula:

[0102] wherein

[0103] Ar^(2a) is phenyl, pyridyl or thienyl;

[0104] X is hydrogen, halo or C₁-C₇ alkoxy;

[0105] R¹ is hydrogen, optionally protected hydroxy or C₁-C₄ alkyl; and

[0106] R² and R³ are independently hydrogen or C₁-C₇ alkyl optionallysubstituted by hydroxy or halo.

[0107] Preferred individual compounds of the formula (VId) are:

[0108] 4-methylamino-N′-propylbenzamide;

[0109] 5-N-methylamino-N′-propylpicolinamide;

[0110] 2-chloro-4-methylamino-N′-propylbenzamide;

[0111] 4-methylamino-N′-(2-(S)-hydroxypropyl)benzamide;

[0112] 4-methylamino-N′-(2-(R)-hydroxypropyl)benzamide;

[0113] 4-methylamino-N′-(2,2,3,3,3-pentafluoropropyl)benzamide; and

[0114] 4-methylamino-N′-tert-amylbezamide.

[0115] Further, the present invention provides compounds selected from

[0116] 2-(3-(S)-fluoropyrrolidin-1-yl)-1-(S)-phenylethanol;

[0117] 2-(3-(S)-fluoropyrrolidin-1-yl)-2-(R)-phenylethanol;

[0118] 2-(R)-phenyl-2-(3 -pyrroline-1-yl)ethanol;

[0119] 2-(3-(R)-fluoropyrrolidin-1-yl)-1-(S)-phenylethanol.

[0120] 2-(3-(R)-fluoropyrrolidin-1-yl)-2-(R)-phenylethanol;

[0121] 2-(3-(S)-fluoropyrrolidin-1-yl)-1-(R)-phenylethanol,

[0122] 2-(3-(S)-fluoropyrrolidin-1-yl)-2-(S)-phenylethanol

[0123] 2-(3-(S)-chloropyrrolidin-1-yl)-2-(S)-phenylethanol; and

[0124] 2-(3-S)-chloropyrrolidin-1-yl)-2-(R)-phenylethanol.

[0125] Further, the present invention provides processes for producing acompound of formula (I), which comprises reacting an amide compound ofthe formula (VId):

[0126] with an ethanol compound selected from compounds (Va), (Vb) and(Vc), and a mixture of compounds (Va) and (Vb):

[0127] in the absence or presence of a base in a reaction inert solvent.

[0128] General Synthesis

[0129] The kappa agonists (kappa-receptor agonists) of formula (I) ofthis invention can be prepared as described in the following schemes.Unless otherwise indicated, in the reaction schemes that follow, A, Ar¹,Ar², R¹, R² and R³ are defined as above.

[0130] In the above Scheme Ia, an optionally substituted styrene oxide(II) or an optionally substituted phenyl-1,2-ethanediol 2-tosylate (III)can be reacted with a pyrrolidine compound (IV) in the absence orpresence of a base such as K₂CO₃ to form a mixture of substitutedpyrrolidinyl ethanols (Va) and (Vb) . This reaction may be carried outin the absence or presence of a reaction inert solvent (e.g., methanol(MeOH), ethanol (EtOH), isopropylalcohol, tetrahydrofuran (THF),dioxane, N,N-dimethylformamide (DMF), dimethylsulfoxide (DMSO),methylene chloride (CH₂Cl₂), water, benzene, toluene, n-hexane orcyclohexane). This reaction can be carried out at a temperature from−78° C. to the reflux temperature of the solvent, preferably at fromroom temperature to a reflux temperature of the solvent for 5 minutes to48 hours, preferably from 0.5 to 12 hours. The compound (Va) or themixture of the compounds (Va) and (Vb), can be treated withmethanesulfonyl chloride in the presence of a base such astrimethylamine in a proper solvent such as dichloroethane, followed bycoupling with a methyl ester compound of formula (VIa) to give anintermediate compound (VII). This coupling reaction can be carried out,in the absence or presence of a base such as sodium hydride (NaH), in asuitable polar solvent such as water, EtOH or DMF, at from roomtemperature to reflux temperature of the solvent, for 15 minutes to 6hours.

[0131] Then, the intermediate compound (VII) may be treated with a basesuch as NaOH in a reaction inert solvent such as methanol, at atemperature from 0 to 100° C. for 5 minutes to 12 hours to give acarboxylic acid compound (VII).

[0132] The carboxylic acid (VII) can be reacted with an alkyl amine inthe presence of a carbodiimide compound to give the pyrrolydinylethylamine compound (I). A convenient carbodiimide compound is1-ethyl-3-(3-dimeythylaminopropyl)carbodiimide (WSC). This reaction maybe carried out by contacting substantially equivalent amounts of thecarboxylic acid and alklamine with, a small excess amount of thecarbodiimide in an appropriate solvent. Appropriate solvents are inertaromatic hydrocarbons, ethers, halogenated hydrocarbons especiallydichloromethane. The reaction may take place at a temperature in therange from −30 to 100° C., usually from 0 to 30° C. for 30 minutes to 24hours, usually 12 to 16 hours at room temperature. The resulting productcan be isolated and purified by standard techniques.

[0133] If required, the hydroxy protecting group in A of the compound(I) obtained (i.e., Y of —OY), can be removed by the appropriate methodfor the particular protecting group chosen. For example, a typicalprotecting group methoxymethyl, can be removed by acid catalyzedhydrolysis in the presence of acid catalyst such as HCl. A furtherconvenient protecting group in A is the tetrahydropyranyl group (THP).This can be also removed by acid-catalyzed hydrolysis. Appropriate acidcatalysts are organic acids, inorganic acids, or Lewis acids such asacetic acid (AcOH), p-toluenesulfonic acid (p-TsOH), hydrochloric acid(HCl), and dimethylaluminium chloride (Me₂AlCl). Preferred acid catalystis HCl.

[0134] An optically inactive compound (I) wherein Ar¹ is optionallysubstituted phenyl, can be prepared by subjecting a correspondingoptically inactive 1-phenyl-1,2-ethanediol 2-tosylate of the formula(III) or 1-phenyl-2-pyrrolidinylethanol (Vb) to the reactions describedin Scheme Ia. Optically inactive compounds (III), wherein Ar¹ isoptionally substituted phenyl, may be prepared according to theprocedures described in for example Tetrahedron, Vol. 47, pp. 9861-9866,1991, Cehm. Rev., Vol. 80, pp. 187-213, 1980 or J. Org. Chem., Vol. 47,pp. 1229-1232, 1982, followed by tosylation such as reaction withp-toluanesulfonyl chloride in pyridine at 0° C. Optically inactive (Vb)can be prepared according to the procedures described for example inTetrahedron Lett, Vol. 35, pp. 1511-1514, 1994 followed by aconventional reduction.

[0135] A compound of the formula (I) wherein A is hydroxy, R² is alkoxyand R³ is hydrogen can be obtained firm a methylbenzoate of formula(VII) wherein A is hydroxy. First the hydroxy group of themethylbenzoate compound may be protected with a suitable protectinggroup such as tert-butyldimethysilyl group. Second the hydroxy-protectedmethyl ester compound can be subjected to hydrolysis to give thecorresponding carboxylic acid. Then the carboxylic acid can be subjectedto amidation to give the compound (I). The hydroxy protection can beconducted by subjecting the compound of the formula (VII) in DMF to areaction with tert-butyldimethylsilylchloride and immidazole solution atabout 0° C. for 1 to 6 hours. The hydrolysis can be carried out in thepresence of a base such as sodium hydroxide in a polar solvent such asmethanol at about the reflux temperature of the solvent for from 1 to 10hours. The amidation can be carried out with a desiredO-alkylhydroxylamine in the presence of a carbodiimide such as WSC atroom temperature for from 1 to 24 hours. If deprotection is required, aconventional procedures can be employed. For example, when the hydroxygroup is protected with tert-butyldimethysilyl group, the amide compoundcan be treated with tetrabutylammonium fluoride in a proper solvent suchas THF at room temperature.

[0136] A compound of formula (I), wherein A is absent and the brokenline is a double bond, can be also prepared by subjecting a2-phenyl-2-(3-pyrrolin-1-yl)ethanol compound (Vc) and a benzamidecompound to the coupling reactions illustrated in Scheme Ia.

[0137] The ethanol compound (Vc) can be prepared by reacting acorresponding phenylglicinol and 1,4-dichlorobutene in the presence ofbase such as Et₃N in a reaction inert solvent such as ethanol at thereflux temperature of the solvent for 1 to 24 hours.

[0138] A compound of the formula (1) wherein A is oxo (═O), can beprepared by oxidation of the corresponding pyrrolidinol compound. Asuitable oxidation is Swern oxidation.

[0139] Further, the compounds of the formula (I) wherein—Ar²—C(═O)-N(R²)—, is a phthalimide group, can be prepared by using acompound of the formula (VIb):

[0140] instead of the compound (VIa) in the above-mentioned Scheme Ia.

[0141] Compounds of the formula (I) wherein Ay² is thienyl, can beprepared by using a methylaminothiophenecarboxamide of the formula(VIc):

[0142] instead of the compound (VIa) in the above-mentioned Scheme Ia.Compounds (VIc) can be prepared, first, by reacting anitrothiophenecarboxaldehyde with the Jones reagent to give anitrothiophenecarboxylic acid. Then, the carboxylic acid obtained can besubjected to condensation with a compound of the formula: NHR²R³, andthen to reduction of the nitro group with iron powder and ammoniumchloride, followed by methylation of the amino group.

[0143] The compounds of formula (II), (III) and (IV) arc either knowncompounds, which can be made by the known methods, or they are analogsof known compounds, which can be prepared by methods analogous to theknown methods.

[0144] According to the well known procedures or the followingprocedures, R, S configuration of compounds (Va) and (Vb) can beselectively determined by subjecting a 3-pyrrolidinol with thecorresponding R,S configuration.

[0145] Compounds of the formula (Va) and (Vb) wherein A is fluorine andAr¹ is phenyl, can be prepared from a commercially available1-benzyl-3-pyrrolidinol. First, hydroxy group of the pyrrolidinol can beconverted to an appropriate leaving group such as p-toluenesulfonate.The conversion can be achieved by subjecting the ptrrolidinol to thereaction with p-toluenesulfonyl chloride in pyridine. Second, theleaving group may be replaced by fluorine by a reaction with a suitablefluorinating agent such as tetrabutylammonium fluoride in a reactioninert solvent such as THF. Then, the 3-fluoropyrrolidine can besubjected to hydrogenation followed by a coupling with a stylene oxideof formula (II). The hydrogenation can be carried out in the presence ofa suitable cat lyst such as palladium hydroxide on carbon under hydrogenatmosphere in a reaction inert solvents such as EtOH at from 0° C. to aroom temperature for 5 minutes to 48 hours preferably 12 to 36 hours.The coupling reaction can take place in the absence or presence of areaction inert solvent such as EtOH.

[0146] Compounds of the formula (Va) and (Vb) wherein A is chlorine andAr¹ is phenyl, can also be prepared from 1-benzyl-3-pyrrolidinol. Forexample, the 1-benzyl-3-pyrrolidinol can be subjected to chlorination togive 1-benzyl-3-chloropyrrolidine. The benzyl group of the 1-benzyl-3-chloropyrrolidine can be removed by treating the1-benzyl-3-chloropyrrolidine with 1-chloroethyl chloroformate followedby coupling with styreneoxide of the formula (II). The chlorination1-benzyl-3-pyrrolidinol can be carried out under a conventionalcondition, for example in the presence of a suitable reagent such astriphenylphosphine in a suitable solvent such as —CCl₄ at roomtemperature. The debenzylation can be carried out according to the wellknown methods. The debenzylation is typically carried out in a reactioninert solvent such as dichloroethane at the reflux temperature of thesolvent for 5 minutes to 3 hours. Then the solvent may be evaporated andthe residue can be subjected to the coupling reaction with styrene oxidein a suitable solvent such as EtOH at the reflux temperature of thesolvent for 5 minutes to 4 hours.

[0147] Compounds (Va) and (Vb) wherein A is halo and Ar¹ is a optionallysubstituted phenyl, can be prepared from a desired N-protected3-pyrrolidinol compound via the corresponding N-protected3-halopyrrolidine. First, 1-benzyl-3-pyrrolidinol can be treated with asuitable halogenation reagent in a reaction inert solvent for example,triphenylphosphine in CCl₄ at the reflux temperature of the solvent forfrom 3 to 36 hours. Second, the 1-benzyl-3-chloropyrrolidine can bepurified, and deprotection can be carried out under conditions known toskilled in the art (e.g., with 1-chloroethyl chloroformate indichloroethane at 0° C. for 30 minutes to 6 hours). Third, the3-chloropyrrolidine can be treated with a styreneoxide compound to givethe ethanols (Va) and (Vb) according to the procedures illustrated inScheme Ia.

[0148] Methyl ester compounds of the formula (VIa), wherein Ar² isoptionally substituted phenyl, are known compounds or can be prepared bytreating a substituted 4-aminobenzoic acid compound with an alkylhalidein the presence of a base such as NaH or Na₂CO₃ in a reaction inertsolvent such as DMF.

[0149] More specifically, the compounds of the formula (Via) can beprepared by the following methods.

[0150] A: Methyl 3-methylaminobenzoate of the formula (VIa) can beprepared by first subjecting 3-acetamidebenzoic acid to methylation inthe presence of a base such as NaH in a reaction inert solvent such asDMF, followed by deacetylation in the presence of an acid catalyst suchas conc. sulfuric acid (H₂SO₄).

[0151] B: A compound of the formula (VIa) wherein Ar² is substituted byfluorine and R¹ is hydrogen, can be prepared from a nitrobenzoic acid bysubjecting the nitrobenzoic acid to esterification followed byreduction. The esterification can be achieved in the presence of acidcatalyst such as sulfuric acid in MeOH at the reflux temperature of thesolvent for 1 to 17 hours. The reduction can be carried out in thepresence of a reducing agent such as iron powder in a suitable solventsuch as acetic acid at from room temperature to 60 ° C. for 0.5 to 6hours. If desired, the amino group can be alkylated by a well knownmethod. For example, first the methyl ester can be treated withtrifluoroacetic anhydride in the presence of base such as Na₂CO₃ in asuitable solvent such as CH₂Cl₂, then can be alkylated with a suitablealkylating agent such as iodomethane. A compound of the formula (VIa)wherein Ar² is substituted by chlorine and R¹ is alkyl, can be preparedfrom a chlorobenzoic acid by alkylation. The alkylation can be takeplace in the presence of a base such as NaH with a suitable alkyl halidein a reaction inert solvent such as DMF at about 0° C. for 1 to 24hours.

[0152] C: A compound of the formula (VIa), wherein Ar² is pyridyl; themethylester group is on the 3-position and the R¹HN— is on the positionof the pyridine ring respectively, can be prepared by esterification ofa 6-aminonicotic acid The crude residue of the methyl ester obtained maybe subjected to methylation of the amino group. A suitableesterificating agent is, for example, trimethylsilyldiazomethane. Themethylation of the amino group can be carried out according to the sameprocedures of the above mentioned preparation of compounds (VIa).

[0153] Alternatively, an amide compound of the general formula (VId)

[0154] wherein Ar^(2a), X, R¹, R² and R³ are defined as above, can besubjected to the coupling reaction with compounds (Va) and (Vb) todirectly give a compound (I). This coupling reaction can be carried outin the absence or presence of a base such as NaH in a reaction inertsolvent. The preferred solvents include EtOH and DMF. The reaction canbe carried out at a temperature in the range of −78° C. to the refluxtemperature of the solvent, preferably from room temperature to thereflux temperature, for 5 minutes to 48 hours, preferably 0.5 to 24hours.

[0155] The amide compounds of the formula (VId) can be preparedaccording to the procedures described below.

[0156] A: A compound of the formula (VId) wherein Ar^(2a) is phenyl; R¹is hydroxy and X is hydrogen, can be obtained by reduction of a knownnitro N-alkylbenzamide compound. Suitable reducing agents include forexample, zinc powder. This reduction can be carried out by adding thereducing agent to a mixture of the nitro N-alkylbenzamide compound andammonium chloride at about room temperature (e.g., 20-25° C.) for from 1to 3 hours.

[0157] B: A compound of the formula (VId) wherein Ar^(2a) is phenyl; R¹is hydrogen or C₁-C₄ alkyl; R² is C₁-C₇ alkyl optionally substituted byhydroxy; R³ is hydrogen and X is hydrogen or halo, may be prepared froma known amino benzoic acid compound, wherein the phenyl ring isoptionally substituted by halo. The benzoic acid can be subjected toamidation under the similar conditions to those illustrated in SchemeIa. If desired, the amino group or the benzamide compound obtained canbe alkylated. For example, preferable alkylating agent is alkylhalide,and this alkylation can be carried out in the presence of base such aspotassium carbonate at about room temperature for 12 to 24 hours.

[0158] C: An amide compound (VId) wherein Ar^(2a) is pyridyl, and —NHR¹group is on the 5-position and the amide group is on the 2-position ofthe pyridine ring respectively, can be prepared by treating anamino-protected picolinic acid with oxalyl chloride followed byamidation with an desired alkyl amine. The treatment of the5-protected-amino picolic acid and oxalyl chloride can be performed in areaction inert solvent such as CH₂Cl₂ or DMF/CH₂Cl₂ in the presence of abase such as triethylamine at room temperature. The amidation can becarried out in the presence of a base in a reaction inert solvent. Thebase is preferably triethylamine and the reaction may be conducted in asuitable solvent, e.g., dichloroethane at about 15° C. If required, theamino protecting group can be removed by the procedures known to thoseskilled in the art.

[0159] An alternative method to prepare the compounds of the formula (I)is illustrated in the following Scheme Ib.

[0160] The mixture of the compounds (Va) and (Vb) can be treated withmethanesulfonyl chloride in a similar way as shown in Scheme Ia,followed by coupling with a cyano compound (VIe) to give the compound ofthe formula (VIIb). This coupling reaction can be carried out in areaction inert solvent such as DMF or ethanol, in the presence orabsence of base such as NaK NaNH₂ or 2,6-lutidine. This reaction maytake place at from room temperature to the reflux temperature of thesolvent for 30 minutes to 12 hours.

[0161] Then, the compound (VIIb) may be reacted with a suitable alkoxidesuch as t-BuOK in the presence of water, in a polar solvent such ast-BuOH. This reaction may take place at reflux temperature of thesolvent for 5 minutes to 6 hours. Then, a proper alkyl halide can beadded to the resulting reaction mixture. The mixture thus obtained isrefluxed for 5 minutes to 5 hours. The target compound (I) can beisolated and purified from a resulting reaction mixture by standardtechniques.

[0162] Cyano compounds of the formula (VIe), wherein Ar² is asubstituted phenyl can be prepared by treating known substituted4-aminobenzonitrile compounds with NaH or K₂CO₃, followed by alkylationwith an alkylhalide in a reaction inert solvent such as DMF.

[0163] The compounds of formula (I) of this invention are basic, andtherefore they will form acid-addition salts. All such salts are withinthe scope of this invention. However, it is necessary to use an acidaddition salts which is pharmaceutically-acceptable for administrationto a mammal. The acid-addition salts can be prepared by standardmethods, e.g., by contacting the basic and acidic compounds insubstantially equivalent proportions in water or an organic solvent suchas methanol or ethanol, or a mixture thereof The salts can be isolatedby evaporation of the solvent. Typical salts which can be formed are thehydrochloride, nitrate, sulfate, bisulfate, phosphate, acetate, lactate,citrate, tartrate, succinate, malate, fumarate, gluconate, saccharate,benzoate, methanesulfonate, p-toluenesulfonate, oxalate and pamoate(1,1′-methylene-bis-(2-hydroxy-3-naphtoate)) salts.

[0164] The compounds of formula (I) of this invention, wherein Ar¹ isphenyl substituted by carboxy-C₁-C₄ alkoxy are acidic, and they willform base salts. All such salts are within the scope of this invention.However, it is necessary to use a base salt which ispharmaceutically-acceptable for administration to a mammal. The basesalts can be prepared by standard methods, e.g., by contacting theacidic and basic compounds in substantially equivalent proportions inwater or an organic solvent such as methanol or ethanol, or a mixturethereof. The salts can be formed are the sodium, potassium, calcium andmagnesium salts, and also salts with ammonia and amines, such asethylamine, diethylamine, cyclohexylamine, piperidine or morpholinesalts.

[0165] Also included within the scope of this invention arebioprecursors (also called as pro-drugs) of the kappa agonist compoundsof the formula (I). A bioprecursor of a kappa agonist of formula (I) isa chemical derivative thereof which is readily converted back into theparent compound of formula (I) in biological systems. In particular, abioprecursor of a kappa agonist of formula (D) is converted back to theparent compound of formula (I) after the bioprecursor has beenadministered to, and absorbed by, a mammalian subject, e.g., a humansubject. For example, it is possible to make a bioprecursor of a kappaagonist of the invention of formula (I) in which one or both of A and R¹is hydroxy groups by making an ester of the hydroxy group. When only oneof A and R¹ is a hydroxy group, only mono-esters are possible. When bothA and R¹ are hydroxy, mono- and di-esters (which can be the same ordifferent) can be made. Typical esters are simple alkanoate esters, suchas acetate, propionate, buryrare, etc. In addition, when A or R¹ is ahydroxy group, bioprecursors can be made by converting the hydroxy groupto an acyloxymethyl derivative (e. g., a pivaloyloxymethyl derivative)by reaction with an acyloxymethyl halide (e. g., pivaloyloxymethylchloride).

[0166] The kappa agonists compounds of the present invention of formula(I) exhibit significant agonist activity toward opioid kappa-receptorand are thus useful as an analgesic, anesthetic, anti-inflammatory agentor neuroprotective agent, and also useful in the treatment of arthritis,stroke or functional bowel disease such as abdominal pain, for thetreatment of a mammalian subject, especially a human subject.

[0167] The activity of the kappa-agonists compounds of formula (I) ofthe present invention, is demonstrated by the opioid receptor bindingactivity. Such activity may be determined in homogenate from guinea pigwhole brain, as described by Regina, A. et al., in J. Receptor Res.,Vol. 12: pp. 171-180, 1992. In summary, tissue homogenate is incubatedat 25° C. for 30 min in the presence of labelled ligand and testcompounds The mu-sites are labelled by 1 nM of(3H)[D-Ala2,MePhe4,Gly-ol5]enkephalin (DAMGO), the delta-sites by 1 nMof (3H)-[D-Pen2,5]enkephalin (DPDPE) and the kappa-sites by 0.5 nM(3H)-CI-977. The non specific binding is measured by use of 1 μM CI-977(kappa), 1 μM (DAMGO) (mu), 1 μM (DPDPE) (delta). Data are expressed asthe IC₅₀ values obtained by a non-linear fitting program using the Chengand Prusoff equation. Some compounds prepared in the Examples showed apotent IC₅₀ value against kappa receptor in the range of 0.01 to 100 nM.

[0168] The analgesic activity of the kappa-agonist compounds at thecentral nervous system can also be demonstrated by the Formalin Test asdescribed by Wheeler-Aceto, H. et al. in Psychopharmacology, Vol. 104:pp. 35-44, 1991. In this testing, male SD rats (80-100 g) are injecteds.c. with a test compound dissolved in 0.1% methyl cellulose saline orvehicle. After 30 min., 50 μl of a 2% formalin are injected into a hindpaw The number of licking the injected paw per observation period ismeasured 15-30 min. after the injection of formalian and expressed as %inhibition compared to the respective vehicle group. Some compoundsprepared in the Examples showed a potent ED₅₀ value in the range of lessthan 25 mg/kg p.o.

[0169] The activity of the kappa agonists, against peripheralacute-pain, can be demonstrated by the Randall-Selitto assay (M. E.Planas, Pain, Vol.60, pp. 67-71, 1995) In this testing, Male SD rats(100- 120 g) were used and the nociceptive threshold at the right pawwas measured by Randall-Selitto (Ugo Basile) method. After three days ofacclimation of assay condition, experiments were carried out.Hyperalgesia was induced by the intraplantar injection of a 0.1 ml/rightpaw of 1% solution of carrageenin. Painful pressure were delivered tothe right plantar via a wedge-shaped piston and the level of responsewere measured at 3.5 and 4.5 hr later the carrageenin injection. Somecompounds, prepared in the working examples as described below, weretested in accordance with the above procedures, and showed good activityagainst acute-pain (i.e. ED₅₀ value of less than 10 mg/kg p.o.).

[0170] The activity of the kappa agonists, against chronic pain at theperiphery, can be demonstrated by the adjuvant-induced hyperalgesia,according to the procedure described by Judith S. Waker et al., asreported in Life Sciences, Vol. 57, PP. 371-378, 1995. In this testing,male SL rats, weighing 180-230 g at the time of inoculation, were used.To produce adjuvant arthritis, rats were anesthetized with ether andinoculated intradermally into the footpad of the right hindpaw with 0.05ml of Mycobacterium butyricum suspended in paraffin oil (2 mg/ml).Nociceptive threshold was evaluated by paw pressure test, using sameprocedures of the Randall-Selitto assay (as being described above), andedema was measured as the width of foot. Assays were done through thewhole period.

[0171] The sedation function of kappa agonists can be determined by theRotarod Test as described by Hayes, A. G. et al. in Br. J. Pharmacol,Vol. 79, pp. 731-736, 1983. In this testing, a group of 6-10 male SDrats (100-120 g) are selected for their ability to balance on a rotatingrod (diameter 9 cm, rate of rotation 5 r.p.m.). The selected rats arethen injected s.c. with a test compound dissolved in 0.1% methylcellulose saline The animals are tested again 30 min. after treatment; arat failing off the bar more than twice within 150 seconds is consideredto be showing motor impairment and the animal's performance (i.e. timeon the rotarod) are recorded. The ED₅₀ value, defined as the dose of thedrug which have the performance time is observed in the control group.Some compounds prepared in the working examples as described below, weretested in accordance with the above procedures.

[0172] The diuresis function of the kappa agonists can be determinedaccording to the procedure described by A Barber et al., (Br. J.Phamacol., Vol. 111, pp. 843-851, 1994). Some compounds, prepared in theworking examples as described below, were tested in accordance with theabove procedures.

[0173] The kappa agonists compounds of formula (I) of this invention canbe administered in either the oral parenteral or topical routes tomammals. A preferable dosage level may be in a range of from 0.01 mg to10 mg per kg of body weight per day, although variations willnecessarily occur depending upon the weight and condition of the subjectbeing treated, the disease state being treated and the particular routeof administration chosen. However, a dosage level that is in the rangeof from 0.01 mg to 1 mg per kg of body weight per day, single or divideddosage is most desirably employed in humans for the treatment of pain ina postoperative patient and a pain like hyperalgesia caused by chronicdiseases.

[0174] The compounds of the present invention may be administered aloneor in combination with pharmaceutically acceptable carriers or diluentsby either of the above routes previously indicated, and suchadministration can be carried out in single or multiple doses. Moreparticularly, the novel therapeutic agents of the invention can beadministered in a wide variety of different dosage forms, i.e., they maybe combined with various pharmaceutically acceptable inert carriers inthe form of tablets, capsules, lozenges, trochees, hard candies,powders, sprays, creams, salves, suppositories, jellies, gels, pastes,lotions, ointments, aqueous suspensions, injectable solutions, elixirs,syrups, and the like. Such carriers include solid diluents or fillers,sterile aqueous media and various nontoxic organic solvents, etc.Moreover, oral pharmaceutical compositions can be suitably sweetenedand/or flavored. In general the therapeutically-effective compounds ofthis invention are present in such dosage forms at concentration levelsranging 5% to 70% by weight, preferably 10% to 50% by weight.

[0175] For oral administration, tablets containing various excipientssuch as microcrystalline cellulose, sodium citrate, calcium carbonate,dipotassium phosphate and glycine may be employed along with variousdisintegrants such as starch and preferably corn, potato or tapiocastarch, alginic acid and certain complex silicates, together withgranulation binders like polyvinylpyrrolidone, sucrose, gelatin andacacia. Additionally, lubricating agents such as magnesium stearatesodium lauryl sulfate and talc are often very useful for tablettingpurposes. Solid compositions of a similar type may also be employed asfillers in gelatine capsules; preferred materials in this connectionalso include lactose or milk sugar as well as high molecular weightpolyethylene grycols When aqueous suspensions and/or elixirs are desiredfor oral administration, the active ingredient may be combined withvarious sweetening or flavoring agents, coloring matter or dyes, and, ifso desired, emulsifying and/or suspending agents as well, together withsuch diluents as water, ethanol, propylene glycol, glycerin and variouslike combinations thereof.

[0176] For parenteral administration, solutions of a compound of thepresent invention in either sesame or peanut oil or in aqueous propyleneglycol may be employed. The aqueous solutions should be suitablybuffered (preferably pH>8) if necessary and the liquid diluent firstrendered isotonic. These aqueous solutions are suitable for intravenousinjection purposes. The only solutions are suitable for intra-articular,intra-muscular and subcutaneous injection purposes. The preparation ofall these solutions under sterile conditions is readily accomplished bystandard pharmaceutical techniques well-known to those skilled in theart. Additionally, it is also possible to administer the compounds ofthe present invention topically when treating inflammatory conditions ofthe skin and this may preferably be done by way of creams, jellies,gels, pastes, ointments and the like, in accordance with standardpharmaceutical practice.

EXAMPLES AND PREPARATIONS

[0177] The present invention is illustrated by the following examplesand preparations. However, it should be understood that the invention isnot limited to the specific details of these examples and preparations.Melting points were taken with a Buchi micro melting point apparatus anduncorrected. Infrared Ray absorption spectra (IR) were measured by aShimadzu infrared spectrometer (IR-470). ¹H and ¹³C nuclear magneticresonance spectra (NMR) were measured in CDCl₃ by a JEOL NMRspectrometer (JNM-GX270, 270 MHz) unless otherwise indicated and peakpositions are expressed in parts per million (ppm) downfield fromtetramethylsilane. The peak shapes are denoted as follows: s, singlet;d, doublet; t, triplet; m, multiplet; br, broad.

Preparation 1 2-(3-(S)-Methoxymethoxypyrrolidin-1yl)-2-(R)-phenylethanol

[0178] To a stirred solution of (S)-( )-1,2,4-butanetriol (10.61 g, 0.1mol) in pyridine (50 ml) was added p-toluensulfonyl chloride (38.13 g,0.2 mol) by portions at 0° C. After 14 h stirring, the reaction mixturewas poured into conc. HCl aqueous solution including ice and acidifiedto pH2. The mixture was extracted with ether (100 ml×3). The extractcombined was washed with brine, dried (Na₂SO₄), and concentrated to give18.58 g of colorless oil. To a stirred solution of this crude ditosylate(18.58 g, 45.7 mmol) and dimethoxymethane (50 ml) in CH₂Cl₂ (50 ml) wasadded P₂O₅ by portions at rt (room temperature) and stirred for 26 h.The CH₂Cl₂ layer was separated and the P₂O₅ (50 g) solid was washed withCH₂Cl₂ (50 ml×4). The CH₂Cl₂ layer combined was washed with saturatedNaHCO₃ aqueous solution and brine. After dry (Na₂SO₄), the solvent wasevaporated to afford 18.01 g of brown viscous oil. A mixture of this oil(18.00 g, 40 mmol),]—(−) 2-phenylglycin 1 (4.80 g, 35 mm and Et₃N (11.3ml, 80 mmol) in ethanol (20 ml) was fluxed with stirring for 8 h. Thesolvent was evaporated and the residue was dissolved in CH₂Cl₂ (200 ml).This solution was washed with saturated NaHCO₃ aqueous solution andbrine, dried (Na₂SO₄), and concentrated to give 16.59 g of brown viscousoil, which was purified by column chromatography (silica gel 200 g,CH₂Cl₂/MeOH: 20/1) to afford 5.13 g (20.4%, over all yield) of clearbrown viscous oil.

[0179]¹H NMR (270 MHz, CDCl₃) δ7.40-7.25 (5H, m), 4.62 (1H, d, J=7.0Hz), 4.58 (1H, d, J=7.0 Hz), 4.25-4.15 (1H, m), 3.88 (1H dd, J=5.9, 10.6Hz), 3.80 (1H, dd, J=5.9, 10.6 Hz), 3.50 (1H, t, J=5.9 Hz), 3.33 (3H,s), 2.76 (1H, dt, J=6.2, 8.4 Hz), 2.71 (1H, dd, J=5.9, 10.3 Hz), 2.63(1H dd, J=3.3, 10.3 Hz), 2.45 (1H, dt, J=6.2, 8.1 Hz), 2.18 (1H, br s),2.16-2.02 (1H, m), 1.87-1.75 (1H, m).

[0180] 1 R(neat): 3450 cm⁻¹

Preparation 2

[0181] 2-(3-(S)-Methoxymethoxypyrrolidin-1-yl)-1-(S) -phenylethanol and2-(3-(S)-Methoxymethoxypyrrolidin-1-yl)-2(R)-phenylethanol

[0182] A mixture of 3-(S)-methoxymethoxypyrrolidine (4.37 g, 33.3 mmol)and (S)-(−)-styrene oxide (4.00 g, 33.3 mmol) in EtOH (40 ml) wasrefluxed with stirring for 2 h. After evaporation of the solvent, theresidue was purified by column chromatography (slicagel: 120 g,CH₂Cl₂:MeOH=40:1-20:1) to give 4.91 g (58.7%) of pale yellow oil as 0.65to 0.35 mixture of title compounds.

[0183]¹H NMR (270 MHz, CDCl₃) δ7.40-7.27 (5H, m), 4.68-4.63 (2.65 H, m),4.35-4.15 (1H, m), 3.90-3.75 (0.7H, m), 3.49 (0.35H, t, J=5.9 Hz), 3.38(1.95H, s), 3.32 (1.05H, s). 3.10-2.90 (1.3H, m), 2.80-2.40 (4H, m),2.20-2.00 (1H, m), 1.95-1.75 (2H, m)

Preparation 3

[0184] 2-(3-(S)-Methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethanol and2-3-(S)-Methoxymethoxypyrrolidin-1-yl)-2-(R)-phenylethanol

[0185] A mixture of 3-(S)-methoxymethoxypyrrolidine (6.10 g, 46.5 mmol),(S)-(+)-1-phenyl-1,2-ethanediol-2-tosylate (13.6 g, 46.5 mmol) and K₂CO₃(7.06 g, 51.1 mmol) in EtOH (80 ml) was refluxed with stirring for 4.5h. After evaporation of the solvent, CH₂Cl₂ was added to the residue andwashed with saturated NaHCO₃ aqueous solution, brine, dried (Na₂SO₄),and concentrated to give 14.94 g of crude products, which was purifiedby column chromatography (slicagel: 150 g, CH₂Cl₂/MeOH=50:1-20:1) toafford 7.75 g (66.4%) of brown oil as 0.65 to 0.35 mixture of titlecompounds.

[0186]¹H NMR (270 MHz, CDCl₃) δ7.40-7.27 (5H, m), 4.68-4.63 (2.65H, m),4.35-4.15 (1H, m), 3.90-3.75 (0.7H, m), 3.49 (0.35H, t, J=5.9 Hz), 3.38(1.95H,s), 3.32 (1.05H, s), 3.10-2.90 (1.3H, m), 2.80-2.40 (4H, m),2.20-2.00 (1H, m), 1.95-1.75 (2H, m)

Preparation 4

[0187]2-(R)-Phenyl-2-(3-(S)-tetrahydropyran-2-yloxypyrrolidin-1-yl)ethanol and1-(S)-Phenyl-2-(3-(S)-tetrahydropyran-2-yloxypyrrolidin-1-yl)ethanol

[0188] This was prepared from 3-(S)-tetrahydropyranyloxypyrrolidine(3.00 g, 17.5 mmol) and (S)-(−)-styrene oxide (2.10 g, 17.5 mmol) in 50%yield as 0.35 to 0.65 mixture of title compounds according to aprocedure similar to that described in Preparation 2.

[0189]¹H NMR (270 MHz, CDCl₃) δ7.50-7.20 (5H, m), 4.71 (0.65H, dd,J=3.3, 10.6 Hz), 4.65-4.50 (1H, m), 4.45-4.25 (1H, m), 3.95-3.75 (1.7Hm), 3.60-3.42 (1.35H, m), 3.20-2.40 (5.3H, m), 2.25-1.45 (9H, m).

Preparation 5

[0190] 2(R)-Phenyl-2-pyrrolidin-1-yl-ethanol and1-(S)-Phenyl-2-pyrrolidin-1-yl-ethanol

[0191] This was prepared from pyrrolidine (592 mg, 8.32 mmol) and(S)-(−)-styrene oxide (1.00 g, 8.32 mmol) in 96% yield as 0.3 to 0.7mixture of title compounds according to a procedure similar to thatdescribed in Preparation 2.

[0192]¹H NMR (270 MHz, CDCl₃) δ7.45-7.27 (5H, m), 4.70 (0.7H, dd, J=3.3,10.6 Hz), 3.87 (0.3H, dd, J−5.9, 10.6 Hz), 3.81 (0.3H, dd, J=5.9, 10.6Hz), 3.47 (0.3H, t, J=5.9 Hz), 2.90-2.70 (1.4H, m), 2.65-2.40 (4H, m),1.90-1.60(5H, m).

Preparation 6

[0193] Methyl 3-methoxy-4-methylaminobenzoate

[0194] To a suspension of NaH (2.43 g, 60.7 ml in DMF (20 ml) was addeda solution of 4-amino-3-hydroxybenzoic acid (3.00 g, 19.6 mmol) in DMF(20 ml) at 0° C. After stirring at room temperature for 1H, iodomethane(3.78 ml, 60.7 mmol) was added to this mixture at 0° C. and stirred atroom temperature for 16h. The mixture was poured into ice water andextracted with nHex: AcOEt : Et₂O=1:1:1 (300 ml). The extract was washedwith water, brine dried (Na₂SO₄), and concentrated to give brown oil,which was purified by column chromato-graphy (silica gel 190 g,nHex/AcOEt=10/1 and silica gel 35 g, CH₂Cl₂ only) to afford 481 mg (13%)of title compound.

[0195]¹H NMR (270 MHz, CDCl₃) δ7.66 (1H, dd, J=1.8, 8.4 Hz), 7.40 (1H,d, J=1.8 Hz), 6.52 (1H, d, J=8.4 Hz), 4.72 (1H, br. s), 3.89 (3H, s),3.86 (3H, s), 2.91 (3H, d, J=5.1 Hz).

Preparation 7

[0196] Methyl 2-methoxy-4-methylaminobenzoate

[0197] This was prepared from 4-amino-2-hydroxybenzoic acid (3.00 g,19.6 mmol) in 22% yield according to a procedure similar to thatdescribed in Preparation 6.

[0198]¹H NMR (270 MHz, CDCl₃) δ7.77 (1H, d, J=8.8 Hz), 6.16 (1H, dd,J=2.2, 8.8 Hz), 6.08 (1H, d, J=1.8 Hz), 4.19 (1H, br. s), 3.88 (3H, s),3.82 (3H, s), 2.89 (3H d, J=5.1 Hz).

Preparation 8

[0199] Methyl 2-chloro-4-methylaminobenzoate

[0200] This was prepared from 4-amino-2-chlorobenzoic acid (2.00 g, 11.7mmol) in 13% yield according to a procedure similar to that described inPreparation 6.

[0201]¹H NMR (270 MHz, CDCl₃) δ7.80 (1H, d, J=8.8 Hz), 6.59 (1H, d,J=2.6 Hz), 6.44 (1H, dd, J=2.6, 8.8 Hz), 4.21 (1H, br, s), 3.86 (3H, s),2.87 (3H, d, J=5.1 Hz).

Preparation 9

[0202] 3-Chloro-4-methylaminobenzonitrile

[0203] This was prepared from 4-amino-3-chlorobenzonitile (2.00 g, 13.1mmol) in 42% yield according to a procedure similar to that described inPreparation 6.

[0204]¹H NMR (270 MHz, CDCl₃) δ7.50 (1H, d, J=1.8 Hz), 7.43 (1H, dd,J=1.8, 8.4 Hz), 6.61 (1H, d, J=8.4 Hz),4.92 (1H, br. s), 2.96 (3H, d,J=5.1 Hz).

Preparation 10

[0205] Methyl 6-methylaminonicotinate

[0206] To a suspension of 6-aminonicotinic acid (1.00 g, 7.24 mmol) inMeOH (20 ml) and MeCN (10 ml) was added 10% solution oftrimethylsilyldiazomethane in CH₂Cl₂ (25 ml) at room temperature. Afterstirring at room temperature for 0.5 h, the solvent was evaporated togive crude methyl 6-aminonicotinate as a yellow solid. Title compoundwas prepared from this crude methyl 6-aminonicotinate in 17% yieldaccording to a procedure similar to that described in Preparation 6.

[0207]¹H NMR (270 Hz, CDCl₃) δ8.75 (1H, d, J=2.2 Hz), 8.01 (1H, dd,J=2.2, 8.8 Hz), 6.36 (1H, d, J=9.2 Hz), 5.11 (1H, br. s), 3.87 (3H, s),2.99 (3H, d, J=5.5 Hz).

Preparation 11

[0208] Methyl 3-methylaminobenzoate

[0209] To a suspension of NaH (1.54 g, 38.5 mmol) in DMF (20 ml) wasadded a solution of 3-acetamidebenzoic acid (3.00 g, 16.7 mmol) in DMF(20 mmol) at 0° C. After stirring at room temperature for 0.5 h,iodomethane (2.40 ml, 38.5 mmol) was added to this mixture at 0° C. andstirred at room temperature for 1.5 h. The mixture was poured into ice6N-HCl aqueous solution and extracted with AcOEt: toluene=2:1 (200ml×3). The extract was washed with water, brine, dried (Na₂SO₄), andconcentrated to give 3.08 g of brown oil. A mixture this brown oil andcH₂SO₄ (5 ml) in MeOH (30 ml) was refluxed with stirring for 7 h. Aftercooling down to room temperature, the solvent was evaporated. Theresidue was basified with saturated NaHCO₃ aqueous solution andextracted with CH₂Cl₂. The extracted was washed with water, brine, dried(Na₂SO₄), and concentrated to give 2.31 g (84%) of brown oil.

[0210]¹H NMR (270 MHz, CDCl₃) δ7.37 (1H, dt, J=1.4, 7.5 Hz), 7.28-7.20(2H, m), 6.78 (1H, ddd, J=0.73, 2.6, 8.1 Hz), 3.89 (3H, s), 2.87 (3H,s).

Preparation 12

[0211] 4-Amino-N′-propylphthalimide

[0212] To a suspension of NaH (493 g, 12.3 mmol) in DMF (10 ml) wasadded a solution of 4-aminophthalimide (2.00 g, 12.3 mmol) in DMF (10ml) at 0° C. After stirring at room temperature for 1 h, iodopropane(1.20 ml, 12.3 mmol) was added to this mixture at 0° C. and stirred atroom temperature for 28 h. The mixture was poured into water andextracted with AcOEt: toluene=2:1 (150ml×3). The extract was washed withwater, brine, dried (Na₂SO₄), and concentrated to give yellow solid,which was purified by column chromatography (silica gel: 130 g, CH₂Cl₂only to CH₂Cl₂/MeOH=75/1) to give 1.14 g (45%) of yellow solid.

[0213]¹H NMR (270 MHz, CDCl₃) δ7.59 (1H, d, J=8.1 Hz), 7.03 (1H, d,J=2.2 Hz), 6.81 (1H, dd, J=2.2, 8.1 Hz), 4.32 (2H, br. s), 3.65-3.55(2H, m), 1.80-1.60 (2H, m), 0.93 (3H, t, J=7.3 Hz).

Preparation 13

[0214] 4-Methylamino-N′-propylphthalimide

[0215] This was prepared from 4-amino-N′-propylphthalimide in 11% yieldaccording to a procedure similar to that described in Preparation 12.

[0216]¹H NMR (270 MHz, CDCl₃) δ7.59 (1H, d, J=8.4 Hz), 6.96 (1H, d,J=2.2 Hz), 6.71 (1H, dd, J=2.2, 8.4 Hz), 4.50 (1H, br. s), 3.65-3.55(2H, m), 2.95 (3H, d, J=5.1 Hz), 1.80-1.60 (2H, m), 0.93 (3H, J=7.3 Hz).

Preparation 14

[0217] 5-Nitro-2-thiophenecarboxylic acid

[0218] To a solution of 5-nitro-2-thiophenecarboxaldehyde (1.00 g, 6.24mmol) in acetone (50 ml) was added Jones reagent (8N in acetone, 8.12ml, 65 mmol) at −20° C. After stirring for 1H, 30 ml of isopropanol wasadded to the mixture. H₂O was added to the mixture and extracted withCH₂Cl₂. The extract was washed with water, brine, dried (Na₂SO₄), andconcentrated to give 967 mg (90%) of yellow amorphous.

[0219]¹H NMR (270 MHz, CDCl₃) δ7.88 (1H, d, J=4.4 Hz), 7.66 (1H, d,J=4.0 Hz), 5.14 (1H, br, s).

Preparation 15

[0220] 5-Nitro-N-propyl-2-thiophenecarboxamide

[0221] To a solution of 5-nitro-2-thiophenecarboxylic acid (967 mg, 5.59mmol) in DMF (0.745 ml) and CH₂Cl₂ (4 ml) was added oxalyl chloride at0° C. After stirring for 0.5 h at rt (room temperature), the solvent wasevaporated below 30° C. to give yellow oil and solid. To a solution ofn-propylamine (0.551 ml, 6.71 mmol) in Et₃N (1.87 ml, 13.4 mmol) andCH₂Cl₂ (25 ml) was added a solution of crude acid chloride in CH₂Cl₂ (10ml) below 20° C. After stirring for 4 h at rt, the mixture was washedwith water, saturated NaHCO₃ aqueous solution, water, brine, dried(Na₂SO₄), and concentrated to give brown solid, which was purified bycolumn chromatography (silica gel 50 g, CH₂Cl₂/MeOH=100/1-30/1) toafford 815 mg (68%) of white solid.

[0222]¹H NMR (270 MHz, CDCl₃) δ7.85 (1H, d, J=4.0 Hz), 7.35 (1H, d,J=4.4 Hz), 6.12 (1H br s), 3.50-3.35 (2H, m), 1.75-1.55 (2H, m), 0.99(3H, t, J=7.3 Hz).

Preparation 16

[0223] 5- Amino-N′-propyl-2-thiophenecarboxamide

[0224] A mixture of 5-nitro-N-propyl-2-thiophenecarboxamide (815 mg,3.81 mmol), iron powder (1.06 g, 19.0 mmol) and NH₄Cl (102 mg, 1.90mmol) in EtOH (12 ml) and H₂O (6 ml) was refluxed with stirring for 2 h.The reaction mixture was filtered and washed with EtOH. The combinedfiltrate was evaporated. The residue was dissolved in AcOEt and washedwith water, brine, dried (Na₂SO₄), and concentrated to give brownamorphous, which was purified by column chromatography (silica gel 40 g,CH₂Cl₂/MeOH=40/1) to afford 411 mg, (59%) of brown amorphous.

[0225]¹H NMR (270 MHz, CDCl₃) δ7.09 (1H d, J=3.7 Hz), 6.07 (1H, d, J=4.0Hz), 5.80-5.60 (1H, m), 4.14 (2H, br, s), 3.40-3.25 (2H, m), 1.70-1.50(2H, m), 0.96 (3H, t, J=7.3 Hz)

Preparation 17

[0226] 5-Methylamino-N′-propyl-2-thiophenecarboxamide

[0227] To a solution of 5-amino-N′-propyl-2-thiophenecarboxamide (411mg, 2.23 mmol) in CH₂Cl₂(12 ml) was added Na₂CO₃ (710 mg, 6.70 mmol) andtrifluoroacetic anhydride (0.631 ml, 4.47 mmol) at rt. After stirringfor 5 h, the solid was filtered off The filtrate was washed with waterand brine, dried (Na₂SO₄) and concentrated to give 396 mg of yellow oil.To a solution of this oil in DMF (6.5 ml) was added Na₂CO₃ (2.35 g, 22.2mmol) and iodomethane (2.90 ml, 46.6 mmol) at rt. After stirring for 22h, the mixture was poured into ice 1N-HCl and extracted withAcOEt:toluene =2 l The extract was washed with water, brine,dried(Na₂SO₄), and concentrated to give 298 mg of orange solid. To asolution of this solid in MeOH (3.5 ml) was added 7% K₂CO₃ aqueoussolution (1.8 ml) at rt. After stirring for 18 h the solvent wasevaporated. The residue was dissolved in AcOEt and water. The organiclayer was washed with water, brine, dried (Na₂SO₄), and concentrated togive brown oil, which was purified by column chromatography (silica gel15 g, CH₂Cl₂/MeOH=60/1-40/1) to afford 122.5 mg (44%) of title compound.

[0228]¹H NMR (270 MHz, CDCl₃) δ7.16 (1H, d, J=4.0 Hz), 5.89 (1H, d,J=4.4 Hz), 5.68 (1H, br, s), 4.32 (1H, br, s), 3.40-3.30 (2H, m), 2.91(3H, d, J=5.1 Hz), 1.70-1.50 (2H, m), 0.96 (3H, t, J=7.3 Hz).

Preparation 18

[0229] (S)-1-(3-Methoxymethoxyphenyl)-1,2-ethanediol

[0230] A mixture of 3-methoxymethoxystyrene (prepared bymethoxymnethylation of 3-hydroxystyrene in a standard manner) (1.54 g,9.39 mmol), and AD-mix-α (13.18 g, 9.41 mmol) in water (48 ml) andt-BuOH (48 ml) was stirred at 0° C. for 6.5 h. To this reaction mixturewas added Na₂SO₃ (14.13 g) and the mixture was stirred at rt for 1 H.The reaction mixture was extracted with ethyl acetate. The extra waswashed with brine, dried (Na₂SO₄), and concentrated to give light brownoil, which was purified by column chromatography (silica gel; 90 g,ethyl acetate/hexane:1/2-3/1) to afford 1.69 g (91%) of desired productas colorless oil.

[0231]¹H NMR (270 MHz, CDCl₃) δ7.25 (1H, dd, J=7.7, 8.1 Hz), 7.03 (1H,d, J=1.8 Hz), 6.98-6.92 (2H, m), 5.15 (2H, s), 4.74 (1H, dd, J=3.3, 8.1Hz), 3.71 (1H, br, d, J=9.9 Hz), 3.65-3.55 (2H, m, including 1H, dd,J=8.1, 11.0 Hz at 3.61 ppm, CHCH2OH), 3.44 (3H, s ), 3.14 (1H, br.s,OH).

Preparation 19

[0232] (S)-1-(3-Methoxymethoxyphenyl)-1,2-ethanediol-2-tosylate

[0233] To a stirred solution of(S)-1-(3-methoxymethoxyphenyl)-1,2-ethanediol (1.69 g, 8.54 mmol) inpyridine (20 ml) was added p-toluenesulfonyl chloride (1.63 g, 8.54mmol) and 4-dimethylaminopyridine (1.04 g, 8.54 mmol) at 0° C. and thereaction mixture was stirred at 0° C. to rt for 16 h at 60° C. for 1 h.The reaction mixture was acidified with 2N HCl aqueous solution andextracted with ethyl acetate. The extract was washed with water andbrine, dried (Na₂SO₄), and concentrated to give brown oil, which waspurified by column chromatography (silica gel: 150 g, ethylacetate/hexane 1/2 to 2/1) to afford 2.01 g (67%) of desired product ascolorless oil. Its optical purity was 98% ee by HPLC.

[0234]¹H NMR (270 MHz, CDCl₃) δ7.77 (2H, d, J=8.4 Hz), 7.34 (2H, d,J=8.1 Hz), 7.25 (1H, dd, J=7.7, 8.4 Hz), 7.00-6.92 (3H, m), 5.15 (2H,s), 4.95 (1H, ddd, J=3.3, 3.3, 8.4 Hz), 4.15 (1H, dd, J=3.3, 10.3 Hz),4.03 (1H, dd, J=8.4, 10.3 Hz), 3.46 (3H, s), 2.65 (1H, s, J=3.3 Hz),2.45 (3H, s).

Preparation 20

[0235]2-(R)-(3-Methoxymethoxyphenyl)-2-(3-(S)-methoxymethoxypyrrolidin-1-yl)ethanoland1-(S)-(3-Methoxymethoxyphenyl)-2-3-(S)-methoxymethoxypyrrolidin-1-yl)ethanol

[0236] This was prepared from(S)-1-(3-methoxymethoxyphenyl)-1,2-ethanediol-2-tosylate in 79% yield as0.25 to 0.75 mixture of title compounds according to a procedure similarto that described in Preparation 3.

[0237]¹H NMR (270 MHz, CDCl₃) δ7.29-7.21 (1H, m), 7.09-6.91 (3H, m),5.22-5.13 (2H, m), 4.80-4.55 (2.75H, m), 4.33-4.15 (1H, m), 3.90-3.72(0.5H, m), 3.51-3.45 (0.25H, m), 3.48 (3H, s), 3.38 (2.25H, s), 3.33(0.75H, s), 3.05-2.90 (1.5H, m), 2.80-2.43 (4H, m). 2.23-2.02 (1H, m),1.95-1.70 (2H, m).

Preparation 21

[0238] (S)-1-(3-Chlorophenyl)-1.2-ethanediol

[0239] This was prepared from 3-chlorostyrene in 100% yield according toa procedure similar to that described in Preparation 18

[0240]¹H NMR (270 MHz, CDCl₃) δ7.40-7.20 (4H, m), 4.90-4.75 (1H, m),3.85-3.75 (1H, m), 3.75-3.60 (1H, m), 2.66 (1H, d, J=2.9 Hz), 2.20-2.05(1H, m).

Preparation 22

[0241] (S)-1-(3-Chlorophenyl)-1,2-ethanediol-2-tosylate

[0242] This was prepared from (S)-1-(3-chlorophenyl)-1,2-ethanediol in74% yield according to a procedure similar to that described inPreparation 19. Its optical purity was 98% ee by HPLC.

[0243]¹H NMR (270 MHz, CDCl₃) δ7.76 (2H, d, J=8.1 Hz), 7.32 (2H, d,J=8.4 Hz), 7.31-7.17 (4H, m), 5.00-4.92 (1H, m), 4.14 (1H, dd, J=3.3,10.6 Hz), 4.02 (1H, dd, J=8.4, 10.6 Hz), 2.63 (1H, d, J=3.7 Hz), 2.46(3H, s).

Preparation 23

[0244]2-(R)-(3-Chlorophenyl)-2-(3-(S)-methoxymethoxypyrrolidin-1-yl)ethanoland1-(S)-(3-Chlorophenyl)-2-(3-(S)-methoxymethoxypyrrolidin-1-yl)ethanol

[0245] This was prepared from(S)1-(3-chlorophenyl)-1,2-ethanediol-2-tosylate in 62% yield as 0.15 to0.85 mixture of title compounds according to a procedure similar to thatdescribed in Preparation 3.

[0246]¹H NMR (270 MHz, CDCl₃) δ7.40-7.20 (4H, m), 4.80-4.57 (2.85H, m),4.32-4.15 (1H, m), 3.85-3.80 (0.3H, m), 3.48-3.40 (0.15H, m), 3.38(2.55H, s), 3.34 (0.45H, s), 3.05-2.92 (1.7H, m), 2.80-2.62 (2H, m),2.58-2.40 (2H, m), 2.23-2.05 (1H, m), 1.95-1.80 (1H, m).

Preparation 24

[0247] (R)-1-Benzyl-3-pyrrolidinol-tosylate

[0248] To a stirred solution of (R)-1-benzyl-3-pyrrolidinol (1.77g, 10mmol) in pyridine(30 ml) was added p-toluenesulfonyl chloride (9.53 g,50 mmol) by portions at 0° C. After 90 h stirring at room temperature,water was added to the reaction mixture and the mixture was extractedwith ether (150 ml). The extract was washed with water, brine,dried(Na₂SO₄), and concentrated to give 3.06 g (92%) of brown oil.

[0249]¹H NMR (270 MHz, CDCl₃) δ7.76 (2H, d, J=8.4 Hz), 7.31 (2H, d,J=8.4 Hz), 7.35-7.20 (5H, m), 5.05-4.90 (1H, m), 3.61 (1H, d, J=12.8Hz), 3.54 (1H, d, J=12.8 Hz), 2.76 (1H, dd, J=6.0, 11.2 Hz), 2.75-2.60(1H, m), 2.55-2.35 (2H, m), 2.44 (3H, s), 2.12-2.05 (1H, m), 2.03-1.90(1H, m).

Preparation 25

[0250] (S)-1-Benzyl-3 -fluoropyrrolidine

[0251] To a solution of (R)-1-benzyl-3-pyrrolidinol-tosylate (3.06 g,9.24 mmol) in THF (30 ml) was added 1.0 M solution of tetrabutylammoniumfluoride in THF (37.0 ml, 37.0 mmol) at room temperature. After 1.5 hstirring at reflux temperature, water (150 ml) was added to the reactionmixture and the mixture was extracted with ethyl acetate (100 ml×2). Thecombined extract was washed with water, brine, dried (Na₂SO₄), andconcentrated to give brown oil, which was purified by columnchromatography (silica gel. 80 g, CH₂Cl₂/MeOH.50/1) to afford 1.18 g(71%) of brown oil.

[0252]¹H NMR (270 MHz, CDCl₃) δ7.45-7.20 (5H, m), 5.29-5.00 (1H, m),3.68 (1H, d, J=13.2 Hz), 3.63 (1H, d, J=12.8 Hz), 2.95-2.60 (3H, m),2.55-2.38 (1H, m), 2.30-1.90 (2H, m).

Preparation 26

[0253] 2-(3-(S)-Fluoropyrrolidin-1-yl)-1-(S)-phenylethanol and2-(3-(S)-Fluoropyrrolidin-1-yl)-2-(R)-phenylethanol

[0254] A suspension mixture of (S)-1-benzyl-3-fluoropyrrolidine (118 g,5.58 mmol) and 20% palladium hydroxide on carbon (354 mg) in EtOH (20ml) was stirred under hydrogen atmosphere at room temperature for 21.5h. After removal or the catalyst by Celite filtration, to this solutionwas added a solution of (S)-(−)-styrene oxide (791 mg, 6.58 mmol) inEtOH (5 ml). The mixture was refluxed with stirring for 3.5 h. Afterevaporation of the solvent, the residue was purified by columnchromatography (slicagel: 80 g, CH₂Cl₂:MeOH=40:1-30:1) to give 713 mg(51.8%) of yellow oil as 0.7 to 0.3 mixture of title compounds.

[0255]¹H NMR (270 MHz, CDCl₃) δ7.45-7.20 (5H, m), 5.35-5.05 (0.7H, m),5.25-4.95 (0.3H, m), 4.71 (0.7H, dd, J=3.3, 10.6 Hz). 3.95-3.75 (0.6H,m), 3.52 (0.3H, t. J=5.9Hz), 3.15-2.40 (5.4H, m), 2.30-1.80 (3H, m)

Preparation 27

[0256] 2-(3-(S)-Methoxymethoxypyrrolidin-1-yl)-1-(R)-phenylethanol and2-(3-(S)-Methoxymethoxypyrrolidin-1-yl)-2-(S)-phenylethanol

[0257] This was prepared from 3-(S)-methoxymethoxypyrrolidine and(R)-(−)-styrene oxide in 53% yield as 0.7 to 0.3 mixture of titlecompounds according to a procedure similar to that described inPreparation 2.

[0258]¹H NMR (270 MHz, CDCl₃) δ7.40-7.20 (5H, m), 4.72 (0.7H, dd, J=3.3,10.6 Hz), 4.66 (0.7H, d, J=7.0 Hz), 4.63 (0.7H, d, J=7.0 Hz),4.63-4.56(0.6H, m), 4.35-4.17 (1H, m), 3.92-3.77 (0.6H, m), 3.50 (0.3H t, J=5.5Hz), 3.37 (2.1H, s), 3.33 (0.9H, s), 3.10-2.50 (5.4H, m), 2.25-2.00 (1H,m), 1.95-1.70 (2H, m)

Preparation 28

[0259] (R)-1-(3-Methoxymethoxyphenyl)-1,2-ethanediol

[0260] This was prepared from 3-methoxymethoxystyrene and AD-mix-β in100% yield according to the procedures similar to those described inPreparation 18.

[0261]¹H NMR (270 MHz, CDCl₃) δ7.31-7.25 (1H, m), 7.06-6.96 (3H, m),5.18 (2H, s), 4.80 (1H, dd, J=3.7, 8.1 Hz), 3.78 (1H, dd, J=3.7, 11.4Hz), 3.66 (1H, dd, J=8.1, 11.4 Hz), 3.48 (3H, s).

Preparation 29

[0262] (R)-1-(3-Methoxymethoxyhenyl)-1,2-ethanediol-2-tosylate

[0263] This was prepared from(R)-1-(3-methoxymethoxyphenyl)-1,2-ethanediol in 77% yield according tothe procedures similar to those described in Preparation 19

[0264]¹H NMR (270 MHz, CDCl₃) δ7.77 (2H, d, J=8.4 Hz), 7.33 (2H, d,J=7.7 Hz), 7.28-7.18 (1H, m), 7.00-6.92 (3H, m), 5.15 (2H, s), 5.00-4.90(1H, m), 4.20-4.00 (2H, m), 3.46 (3H, s), 2.80-2.60 (1H, m), 2.45 (3H,s)

[0265] 97% ee (by HPLC)

Preparation 30

[0266] 2-(R)-Phenyl-2-(3 -pyrroline-1-yl)ethanol

[0267] This was prepared from R-(−)-2-phenylglycinol andcis-1,4-dichloro-2-butene in 58% yield according to the proceduressimilar to those described in Preparation 1

[0268]¹H NMR (270 MHz, CDCl₃) δ7.36-7.29 (5H, m), 5.77 (2H, s), 3.83(2H, d, J=5.9 Hz), 3.66 (1H, m), 3.50 (4H, s).

Preparation 31

[0269] (S)-1-Benzyl-3-pyrrolidinol-tosylate

[0270] This was prepared from (S)-1-benzyl-3-pyrrolidinol andp-toluenesulfonyl chloride in 98% yield according to the proceduressimilar to those described in Preparation 24.

[0271]¹H NMR (270 Hz, CDCl₃) δ7.76 (2H, d, J=8.4 Hz), 7.33-7.26 (7H, m),4.97 (1H, t, J=2.9 Hz), 3.69-3.58 (2H, m), 2.89-2.83 (1H, m), 2.73-2.68(2H, m), 2.58-2.55 (1H, m), 2.44 (3H, s), 2.20-2.12(1H, m), 1.99-1.93(1H, m).

Preparation 32

[0272] (R)-1-Benzyl-3-fluoropyrrolidine

[0273] This was prepared from (S)-1-benzyl-3-pyrrolidinol-tosylate in61% yield according to the procedures similar to those described inPreparation 25.

[0274]¹H NMR (270 MHz, CDCl₃) δ7.33-7.23 (5H, m), 5.28-5.04 (1H, m),3.71-3.61 (2H, m), 2.91-2.67 (3H, m), 2.50-2.42 (1H, m), 2.24-2.00 (2H,m).

Preparation 33

[0275] 2-(3-(R)-Fluoropyrrolidin-1-yl)-1-(S)-phenylethanol and2-(3-(R)-Fluoropyrrolidin-1-yl)-2-(R)-phenylethanol

[0276] This was prepared (R)-1-benzyl-3-fluoropyrrolidine in 76% overall yield as 0.6 to 0.4 mixture of title compounds according to theprocedures similar to those described in Preparation 26.

[0277]¹H NMR (270 MHz, CDCl₃) δ7.40-7.24 (5H, m), 5.32-5.27 (0.3H, m),5.25-5.21 (0.2H, m), 5.11-5.07 (0.3H, m), 5.07-5.01 (0.2H, m), 4.71(0.6H, dd, J=3.3, 10.3 Hz), 3.90-3.78 (0.6H, m), 3.55-3.51 (0.4H, m),3.13-2.44 (5.4H, m), 2.23-1.94 (2H, m).

Preparation 34

[0278] 2-(3-(S)-Fluoropyrrolidin-1-yl)-1-(R)-phenylethanol and 2-(3-(S)-Fluoropyrrolidin-1-yl)-2-(S)-phenylethanol

[0279] This was prepared from 3-(S)-fluoropyrrolidine and(R)-(+)-styreneoxide in 72% yield as 0.7 to 0.3 mixture of the titlecompounds according to the procedures similar to those described inPreparation 26

[0280]¹H NMR (270 MHz, CDCl₃) δ7.39-7.24 (5H, m), 5.31-5.28 (0.35H, m),5.73-5.22 (0.15H, m), 5.12-5.07 (0.35H, m), 5.06-5.01 (0.15H, m),4.73-4.68 (0.7H, m), 3.88-3.79 (0.7H, m), 3.54-3.50 (0.3H, m), 3.13-2.44(5.3H, m), 2.20-1.93 (2H, m).

Preparation 35

[0281] (S)-1-Benzyl-3 -chloropyrrolidine

[0282] To a stirred solution of (R)-1-benzyl-3-pyrrolidinol (886 mg, 5.0mmol) in CCl₄ (20 ml) was added triphenylphosphine(1.574 g, 6.0 mmol) atrt. After 20 h stirring at reflux temperature, the solvent wasevaporated. Saturated NaHCO₃ aqueous solution and water was added to theresidue, and the mixture was extracted with AcOEt. The extract wasbrine, dried(Na₂SO₄), and concentrated to give brown oil, which waspurified by column chromatography (silica gel, 100 g, CH₂Cl₂/MeOH.50/1-45/1) to give 706 mg(72%) of pale yellow oil.

[0283]¹H NMR (270 MHz, CDCl₃) δ7.33-7.23 (5H, m), 4.42-4.33 (1H, m),3.73-3.61 (2H, m), 3.09 (1H, dd, J=6.6, 10.6 Hz), 2.81-2.61 (3H, m),2.48-2.35 (1H, m), 2.13-2.03 (1H, m)

Preparation 36

[0284] 2-(3 -(S)-Chloropyrrolidin-1-yl)-1-(S)-phenylethanol and2-(3-(S)-Chloropyrrolidin-1-yl)-2-R)-2-phenylethanol

[0285] To a stirred solution of (S)-1-benzyl-3-chloropyrrolidine (695mg, 3.55 mmol) in dichloroethane (10 ml) was added 1-chloroethylchloroformate (0.38 ml, 3.55 mmol) at 0° C. The mixture was stirred at0° C. for 10 min and refluxed for 1.5 h. After cooling down to rt, thesolvent was evaporated. The residue was dissolved in MeOH (5 ml) andrefluxed for 1 h. After cooling down to rt, the solvent was evaporatedto give 787 mg of brown solid.

[0286] Title compounds were prepared from the above solid and(S)-(−)-styreneoxide in 39% over all yield as 0.67 to 0.33 mixture ofthe title compounds according to the procedures similar to thosedescribed in Preparation 2.

[0287]¹H NMR (270 MHz, CDCl₃) δ7.39-7.27 (5H, m), 4.70 (0.67H, dd,J=3.3, 10.3 Hz), 4.45-4.40 (0.67H, m), 4.38-4.32 (0.33H, m), 3.91-3.02(2.33H, m), 2.88-2.56 (4H, m), 2.50-2.31 (1H, m), 2.17-2.03 (1H, m).

Preparation 37

[0288] Methyl 3-fluoro-4-nitrobenzoate

[0289] A mixture of 3-fluoro-4-nitrobenzoic acid (2.07 g, 11.2 mmol) andcH₂SO₄(0.5 ml) in MeOH(10 ml) was refluxed for 8 h. The solvent wasevaporated The residue was dissolved in AcOEt and washed with saturatedNaHCO₃ aqueous solution, water, brine, dried (Na₂SO₄), and concentrratedto give 2.14 g (96%) of ivory solid.

[0290]¹H NMR (270 MHz, CDCl₃) δ8.15-8.07 (1H, m), 7.99-7.96 (1H, m),7.95-7.92 (1H, m), 3.99 (3H, S).

Preparation 38

[0291] Methyl 4-amino-3-fluorobenzoate

[0292] A mixture of methlyl 3-fluoro-4-nitrobenzoate (2.14 g, 10.8 mmol)and iron powder (2.63 g) in acetic acid (22 ml) was stirred at 50° C.for 2.5h. After cooling down to room temperature, CH₂Cl₂ (100 ml) andwater (300 ml) was added to the mixture and filtered to remove ironpowder. The organic layer was separated and the aqueous layer wasextracted with CH₂Cl₂ (70 ml×2). The CH₂Cl₂ solution was combined,washed with water, brine, dried (Na₂SO₄), and concentrated to give 1.77g (97%) of pale brown solid

[0293]¹H NMR (270 MHz, CDCl₃) δ7.70-7.62 (2H, m), 6.79-6.70 (1H, m),4.13 (2H, br. s,) 3.86 (3H, S).

Preparation 39

[0294] Methlyl 3-fluoro-4-methylaminobenzoate

[0295] To a solution of methlyl 4-amino-3-fluorobenzoate (1.77 g, 10.5mmol) in CH₂Cl₂ (50 ml) was added Na₂CO₃ (3.33 g, 31.4 mmol) andtrifluoroacetic anhydride (2.96 ml, 20.9 mmol) at room temperature.After stirring for 2.5 h, the solid was filtered off. The filtrate waswashed with water, brine, dried(Na₂SO₄), and concentrated to give 2.70 g(97%) of white solid. To a solution of this solid (2.70 g, 10.2 mmol) inDF (48 ml) was added Na₂CO₃ (16.9 g, 160 mmol) and iodomethane (20.8 ml,334 mmol) at 0° C. After stirring for 2 h at 0° C., for 1 h at roomtemperature, the mixture was poured into 2NHCl with ice and extractedwith AcOEt toluene=2:1 (200 ml×2). The extract was washed with water,brine, dried (Na₂SO₄), and concentrated to give 3.06 g (quant) of brownoil. This oil was dissolved in MeOH (25 ml) and 7% K₂CO₃ solution (12.5ml) was added at 0° C. After stirring for 2 h at 0° C., for 4 h at roomtemperature, 7% K₂CO₃ solution (12.5 ml) was added. After stirring for1.5 h at room temperature, the mixture was acidified with 5NHCl and MeOHwas evaporated. The residue was extracted with AcOEt. The extract waswashed with water, brine, dried (Na₂SO₄), and concentrated to give 1.83g (98%) of pale brown solid.

[0296]¹H NMR (270 MHz, CDCl₃) δ7.80-7.72 (1H, m), 7.62 (1H, dd, J=1.8,12.5 Hz), 6.63 (1H, t, J=8.6 Hz), 4.40 (1H, br, s), 3.86 (3H, S), 2.94(3H, d, J=5.1 Hz).

Preparation 40

[0297] 5-[N-tert-Butoxycarbonyl)-N-methylamino]-N′-2-propylpicolinamide

[0298] To a solution of5-[N-(tert-butoxycarbonyl)-N-methylamino]picolinic acid (1.93 g, 7.66mmol) and triethylamine (1.60 ml, 11.5 mmol) in DMF (0.678 ml) andCH₂Cl₂ (14 ml) was added oxalyl chloride (0.989 ml, 11.3 mmol) dropwiseat room temperature. After stirring for 30 min at room temperature, thesolvent was evaporated The residue was dissolved in CH₂Cl₂ (14 ml). Thissolution was added dropwise to a stirred, cooled solution ofn-propylamine (0.756 ml, 9.19 mmol) and triethylamine (3.20 ml, 23.0mmol) in CH₂Cl₂ (28 ml) while the temperature was kept below 15° C.After stirring for 15 h at room temperature, the mixture was washed withwater, brine, dried (Na₂SO₄), and concentrated to give brown oil, whichwas purified by column chromatography (silica gel; 100 g, CH₂Cl₂/MeOH:60/1) to give 1.82 g (81%) of pale brown oil.

[0299]¹H NMR (270 MHz, CDCl₃) δ8.49 (1H, d, J=2.6 Hz), 8.16 (1H, d,J=8.4 Hz), 7.95 (1H, br, s), 7.71 (1H, dd, J=2.6, 8.4 Hz), 3.50-3.40(2H, m), 3.32 (3H, S), 1.75-1.55 (2H, m), 1.48 (9H, s), 1.00 (3H, t,J=7.3 Hz).

Preparation 41

[0300] 5-N-Methylamino-N′-propylpicolinamide

[0301] A solution of5-[N-(tert-butoxycarbonyl)-N-methylamino]-N′-propylpicolinamide (1.82 g,6.21 mmol) in trifuoroacetic acid (30 ml) was stirred at 0° C. for 2 h.After removal of the solvent, the residue was dissolved in CH₂Cl₂ and25% ammonia solution. The organic layer was separated and washed withbrine, dried (Na₂SO₄), and concentrated to give 1.20 g (100%) of brownsolid.

[0302]¹H NMR (270 MHz, CDCl₃) δ8.01 (1H, d, J=8.4 Hz), 7.88 (1H, d,J=2.9 Hz), 7.78 (1H, br s), 6.90 (1H, dd, J=2.9, 8.4 Hz), 4.17 (1H, br,s), 3 45-3.35 (2H, m), 2.91 (3H, d, J=5.1 Hz), 1.75-1.55 (2H, m), 0.98(3H, t, J=7.3 Hz).

Preparation 42

[0303] 4-N-Hydroxyamino-N′-2-propylbenzamide

[0304] To a solution of 4-nitro-N-propylbenzamide (2.75 g, 13.2 mmol)and ammonium chloride (812 mg, 15.2 mmol) in EtOH (20 ml) and water (10ml) was added zinc powder (1.70 g, 26.0 mmol) portionwise with watercooling. After stirring for 30 min at room temperature, zinc powder(0.50 g, 7.65 mmol) was added to the mixture and stirred for 30 min atroom temperature. The solid was removed through celite and washed withMeOH. The filtrate and washings were combined and concentrated to giveyellow solid, which was purified by column chromatography (silica gel,30 g, CH₂Cl₂/MeOH: 25/1-10/1) to give 2.06 g (80%) of ivory solid.

[0305]¹H NMR (270 MHz, CDCl₃-DMSO-d6) δ8.32 (1H, d, J=2.2 Hz), 7.72 (2H,d, J=8.4 Hz), 7.25-7.10 (1H, m), 6.95 (2H, d, J=8.8 Hz), 3.45-3.30 (2H,m), 2.91 (1H, s), 1.70-1.55 (2H, m), 0.96 (3H, t, J=7.3 Hz).

Preparation 43

[0306] 4-Amino-2-chloro-N′-propylbenzamide

[0307] A mixture of 4-amino-2-chlorobenzoic acid (3.00 g, 17.5 mmol),n-propylamine (2.88 ml, 35.0 mmol) and WSC (6.71 g, 35.0 mmol) in CH₂Cl₂(35 ml) was stirred at room temperature for 16 h. The mixture was washedwith water, brine, dried (Na₂SO₄), and concentrated to give brown oil,which was purified by column chromatography (silica gel; 180 g,CH₂Cl₂/MeOH: 30/1-10/1) to give 2.32 g (62%) of pale ivory solid.

[0308]¹H NMR (270 MHz, CDCl₃) δ7.64 (1H, d, J=8.4 Hz), 6.64 (1H, d,J=2.6 Hz), 6.57 (1H, dd, J=2.6, 8.4 Hz), 6.44 (1H, br, s), 3.97 (2H, br,s), 3.50-3.30 (2H, m), 1.75-1.55 (2H, m), 0.99 (3H, t, J=7.3 Hz).

Preparation 44

[0309] 2-Chloro4-methylamino -N′-propylbenzamide

[0310] A mixture of 4-amino-2-chloro-N′-propylbenzamide (2.32 g, 10.9mmol), iodomethane (0.68 ml, 10.9 mmol) and K₂CO₃ (1.51 g, 10.9 mmol) inDMF (50 ml) was stirred at room temperature for 20 h. Water was added tothe mixture and extracted with AcOEt toluene=1:1. The extract was washedwith water, brine, dried (Na₂SO₄), and concentrated to give pale brownsolid, which was purified by column chromatography (silica gel; 120 g,CH₂Cl₂/MeOH: 40/1) to give 887 mg (36%) of pale brown solid.

[0311]¹H NMR (270 MHz, CDCl₃) δ7.57 (1H, d, J=8.4 Hz), 6.80 (1H, br, s),6.53 (1H, d, J=2.2 Hz), 6.50 (1H, dd, J=2.2, 8.4 Hz), 5.00-4.80 (1H, m),3.45-3.30 (2H, m), 2.82 (3H, d, J=5.1 Hz), 1.75-1.55 (2H, m), 0.99 (3H,t, J=1.3 Hz).

Preparation 45

[0312] 4-Methylamino -N′-(2-(S)-hydroxypropyl)benzamide

[0313] This was prepared from 4-(methylamino)benzoic acid and(S)-(+)-1-amino-2-propanol in 22% yield according to the proceduressimilar to those described in Preparation 43.

[0314]¹H NMR (270 MHz, CDCl₃-DMSO-d6) δ7.69 (2H, d, J=8.4 Hz), 7.14 (1H,br, s), 6.56 (2H, d, J=8.8 Hz), 4.60-4.30 (2H, m), 3.98-3.94 (1H, m),3.64-3.55 (1H, m), 3.28-3.18 (1H, m), 2.85 (3H, s), 1.20 (3H, d, J=6.2Hz).

Preparation 46

[0315] 4-Methylamino -N′-(2-(R)-hydroxypropyl)benzamide

[0316] This was prepared from 4-(methylamino)benzoic acid and(R)-(−)-1-amino-2-propanol in 41% yield according to the proceduressimilar to those described in Preparation 43.

[0317]¹H NMR (270 MHz, CDCl₃-DMSO-d6) δ7.68 (2H dd, J=1.8, 7.0 Hz), 7.12(1H, br, s), 6.55 (2H, dd, J=1.8, 7.0 Hz), 4.50 (1H, br, s), 4.37 (1H,br, s), 3.98-3.93 (1H, m), 3.64-3.55 (1H, m), 3.28-3.18 (1H, m), 2.85(3H, d, J=4.8 Hz), 1.20 (3H, d, J=6.2 Hz)

Preparation 47

[0318] 4-Methylamino -N′-propylbenzamide

[0319] This was prepared from 4-(methylamino)benzoic acid andn-propylamine in 82% yield according to the procedures similar to thosedescribed in Preparation 43

[0320]¹H NMR (270 MHz, CDCl₃) δ7.63 (2H, d, J=8.8 Hz), 6.56 (2H, d,J=8.8 Hz), 6.05 (1H, br, s), 4.11 (1H, br, s), 3.45-3.30 (2H, m), 2.86(3H, s), 1.70-1.50 (2H, m), 0.97 (3H, t, J=7.3 Hz).

Preparation 48

[0321]4-[N-(Benzyloxycarbonyl)-N-methylamino]-N′-(2,2,3,3,3-pentafluoropropyl)benzamide

[0322] To a solution of 4-[N-(benzyloxycarbonyl)-N-methylamino]benzoicacid (100 mg, 0.351 mmol) in CH₂Cl₂ (1 ml) was added oxalyl chloride(0.122 ml, 1.40 mmol) and DMF (0.026 ml) at room temperature. Afterstirring for 4 h at room temperature, the solvent was evaporated. Theresidue was dissolved in CH₂Cl₂ (10 ml). To this solution was added2,2,3,3,3-pentafluoropropylamine (523 mg, 3.51 mmol) and triethylamine(0.372 ml, 2.67 mmol) at room temperature. After stirring for 18 h atroom temperature, saturated NaHCO₃ aqueous solution was added to themixture and extracted with CH₂Cl₂. The extract was washed with brine,dried (Na₂SO₄), and concentrated to give brown oil, which was purifiedby column chromatography (silica gel, 30 g, CH₂Cl₂ only-CH₂CI₂/MeOH:50/1) to give 532 mg (72%) of title compound.

[0323]¹H NMR (270 MHz, CDCl₃) δ7.75 (2H, d, J=8.8 Hz), 7.39-7.31 (7H,m), 6.42-6.31 (1H, m), 5.19 (2H, s), 4.17 (2H, ddd, J=6.2, 14.7, 14.7 Hz), 3.36 (3H, s).

Preparation 49

[0324] 4-[N-(Benzyloxcarbonyl)-N-methylamino]-N′-tert-amylbenzamide

[0325] This was prepared from4-[N-(benzyloxycarbonyl)-N-methylamino]benzoic acid and tert-amylaminein 22% yield according to the procedures similar to those described inPreparation 48.

[0326]¹H NMR (270 MHz, CDCl₃) δ7.69 (2H, d, J=8.4 Hz), 7.32-7.29 (7H,m), 5.86-5.75 (1H, m), 5.17 (2H, s), 3.33 (3H, s), 1.88-1.80 (2H, m),1.40 (6H, s), 0.89 (3H, t, J=7.3 Hz).

Preparation 50

[0327] 4-[N-(Benzyloxycarbonyl-N-methylamino]-N′-tert-butylbenzamide

[0328] This was prepared from4-[N-benzyloxycarbonyl)-N-methylamino]benzoic acid and tert-butylaminein 93% yield according to the procedures similar to those described inPreparation 48.

[0329]¹H NMR (270 MHz, CDCl₃) δ7.69 (2H, d, J=8.8 Hz), 7.32-7.29 (7H,m), 5.89 (1H, br s), 5.17 (2H, s), 3.33 (3H, s), 1.46 (9H, s).

Preparation 51

[0330] 4-Methylamino-N′-(2,2,3,3,3,-pentafluoropropyl)benzamide

[0331] A suspension mixture of4-[N-(benzyloxycarbonyl)-N-methylamino]-N′-(2,2,3,3,3,-pentafluoropropyl)benzamide(532 mg, 1.28 mmol) and 10% palladium carbon (41 mg) in MeOH (5 ml) wasstirred under hydrogen atmosphere at room temperature for 6 h. Thecatalyst was removed through Celite and washed with MeOH. The filtrateand washings were combined and concentrated to give 345 mg (96%) oftitle compound.

[0332]¹H NMR (270 MHz, CDCl₃) δ7.66 (2H, d, J=8.4 Hz), 6.58 (2H, d,J=8.4 Hz), 6.15-6.12 (1H, m), 4.23-4.09 (3H, m), 2.89 (3H, d, J=4.4 Hz).

Preparation 52

[0333] 4-Methylamino-N′-tert-amylbenzamide

[0334] This was prepared from4-[N-(benzyloxycarbonyl)-N-methylamino]-N′-tert-amylbenzamide in 88%yield according to the procedures similar to those described inPreparation 51.

[0335]¹H NMR (270, CDCl₃) δ7.58 (2H, d, J=8.4 Hz), 6.56 (2H, d, J=8.8Hz), 5.70 ( 1H, br s), 4.00 (1H br, s), 2.87 (3H, s), 1.83 (2H, q, J=7.7Hz), 1.39 (6H, s), 0.89 (3H, t, J=7.7 Hz).

Preparation 53

[0336] 4-Methylamino-N′-tert-butylbenzamide

[0337] This was prepared from4-[N-(benzyloxycarbonyl)-N-methylamino]-N′-tert-butylbenzamide in 100%yield according to the procedures similar to those described inPreparation 51.

[0338]¹H NMR (270 MHz, CDCl₃) δ7.58 (2H, d, J=8.4 Hz), 6.56 (2H, d,J=8.8 Hz), 5.78 (1H, br s), 2.86 (3H, s), 1.45 (9H, s).

Example 1

[0339] Preparation of4-{N-[2-(3-(S)-Methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-propylbenzamide

[0340] (i) Methyl4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}benzoate

[0341] To a stirred solution of the mixture of2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethanol and2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-2-(R)-phenylethanol (2.01 g,8.00 mmol) and triethylamine (1.34 ml, 9.60 mmol) in CH₂Cl₂ (35 ml) wasadded methanesulfonyl chloride (0.744 ml, 9.60 mmol) dropwise at 0° C.(ice bath). After 5.5 h stirring at room temperature, the reactionmixture was washed with saturated NaHCO₃ aqueous solution, brine, dried(Na₂SO₄), and concentrated to give 2.16 g of brown viscous oil. To thisoil was added Methyl 4-methylaminobenzoate (1.45 g, 8.80 mmol) andethanol (16 ml) and the mixture was stirred at reflux temperature for1.5 h. The solvent was evaporated. The residue was dissolved in CH₂Cl₂and washed with saturated NaHCO₃ aqueous solution and brine, dried(Na₂SO₄), and concentrated to give brown oil, which was purified bycolumn chromato-graphy (silica gel 150 g, CH₂Cl₂/MeOH: 100/1-35/1) toafford 1.99 g (62.5%) of brown oil.

[0342]¹H NMR (270 MHz, CDCl₃) δ7.89 (2H, d, J=9.2 Hz), 7.35-7.20 (5H,m), 6.78 (2H, d J=9.2 Hz), 5.17 (1H, dd, J=6.6, 8.1 Hz), 4.59 (1H, d,J=7.0 Hz), 4.55 (1H, J, J=7.0 Hz), 4.22-4.12 (1H, m), 3.85 (3H, s), 3.30(3H, s), 3.10 (1H, dd, J=6.2, 12.8 Hz), 3.03 (1H, dd, J=8.4, 12.8 Hz),2.86 (3H, s), 2.85-2.80 (1H, m), 2.77-2.67 (1H, m), 2.65-2.53 (2H, m),2.05 (1H, ddd, J=7.5, 13.9, 13.9 Hz), 1.83-1.70 (1H, m).

[0343] (ii) 4-{N-[2-(3-(S)-Methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}benzoicacid

[0344] A mixture of methyl4{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}benzoate(1.99 g, 5.00 mmol) and 4 N-NaOH (12.5 ml, 50.0 mmol) in MeOH (35 ml)was stirred at 75° C. for 3 h The mixture was neutralized with 5N-NaOHat 0° C. The solvent was removed in vacuo. CH₂Cl₂ was added to theresidue and insoluble solid was removed by filtration. The filtrate wasconcentrated to give 2.04 g (quant) of pale brown amorphous.

[0345]¹H NMR (270 MHz, CDCl₃) δ7.93 (2H, d, J=8.8 Hz), 7.40-7.10 (5H,m), 6.81 (2H, d, J=9.2 Hz), 5.85 (1H, br, s), 5.26 (1H, dd, J=6.2, 8.1Hz), 4.60 (1H, d, J=7.0 Hz), 4.56 (1H, d, J=7.0 Hz), 4.25-4.15 (1H, m),3.30 (3H, s), 3.20-3.05 (2H, m), 2.97 (1H, dd, J=6.2, 9.9 Hz), 2.87 (3H,s), 2.80-2.65 (3H, m), 2.15-2.00 (1H, m), 1.90-1.75 (1H, m)

[0346] (iii)4-{N-[2-(3-(S)-Methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethy]-N-methylamino}-N′-propylbenzamide

[0347] To a stirred solution of4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}benzoicacid (2.04 g, 5.00 mmol) and n-propylamine (0.822 ml, 10.0 mmol) inCH₂Cl₂ (35 ml) was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimidehydrochloride (1.92 g, 10 mmol) at room temperature.

[0348] After 15.5 hr stirring, the reaction mixture was washed withwater and brine, dried (Na₂SO₄), and concentrated to give brown oil,which was purified by column, chromatography (silica gel; 100 g,CH₂Cl₂/MeOH: 25/1) to give 1.52 g (72%) of pale brown amorphous.

[0349]¹H NMR (270 MHz, CDCl₃) δ7.65 (2H, d, J=8.8 Hz), 7.35-7.20 (5H,m), 6.79 (1H, d, J=9.2 Hz), 6.05-5.90 (1H, m), 5.14 (1H, dd, J=6.6, 8.1Hz), 4.59 (1H, d, J=7.0 Hz), 4.55 (1H, d, J=7.0 Hz), 4.24-4.10 (1H, m),3.39 (2H, dd, J=6.6, 13.9 Hz), 3.30 (3H, s), 3.14-2.96 (2H, m),2.90-2.80 (1H, m), 2.85 (3H, s), 2.78-2.52 (3H, m), 2.14-1.96 (1H, m),1.84-1.70 (1H, m), 1.68-1.56 (2H, m), 0.97 (3H, t, J=7.3 Hz)

Example 2

[0350] Preparation of4-{N-[2-(3-(S)-Hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-propylbenzamide

[0351] A mixture of4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-propylbenzamide(1.52 g, 3.58 mmol) and 10% HCl in MeOH (25 ml) was stirred at roomtemperature for 6 h. The solvent was evaporated The residue was basifiedwith 25% ammonium hydroxide, extracted with CH₂Cl₂. The extract waswashed with brine, dried (Na₂SO₄) and concentrated to give pale brownamorphous, which was purified by column chromatography (silica gel, 65g, CH₂Cl₂/MeOH: 20/1-15/1) to give 1.21 g (89%) of pale brown amorphous.

[0352]¹H NMR (270 MHz, free amine, CDCl₃) δ7.66 (2H, d, J=9.2 Hz),7.40-7.20 (5H, m), 6.81 (2H, d, J=9.2 Hz), 6.05-5.90 (1H, m), 5.15 (1H,dd, J=5.9, 9 2 Hz), 4.28-4.16 (1H, m), 3.46-3.32 (2H, m), 3.13 (1H, dd,J=9.2, 12.8 Hz), 3.03 (1H, dd, J=5.9, 12.8 Hz), 2.90 (1H, ddd, J=5.0,8.5, 8.5 Hz), 2.84 (3H, s), 2.73 (1H, d, J=9.9 Hz), 2.56 (1H, dd, J=4 6,9.7 Hz), 2.32 (1H, ddd, J=6.1, 9.0, 9.0 Hz), 2.18-2.00 (1H, m),1.90-1.50 (4H, m), 0.98 (3H, t, J=7.3 Hz)

[0353] 600 mg of this amorphous was dissolved in 10% HCl in MeOH (10ml). The solvent was concentrated to give 625 mg of HCl salt as palebrown amorphous.

[0354] 1R(KBr): 3300, 1610 cm⁻¹.

[0355] MS m/z: 382 (M+H)⁺

[0356] Anal. Calcd for C₂₃H₃₁N₃O₂.HCl.1.5H₂O. C, 62.08 H. 7.93; N, 9.44.

[0357] Found: C, 62.29; H, 8.01; N, 9.42.

Example 3

[0358] Preparation of4-{N-[2-(3-(S)-Methoxymethoxypyrrolidin-1-yl-1-(S)-phenylethyl]-N-methylamino}-N-methylbenzamide

[0359] This was prepared from4-}N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}benzoicacid and methylamino hydrochloride in 26% yield according to a proceduresimilar to that described in Example 1 (iii).

[0360]¹H NMR (270 MHz, CDCl₃) δ7.64 (2H, d, J=8.8 Hz), 7.40-7.20 (5H,m), 6.79 (2H, d, J=8.8 Hz), 6.02 (1H, br, s), 5.13 (1H, dd, J=6.6, 8.1Hz), 4.59 (1H, d, J=7.0 Hz), 4.55, (1H, d, J=6.6 Hz), 4.20-4.13 (1H, m),3.30 (3H, s), 3.15-3.00 (2H, m), 2.97 (3H d, J=5.1 Hz), 2.90-2.80 (1H,m), 2.83 (3H, s), 2.75-2.55 (3H, m), 2.05 (1H, ddd, J=7.7, 14.3, 13.9Hz), 1.90-1.70 (1H, m)

Example 4

[0361] Preparation of4-{N-[2-(3-(S)-Hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-methylbenzamide

[0362] This was prepared from4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-methylbenzamidein 82% yield according to a procedure similar to that described inExample 2.

[0363]¹H NMR (270 MHz, free amine, CDCl₃) δ7.66 (2H, d, J=9.2 Hz),7.40-7.20 (5H, m), 6.81 (2H, d, J=8.8 Hz), 6.00-5.95 (1H, m), 5.15 (1H,dd, J=6.0, 9.0 Hz), 4.25-4.20 (1H, m), 3.13 (1H, dd, J=9.2, 12.8 Hz),3.03 (1H, dd, J=5.9, 12.8 Hz), 2.98 (3H, d, J=5.1 Hz), 2.95-2.80 (1H,m), 2.83 (3H, s), 2.74 (1H, d, J=9.9 Hz), 2.55 (1H, dd, J=4.6, 9.7 Hz),2.35-2.25 (1H, m), 2.17-2.05 (1H, m), 1.80-1.60 (2H, m)

[0364] HCl salt: amorphous solid.

[0365] 1R(KBr): 3350, 1610 cm⁻¹.

[0366] Anal. Calcd for C₂₁H₂₇N₃O₂.HCl.1.2H₂O C, 61.29; H, 7.45; N, 10.21

[0367] Found: C,61.68; H, 7.84; N,10.20.

Example 5

[0368] Preparation of4-{N-[2-(3-(S)-Methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-ethylbenzamide

[0369] This was prepared from4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}benzoicacid and ethylamine hydrochloride in 33% yield according to a proceduresimilar to that described in Example 1 (iii).

[0370]¹H NMR (270 MHz, CDCl₃) δ7.64 (2H, d, J=8.8 Hz), 7.34-7.24 (5H,m), 6.79 (2H, d, J=8.8 Hz), 5.95-5.83 (1H, m), 5.13 (1H, dd, J=7.0, 7.5Hz), 4.59 (1H, d, J=7.0 Hz), 4.55 (1H, d, J=6.6 Hz), 4.25-4.14 (1H, m),3.52-3.42 (2H, m), 3.30 (3H, s), 3.10-3.01 (2H, m), 2.89-2.80 (1H m),2.83 (3H, s), 2.75-2.53 (3H, m), 2.11-2.01 (1H, m), 1.80-1.74 (1H, m),1.23 (3H, t, J=7.1 Hz)

Example 6

[0371] Preparation of4-{N-[2-(3-(S)-Hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-ethylbenzamide

[0372] This was prepared from4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-ethylbenzamidein 43% yield according to a procedure similar to that described inExample 2.

[0373]¹H NMR (270 MHz, free amine, CDCl₃) δ7.65 (2H, d, J=8.8 Hz),7.34-7.23 (5H, m), 6.80 (2H, d, J=8.8 Hz), 6.01 (1H, br, s), 5.14 (1H,dd, J=6.2, 8.8 Hz), 4.22-4.18 (1H, m), 3.50-3.40 (2H, m), 3.11 (1H, dd,J=8.8, 12.8 Hz), 3.02 (1H, dd, J=5.9, 12.8 Hz), 2.92-2.85 (1H, m), 2.82(3H, s), 2.70 (1H, d, J=9.5 Hz), 2.57 (1H, dd, J=4.8, 9.9 Hz), 2.37-2.29(1H, m), 2.12-2.01 (2H, m), 1.68-1.60 (1H, m), 1.21 (3H, t, J=7.3 Hz)

[0374] HCl salt: amorphous solid.

[0375] 1R(KBr): 3350, 1610 cm⁻.

[0376] Anal. Calcd for C₂₂H₂₉N₃O₂.HCl.4H₂O C, 55.72, H, 7.70, N, 8.97

[0377] Found: C, 55.51; H. 8.05; N, 8.83.

Example 7

[0378] Preparation of4-{N-[2-(3-(S)-Methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-butylbenzamide

[0379] This was prepared from4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}benzoicacid and n-butylamine in 40% yield according to a procedure similar tothat described in Example 1 (iii).

[0380]¹H NMR (270 MHz, CDCl₃) δ7.63 (2H, d, J=9.2 Hz), 7.34-7.24 (5H,m), 6.79 (2H, d, J=9.2 Hz), 6.00-5.85 (1H, m), 5.12 (1H, dd, J=6.6, 7.1Hz), 4.59 (1H, d, J=6.6 Hz), 4.55 (1H, d, J=6.6 Hz), 4.19-4.15 (1H, m),3.50-3.40 (2H, m), 3.29 (3H, s), 3.07-3.02 (2H, m), 2.90-2.80 (1H, m),2.84 (3H, s), 2.72-2.57 (3H, m), 2.08-2.01 (1H, m), 1.78-1.60 (1H, m),1.58-1.36 (4H, m), 0.94 (3H, t, J=7.3 Hz)

Example 8

[0381] Preparation of4-{N-[2-(3-(S)-Hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-butylbenzamide

[0382] This was prepared from4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino)}-N′-butylbenzamidein 59% yield according to a procedure similar to that described inExample 2.

[0383]¹H NMR (270 MHz, free amine, CDCl₃) δ7.65 (2H, d, J=8.8 Hz),7.35-7.24 (5H, m), 6.80 (2H, d, J=8.8 Hz), 5.82-5.78 (1H, m), 5.15 (1H,dd, J=5.9, 8 8 Hz), 4.26-4.24 (1H, m), 3.43 (2H, dd, J=7.0, 12.8 Hz),3.13 (1H dd, J=8.8, 12.8 Hz), 3.03 (1H, dd, J=6.2, 12.8 Hz), 2.93-2.85(1H, m), 2.84 (3H, s), 2.73 (1H, d, J=9.5 Hz ), 2.56 (1H, dd, J=4.8, 9.5Hz), 2.37-2.28 (1H, m), 2.10-2.06 (1H, m), 1.72-1.52 (4H, m), 1.47-1.25(2H, m), 0.95 (3H, t, J=7.3 Hz)

[0384] HCl salt: amorphous solid.

[0385] 1 R(KBr) 3350, 1610 cm⁻¹.

[0386] MS m/z: 396 (M+H)⁺.

[0387] Anal. Calcd for C₂₄H₃₃N₃O₂.HCl.1.4H₂O C, 63.05, 8.11. N, 9.19

[0388] Found C,63.06;H,8.04;N,8.98.

Example 9

[0389] Preparation of 4-{N-[1-(S)-Phenyl-2-(3-(S)-tetrahydropyran-2-yloxypyrrolidin-1-yl)-ethyl]-N-methylamino}-N′-pentylbenzamide

[0390] This was prepared from2-(R)-phenyl-2-(3-(S)-tetrahydropyran-2-yloxypyrrolidin-1-yl)ethanol and1-(S)-phenyl-2-(3-(S)-tetrahydropyran-2-yloxypyrrolidin-1-yl)ethanol in33% over all yield according to a procedure similar to that described inExample 1 (i)-(iii).

[0391]¹H NMR (270 MHz CDCl₃) δ7.70-7.60 (2H, m), 7.40-7.20 (5H, m), 6.79(2H, d, J=8.8 Hz), 6.00-5.90 (1H, m), 5.20-5.10 (1H, m), 4.60-4.55(0.6H, m), 4.50-4.40 (0.4H, m), 4.35-4.20 (1H, m), 3.90-3.72 (1H, m),3.50-3.35 (3H, m), 3.15-2.90 (3H, m), 2.84 (1.8H, s), 2.83 (1.2H, s),2.80-2.50 (3H, m), 2.20-1.95 (1H, m), 1.90-1.25 (13H, m), 0.91 (3H, t,J=7.0 Hz).

Example 10

[0392] Preparation of4-{N-[2-(3-(S)-Hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-pentylbenzamide

[0393] This was prepared from4-{N-[1-(S)-phenyl-2-(3-(S)-tetrahydropyran-2-yloxypyrrolidin-1-yl)ethyl]-N-methylanmio}-N′-pentylbenzamidein 98%-yield according to a procedure similar to that described inExample 2.

[0394]¹H NMR (270 MHz, free amine, CDCl₃) δ7.65 (2H, d, J=9.2 Hz),7.40-7.20 (5H, m), 6.81 (2H, d, J=8.8 Hz), 6.00-5.90 (1H, m), 5.16 (1H,dd, J=6.0, 9.0 Hz), 4.26-4.13 (1H, m), 3.50-3.37 (2H, m), 3.13 (1H, dd,J=9.2, 12.8 Hz), 3.03 (1H dd, 6.3, 12.8 Hz). 2.93-2.80 (1H, m), 2.84(3H, s), 2.73 (1H, d, J=9.2 Hz ), 2.56 (1H, dd, J=4.8, 9.5 Hz),2.37-2.28 (1H, m), 2.17-2.00 (1H, m), 1.90-1.55 (4H, m), 1.50-1.30 (4H,m), 0.93 (3H. t, J=7.3 Hz)

[0395] HCl salt: amorphous solid.

[0396] 1 R(KBr) 3350, 1610 cm⁻¹

[0397] Anal. Calcd for C₂₅H₃₅N₃O₂HCl.0.25H₂O C, 66.65; H, 8.17,1, 9.33

[0398] Found. C, 66.57; H, 8.47; N,9.31.

Example 11

[0399] Preparation of4-{N-[2-(3-(S)-Methoxymethoxypyrrolidin-1-yl-1-(S)-phenylethyl]-N-methylamino}-N′-isopropylbenzamide

[0400] This was prepared from4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}benzoicacid and isopropylamine in 15% yield according to a procedure similar tothat described in Example 1 (iii).

[0401]¹H NMR (270 MHz, CDCl₃) δ7.63 (2H, d, J=9.2 Hz), 7.34-7.21 (5H,m), 6.78 (2H, d, J=9.6 Hz), 5.75-5.72 (1H, m), 5.12 (1H, dd, J=6.2, 8.8Hz), 4.59 (1H, d, J=6.6 Hz), 4.55 (1H, d, J=6.6 Hz), 4.30-4.23 (1H, m),4.18-4.14 (1H, m), 3.30 (3H, s), 3.06-3.03 (2H, m), 2.90-2.80 (1H, m),2.85 (3H, s), 2.81-2.72 (1H, m), 2.66-2.57 (2H, m), 2.08-2.01 (1H, m),1.79-1.76 (1H, m), 1.23 (6H, d, J=6.6 Hz)

Example 12

[0402] Preparation of4-{N-[2-(3-(S)-Hydroxpyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-isopropylbenzamide

[0403] This was prepared from4{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N-isopropylbenzamidein 80% yield according to a procedure similar to that described inExample 2.

[0404]¹H NMR (270 MHz, free a CDCl₃) δ7.64 (2H, d, J=8.8 Hz), 7.34-7.22(5H, m), 6.80 (2H, d, J=8.8 Hz), 5.79-5.77 (1H, m), 5.15 (1H, dd, J=6.2,8.8 Hz), 4.30-4.19 (2H, m), 3.03 (1H, dd, J=9.2, 12.8 Hz), 3.03 (1H, dd,J=6.2, 12.8 Hz), 2.93-2.84 (1H, m), 2.82 (3H, s), 2.72 (1H, d, J=9.5Hz), 2.57 (1H, dd, J=4.8, 9.9 Hz), 2.38-2.29 (1H, m), 2.14-2.02 (2H, m),1.68-1.58 (1H, m), 1.23 (6H, d, J=6.6 Hz)

[0405] HCl salt: amorphous solid.

[0406] 1 R(KBr): 3350, 1610 cm⁻¹.

[0407] MS m/z: 382 (M+H)⁺.

[0408] Anal. Calcd for C₂₃H₃₁N₃O₂HCl.1.9H₂O: C, 61.09; H, 7.98; N, 9.29

[0409] Found: C, 61.16; H, 7.61 , N, 9.12.

Example 13

[0410] Preparation of4-{N-[2-(3-(S)-Methoxymethoxypyrrolidin-1-yl-1-(S)-phenylethyl]-N-methylamino}-N′-phenylbenzamide

[0411] This was prepared from4-{N-[2-3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}benzoicacid and aniline in 48% yield according to a procedure similar to thatdescribed in Example 1 (iii).

[0412]¹H NMR (270 MHz, CDCl₃) δ7.63 (2H, d, J=8.8 Hz), 7.69 (1H, br s),7.62 (2H, d, J=7.7 Hz), 7.40-7.24 (7H, m), 7.11 (1H, t, J=7.3 Hz),6.88-6.80 (2H, m), 5.18 (1H, dd, J=7.7, 15.0 Hz), 4.60 (1H, d, J=7.0Hz), 4.56 (1H, d, J=7.0 Hz), 4.25-4.10 (1H, m), 3.31 (3H, s), 3.15-3.05(2H, m), 2.89 (3H, s), 2.95-2.80 (1H, m), 2.80-2.55 (3H, m), 2.15-2.00(1H, m), 1.90-1.70 (1H, m)

Example 14

[0413] Preparation of4-{N-[2-(3-(S)-Hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}N′-phenylbenzamide

[0414] This was prepared from4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-phenylbenzamidein 16% yield according, to a procedure similar to that described inExample 2.

[0415]¹H NMR (270 MHz, free amine, CDCl₃) δ7.84 (1H, br, s), 7.76 (2H,d, J=8.8 Hz), 7 66-7.60 (2H, m), 7.40-7.24 (7H, m), 7.10 (1H, t, J=7.3Hz), 6.84 (2H, d, J=9.2 Hz), 5.18 (1H, dd, J=6.2, 8.8 Hz), 4.30-4.17(1H, m), 3.15 (1H, dd, J=9.2, 12.8 Hz), 3.05 (1H, dd, J=5.9, 12.8 Hz),3.00-2.85 (1H, m), 2.85 (3H, s), 2.74 (1H, d, J=9.5 Hz), 2.59 (1H, dd,J=4.8, 9.5 Hz), 2.45-2.30 (1H, m), 2.25 (1H, br, s), 2.15-2.00 (1H, m),1.80-1.60 (1H, m)

[0416] HCl salt: amorphous solid.

[0417] 1 R(YBr) 3400, 1600 cm⁻¹.

[0418] Anal. Calcd for C₂₆H₂₉N₃O₂.HCl.H₂O C, 66.44 H, 6.86, N, 8.94

[0419] Found: C, 66.33; H, 7.16; N, 8.86.

Example 15

[0420] Preparation of4-{N-[2-(3-(S)-Methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-(2-chlorobenzyl)benzamide

[0421] This was prepared from4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}benzoicacid and 2-chlorobenzylamine in 88% yield according to a proceduresimilar to that described in Example 1 (iii).

[0422]¹H NMR (270 MHz, CDCl₃) δ7.68 (2H, d, J=9.2 Hz), 7.50-7.20 (9H,m), 6.80 (2H, d. J=9.2 Hz), 6.50-6.40 (1H, m), 5.13 (1H, dd, J=6.6, 8.1Hz), 4.71 (2H, d, J=5.9 Hz), 4.59 (1H, d, J=7.0 Hz), 4.54 (1H, d, J=7.0Hz), 4.22-4.10 (1H, m), 3.29 (3H, s), 3.15-2.97 (2H, m), 2.87-2.80 (1H,m), 2.85 (3H, s), 2.75-2.52 (3H, m), 2.13-1.98 (1H, m), 1.85-1.70 (1H,m)

Example 16

[0423] Preparation of4-{N-[2-(3-(S)-Hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-(2-chlorobenzyl)benzamide

[0424] This was prepared from4-{N-[2-3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-(2-chlorobenzyl)benzamidein 98% yield according to a procedure similar to that described inExample 2.

[0425]¹H NMR (270 MHz free amine, CDCl₃) δ7.68 (2H, d, J=8.8 Hz),7.50-7.20 (9H, m), 6.79 (2H, d, J=8.8 Hz), 6.50-6.40 (1H, m), 5.14 (1H,dd, J=6.0, 9.0 Hz), 4.71 (2H, d, J=5.9 Hz), 4.25-4.20 (1H, m), 3.12 (1H,dd, J=8.8, 12.8 Hz), 3.03 (1H, dd, J=6.2, 12.8 Hz), 2.95-2.80 (1H, m),2.84 (3H, s), 2.72 (1H, d, J=9.9 Hz), 2.56 (1H, dd, J=4.4, 9.9 Hz,2.40-2.32 (1H, m), 2.16-2.00 (1H, m), 1.80-1.55 (2H, m)

[0426] HCl salt: amorphous solid.

[0427] 1 R(KBr) : 3300, 1630, 1605 cm⁻.

[0428] Anal. Calcd for C₂₇H₃₀N₃O₂Cl.HCl.H₂O.0.3C₃H₈O . C, 62.46; H,6.65; N, 7.83

[0429] Found: C, 62.51; E, 7.02; N, 7.94.

Example 17

[0430] Preparation of4-{N-[2-(3-(s)-Methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′,N′-dimethylbenzamide

[0431] This was prepared from4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}benzoicacid and dimethylamine hydrochloride in 71% yield according to aprocedure similar to that described in Example 1 (iii).

[0432]¹H NMR (270 MHz, CDCl₃) δ7.50-7.20 (7H, m), 7.00-6.75 (2H, m),5.35-5.25 (1H, m), 4.62 (1H, d, J=7.0 Hz), 4.58 (1H, d, J=6.6 Hz),4.35-4.20 (1H, m), 3.40-3.20 (2H, m), 3.32 (3H, s), 3.15-3.30 (1H, m),3.07 (6H, s), 2.95-2.70 (2H, m), 2.81 (3H, s), 2.25-2.05 (1H, m),2.00-1.80 (1H, m), 1.80-1.55 (1H, m)

Example 18

[0433] Preparation of4-{N-[2-(3-(S)-Hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′,N′-dimethylbenzamide

[0434] This was prepared from4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′,N′-dimethylbenzamidein 88% yield according to a procedure similar to that described inExample 2.

[0435]¹H NMR (270 MHz, free amine, CDCl₃) δ7.37 (2H, d, J=8.8 Hz),7.35-7.20 (5H, m), 6.79 (2H, d, J=9.2 Hz), 5.13 (1H, dd, J=6.0, 9.0 Hz),4.25-4.17 (1H, m), 3.18-2.98 (2H, m), 3.07 (6H, s), 2.91 (1H, ddd,J=5.1, 8.4, 8.4 Hz), 2.81 (3H, s), 2.74 (1H, d, J=9.2 Hz), 2.55 (1H, dd,J=4.8, 9.5 Hz), 2.37-2.25 (1H, m), 2.20-2.00 (1H, m), 1.80-1.55 (2H, m)

[0436] HCl salt: amorphous solid.

[0437] 1 R(KBr): 3400, 1610 cm⁻¹.

[0438] Anal. Calcd for C₂₂H₂₉N₃O₂.HCl.H₂O: C, 62.62; H, 7.64,; N,9.96

[0439] Found :C, 62.52 ; H, 7.86 ;N, 9.98.

Example 19

[0440] Preparation of4-{N-[1-(S)-Phenyl-2-(3-(S)-tetrahydropyran-2-yloxypyrrolidin-1-yl)-ethyl]-N-methylamino}-N-methyl-N′-propylbenzamide

[0441] This was prepared from2-(R)-phenyl-2-(3-(S)-tetrahydropyran-2-yloxypyrrolidin-1-yl)ethanol and1-(S)-phenyl-2-(3-(S)-tetrahydropyran-2-yloxypyrrolidin-1-yl)ethanol in32% over all yield according to a procedure similar to that described inExample 1 (i)-(iii).

[0442]¹H NMR (270 MHz, CDCl₃) δ7.40-7.20 (7H, m), 6.77 (2H, d, J=8.8Hz), 5.11 (1H, dd, J=7.0, 7.7 Hz), 4.60-4.55 (0.6H, m), 4.53-4.47 (0.4H,m), 4.38-4.25 (1H, m), 3.90-3.75 (1H, m), 3.55-3.30 (3H, m), 3.15-2.92(2H, m), 3.03 (3H, s), 2.81 (1.8H, s), 2.80 (1.2H, s), 2.80-2.70 (1H,m), 2.68-2.50 (3H, m), 2.15-1.95 (1H, m), 1.90-1.45 (9H, m), 1.00-0.80(3H, m),

Example 20

[0443] Preparation of4-{N-[2-(3-(S)-Hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-methyl-N′-propylbenzamide

[0444] This was prepared from4-{N-[1-(S)-phenyl-2-(3-(S)-tetrahydropyran-2-yloxypyrrolidin-1-yl)ethyl]-N-methylamino}-N′-methyl-N′-propylbenzamidein 83% yield according to a procedure similar to that described inExample 2.

[0445]¹H NMR (270 MHz, free amine, CDCl₃) δ7.40-7.20 (7H, m), 6.79 (2H,d, J=8.8 Hz), 5.11 (1H, dd, J=6.2, 8.8 Hz), 4.28-4.16 (1H, m), 3.46-3.32(2H, m), 3.18-2.98 (1H m), 3.03 (3H, s), 2.90 (1H, ddd, J=5.1, 8.4, 8.5Hz), 2.81 (3H, s), 2.78-2.70 (1H, m), 2.56 (1H, dd, J=4.6, 9.7 Hz), 2.32(1H, ddd, J=6.2, 9.2, 9.2 Hz), 2.18-2.00 (1H, m), 1.90-1.50 (4H, m),1.00-0.80 (3H, m)

[0446] HCl salt: amorphous solid.

[0447] 1 R(KBr): 3350, 1610 cm⁻¹.

[0448] Anal. Calcd for C₂₄H₃₃N₃O₂.HCl.0.75H₂O: C, 64.70 H, 8.03; N,9.43

[0449] Found: C, 64.68; H, 8.39; N, 9.49.

Example 21

[0450] Preparation of3-{N-[2-(3-(S)-Methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-propylbenzamide

[0451] (i)Methyl-3-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}benzoate

[0452] This was prepared from2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-2-R)-phenylethanol and methyl3-methylaminobenzoate in 78% yield according to a procedure similar tothat described in Example 1 (i).

[0453]¹H NMR (270 MHz, CDCl₃) δ7.51-7.48(1H, m), 7.39-7.34 (1H, m),7.33-7.20 (6H, m), 7.04-6.98 (1H, m), 5.15-5.05 (1H, m), 4.59 (1H, d,J=7.0 Hz), 4.55 (1H, d, J=7.0 Hz), 4.20-4.10 (1H, m), 3.89 (3H, s), 3.30(3H, s), 3.15-2.97 (2H, m), 2.90-2.80 (1H, m), 2.82 (3H, s), 2.77-2.55(3H, m), 2.12-1.98 (1H, m), 1.83-1.60 (1H, m)

[0454] (ii)3-{N-[2-(3-(S)-Methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}benzoicacid

[0455] This was prepared from methyl3-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}benzoatein 100% yield according to a procedure similar to that described inExample 1 (ii)

[0456]¹H NMR (270 MHz, CDCl₃) δ7.98 (1H, br s), 7.47 (1H, d, J=7.7 Hz),7.30-7.10 (6 H, m), 6.82 (1H, d, J=2.2, 8.4 Hz), 5.70-5.60 (1H, m), 4.63(1H, d, J=6.6 Hz), 4.59 (1H, d, J=6.6 Hz), 4.40-4.30 (1H, m), 4.04 ( 1H,br, s), 3.77 (1H, dd, J=5.9, 11.7 Hz), 3.68-3.53 (1H, m), 3.48-3.28 (2H,m), 3.32 (3H, s), 3.12-3.00 (1H, m), 2.96-2.84 (1H, m), 2.01 (3H, s),2.26-2.12 (1H, m), 2.06-1.92 (1H, m)

[0457] (iii)3-{N-[2-(3-(S)-Methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-propylbenzamide

[0458] This was prepared from3-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}benzoicacid and n-propylamine in 78% yield according to a procedure similar tothat described in Example 1 (iii).

[0459]¹H NMR (270 MHz, CDCl₃) δ7.34-7.19 (7H, m), 6.98 (1H, d, J=7.3Hz), 6.91 (1H, dd, J=2.2, 8.1 Hz), 6.22 (1H, br, s),5.16-5.06 (1H, m),4.57 (1H, d, J=6.6 Hz), 4.53 (1H, d, J=6.6 Hz), 4.22-4.12 (1H, m),3.46-3.32 (2H, m), 3.28 (3H, s), 3.16-2.96 (1H, m), 2.81 (3H, s),2.86-2.52 (4H, m), 2.14-1.98 (1H, m), 1.82-1.56 (4H, m), 0.98 (3H, t,J=7.3 Hz)

Example 22

[0460] Preparation of3-{N-[2-(3-(S)-Hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-propylbenzamide

[0461] This was prepared from3-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-propylbenzamidein 90% yield according to a procedure similar to that described inExample 2.

[0462]¹H NMR (270 MHz, CDCl₃) δ7.42-7.37 (1H, m), 7.36-7.19 (6H, m),6.97 (1H, d, J=7.7 Hz), 6.92 (1H, dd, J=2.6, 8.1 Hz), 6.21 (1H, br s),5.13 (1H, dd, J=59, 8.8 Hz), 4.26-4.14 (1H, m), 3.48-3.32 (2H, m),3.18-3.00 (2H, m), 2.92 (1H, ddd, J=4.8, 8.4, 8.4 Hz), 2.86-2.72 (1H,m), 2.78 (3H, s), 2.50 (1H, dd, J=4.8, 9.9 Hz), 2.36-2.22 (2H, m),2.20-2.02 (1H, m), 2.00-1.70 (2H, m), 1.63 (2H, ddd, J=7.3, 14.7, 14.7Hz). 0.93 (3H, t, J=7.3 Hz)

[0463] HCl salt. brown powder.

[0464] mp. 105-114° C.

[0465] 1 R(KBr): 3350, 1635 cm⁻¹.

[0466] MS m/z: 381 (M⁺).

[0467] Anal. Calcd for C₂₃H₃₁N₃O₂.HCl.0.7H₂O.0.3C₆H₁₄O: C,64.58 H, 8.22,N, 9.11

[0468] Found: C, 64.42,; H, 8.54; N, 9.34,

Example 23

[0469] Preparation of2-Chloro-4-{N-[1-(S)-phenyl-2-(3-(S)-tetrahydropyran-2-yloxypyrrolidin-1-yl)ethyl]-N-methylamino}-N′-propylbenzamide

[0470] (i) Methyl2-chloro-4-{N-[1-(S)-phenyl-2-(3-(S)-tetrahydropyran-2-yloxypyrrolidin-1-yl-ethyl]-N-methylamino}benzoate

[0471] This was prepared from2-(R)-phenyl-2-(3-(S)-tetrahydropyran-2-yloxypyrrolidin-1-yl)ethanol and1-(S)-phenyl-2-(3-(S)-tetrahydropyran-2-yloxypyrrolidin-1-yl)ethanol andmethyl 2-chloro4-methylaminobenzoate in 40% yield according to aprocedure similar to that described in Example 1 (i).

[0472]¹H NMR (270 MHz, CDCl₃) δ7.86-7.80 (5H, m), 7.38-7.22 (5H, m),6.83-6.78 (1H, m), 6.72-6.65 (1H, m), 5.10 (1H, dd, J=6.6, 7.7 Hz),4.60-4.55 (0.6H, m), 4.50-4.45 (0.4H, m), 4.38-4.22 (1H, m), 3.86 (3H,s), 3.85-3.75 (1H, m), 3.50-3.37 (1H, m), 3.13-2.90 (3H, m), 2.85 (1.8H,s), 2.84 (1.2H, s), 2.80-2.50 (3H, m), 2.20-1.95 (1H, m), 1.95-1.40 (7H,m),

[0473] (ii)2-Chloro-4-{N-[1-(S)-phenyl-2-(3-(S)-tetrahydropyran-2-yloxypyrrolidin-1-yl)ethyl]-N-methylamino}benzoicacid

[0474] This was prepared from methyl2-chloro-4-{N-[1-(S)-phenyl-2-(3-(S)-tetrahydropyran-2-yloxypyrrolidin-1-yl)ethyl]-N-methylamino}benzoate in 100% yield according to a procedure similar to thatdescribed in Example 1 (ii).

[0475]¹H NMR (270 MHz, CDCl₃) δ7.86-7.75 (1H, m), 7.33-7.22 (5H, m),6.80-6.60 (2H, m), 5.20-5.10 (1H, m), 4.60-4.55 (0.6H, m), 4.50-4.45(0.4H, m), 4.38-4.22 (1H, m), 3.35-3.37 (3H, m), 3.20-3.00 (2H, m),2.80-2.50 (4H, m), 2.69 (3H, s), 2.20-1.95 (1H, m), 1.95-1.40 (7H, m),

[0476] (iii)2-Chloro-4-{N-[1-(S)-phenyl-2-(3-(S)-tetrahydropyran-2-yloxypyrrolidin-1-yl)-ethyl]-N-methylamino}-N′-propylbenzamide

[0477] This was prepared from2-chloro-4-{N-[2-(S)-phenyl-2-(3-(S)-tetrahydropyran-2-yloxypyrrolidin-1-yl)ethyl]-N-methylamino}benzoicacid and n-propylamine in 68% yield according to a procedure similar tothat described in Example 1 (iii).

[0478]¹H NMR (270 MHz, CDCl₃) δ7.78-7.72 (1H, m), 7.38-7.22 (5H, m),6.79-6.70 (2H, m), 6.60-6.48 (1H, m), 5.07 (1H, dd, J=6.6, 7.3 Hz),4.60-4.55 (0.6H, m), 4.50-4.45 (0.4H, m), 4.38-4.22 (1H, m), 3.90-3.75(1H, m), 3.50-3.37 (3H, m), 3.13-2.90 (2H, m), 2.82 (3H, s), 2.80-2.50(4H, m), 2.20-1.95 (1H, m), 1.95-1.40 (9H, m), 0.99 (3H, t, J=7.3 Hz).

Example 24

[0479] Preparation of2-Chloro-4-{N-[2-(3-(S)-hydroxylpyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-propylbenzamide

[0480] This was prepared from2-chloro4-{N-[1-(S)-phenyl-2-3-(S)-tetrahydropyran-2-yloxypyrrolidin-1-yl)-ethyl]-N-methylamino}-N′-propylbenzamidein 89% yield according to a procedure similar to that described inExample 2.

[0481]¹H NMR (270 MHz free amine, CDCl₃) δ7.76 (1H, d, J=8.8 Hz),7.40-7.20 (5H, m), 6.75 (1H, dd, J=2.6, 8.8 Hz), 6.72 (1H, d, J=2.6 Hz),6.54 (1H, br, s), 5.07 (1H, dd, J=5.9, 9.2 Hz), 4.30-4.20 (1H, m),3.46-3.35 (2H, m), 3.12 (1H, dd, J=9.2, 12.8 Hz), 3.01 (1H, dd, J=6.0,13.0 Hz), 2.95-2.78 (1H, m), 2.83 (3H, s), 2.72 (1H, d, J=9.9 Hz), 2.58(1H, dd, J=4.8, 9.5 Hz), 2.35 (1H, ddd, J=6.0, 8.9, 9.0 Hz), 2.18-2.00(1H, m), 1.90-1.50 (4H, m), 0.99 (3H, t, J=7.7 Hz)

[0482] HCl salt: amorphous solid.

[0483] 1 R(KBr) :3350, 1600 cm⁻¹.

[0484] Anal. Calcd for C₂₃H₃₀N₃O₂Cl.HCl.0.2H₂O. C, 60.58 H, 6.94; N,9.21

[0485] Found : C, 60.29; H, 7.13 ; N, 9.13.

Example 25

[0486] Preparation of2-Methoxy-4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-propylbenzamide

[0487] (i) Methyl2-methoxy-4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}benzoate

[0488] This was prepared from2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethanol and2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-2-(R)-phenylethanol and methyl2-methoxy-4-methylaminobenzoate in 41% yield according to a proceduresimilar to that described in Example 1 (i).

[0489]¹H NMR (270 MHz, CDCl₃) δ7.79 (1H, d, J=9.2 Hz), 7.36-7.20 (5H,m), 6.40 (1H, dd, J=2.4, 8.9 Hz), 6.27 (1H, d, J=2.6 Hz), 5.13 (1H, dd,J=7.0, 8.1 Hz), 4.60 (1H, d, J=7.0 Hz), 4.56 (1H, d, J=6.6 Hz),4.25-4.15 (1H, m), 3.86 (3H, s), 3.82 (3H, s), 3.30 (3H, s), 3.14-2.96(2H, m), 2.87 (3H, s), 2.90-2.80 (1H, m), 2.78-2.52 (3H, m), 2.14-1.96(1H, m), 1.84-1.70 (1H, m)

[0490] (ii)2-Methoxy-4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}benzoicacid

[0491] This was prepared from methyl2-methoxy-4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}benzoatein 100% yield according to a procedure similar to that described inExample 1 (ii).

[0492]¹H NMR (270 MHz, CDCl₃) δ7.98 (1H, d, J=8.8 Hz), 7.38-7.16 (5H,m), 6.54 (1H, dd, J=2.4, 9.0 Hz), 6.35-6.25 (1H, m), 5.20-5.05 (1H, m),4.60 (1H, d, J=7.0 Hz), 4.56 (1H, d, J=7.0 Hz), 4.25-4.15 (1H, m), 3.99(3H, s), 3.30 (3H, s), 3.14-3.05 (2H, m), 2.91 (3H, s), 2.90-2.52 (4H,m), 2.14-2.00 (1H, m), 1.90-1.70 (1H, m),

[0493] (iii)2-Methoxy-4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-propylbenzamide

[0494] This was prepared from2-methoxy-4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}benzoicacid and n-propylamine in 84% yield according to a procedure similar tothat described in Example 1 (iii).

[0495]¹H NMR (270 MHz, CDCl₃) δ8.07 (1H, d, J=8.8 Hz), 7.78-7.68 (1H,m),7.36-7.20 (5H, m), 6.51 (1H, dd, J=2.4, 9.0 Hz), 6.27 (1H, d, J=2.2Hz), 5.11 (1H, dd, J=5.6, 8.1Hz), 4.60 (1H, d, J=7.0 Hz), 4.56 (1H, d,J=6.6 Hz), 4.25-4.15 (1H, m), 3.89 (3H, s), 3.45-3.35 (2H, m), 3.30 (3H,s), 3.14-2.96 (2H, m), 2.86 (3H, s), 2.90-2.80 (1H, m), 2.78-2.52 (3H,m), 2.14-1.96 (1H, m), 1.84-1.70 (1H, m), 1.68-1.50 (2H, m), 0.97 (3H,t, J=7.3 Hz)

Example 26

[0496] Preparation of4-{N-[2-(3-(S)-Hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-2-methoxy-N′-propylbenzamide

[0497] This was prepared from2-methoxy-4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-propylbenzamidein 85% yield according to a procedure similar to that described inExample 2.

[0498]¹H NMR (270 MHz, free amine, CDCl₃) δ8.07 (1H, d, J=8.8 Hz),7.78-7.68 (1H, m), 7.38-7.22 (5H, m), 6.53 (1H, dd, J=2.2, 8.8 Hz), 6.27(1H, d, J=2.2 Hz), 5.13 (1H, dd, J=6.2, 8.4 Hz), 4.30-4.20 (1H, m), 3.89(3H, s),3.45-3.35 (2H, m), 3.20-3.00 (2H, m), 2.95-2.80 (1H, m), 2.85(3H, s), 2.74 (1H, d, J=9.5 Hz), 2.58 (1H, dd, J=4.8, 9.5 Hz), 2.40-2.27(1H, m), 2.18-2.02 (1H, m), 1.95-1.55 (4H, m), 0.97 (3H, J=7.3 Hz)

[0499] HCl said: amorphous solid.

[0500] 1 R(YBr)): 3400, 1600 cm⁻¹.

[0501] Anal. Calcd for C₂₄H₃₃N₃O₃.HCl.0.8CH₄O: C, 62.89; H, 7.92; N,8.87

[0502] Found: C, 63.16 ; H, 8.32; N, 9.20.

Example 27

[0503] Preparation of3-Methoxy-4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-propylbenzamide

[0504] (i) Methyl3-methoxy-4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl-)-(S)-phenylethyl]-N-methylamino}benzoate

[0505] This was prepared from2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethanol and2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-2-(R)-phenylethanol and methyl3-methoxy-4-methylaminobenzoate in 60% yield according to a proceduresimilar to that described in Example 1 (i). ¹H NMR (270 MHz, CDCl₃)δ7.58-7.53 (2H, m), 7.31-7.20 (5H, m), 6.71 (1H, d, J=8.4 Hz), 5.13 (1H,t, J=7.3 Hz), 4.59 (1H, d, J=7.0 Hz), 4.55 (1H, d, J=7.0 Hz), 4.15-4.05(1H,m), 3.95 (3H, s), 3.89 (3H, s), 3.30 (3H, s), 3.09 (2H, d, J=7.3Hz), 2.87 (1H, dd, J=6.2, 9.9 Hz), 2.60 (3H, s), 2.60-2.52 (2H, m), 2.47(1H, dd, J=4.0, 9.9 Hz), 2.08-1.92 (1H, m), 1.73-1.60 (1H, m)

[0506] (ii) 3-Methoxy-4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}benzoicacid

[0507] This was prepared from methyl3-methoxy4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}benzoatein 100% yield according to a procedure similar to that described inExample 1 (ii).

[0508]¹H NMR (270 MHz, CDCl₃) δ7.52-7.45 (2H, m), 7.32-7.12 (5H, m),6.65 (1H, d, J=8.4 Hz), 5.47 (1H, dd, J=6.6, 7.0 Hz), 4.64 (1H, d, J=7.0Hz), 4.60 (1H, d, J=6.6 Hz), 4.45-4.35 (1H, m), 4.02 (3H, s), 3.85-3.70(3H m), 3.68-3.57 (1H, m), 3.32 (3H, s), 3.30-3.05 (2H, m), 2.64 (3H,s), 2.40-2.23 (1H, m), 2.15-2.00 (1H, m)

[0509] (iii)3-Methoxy-4-{N-[2-3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-propylbenzamide

[0510] This was prepared from3-methoxy-4{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}benzoicacid and n-propylamine in 64% yield according to a procedure similar tothat described in Example 1 (iii).

[0511]¹H NMR (270 MHz, CDCl₃) δ7.45 (1H, d, J=1.8 Hz), 7.32-7.18 (5H,m), 7.11 (1H, dd, J=1.8, 8.4 Hz), 6.66 (1H, d, J=8.1 Hz), 6.15-4.05 (1H,m), 5.03 (1H, t, J=7.7 Hz), 4.59 (1H, d, J=7.0 Hz), 4.54 (1H, d, J=7.0Hz), 4.15-4.05 (1H, m), 3.96 (3H, s), 3.45-3.35 (2H, m), 3.30 (3H, s),3.08 (2H, d, J=7.7 Hz), 2.95-2.85 (1H, m), 2.65-2.50 (2H, m), 2.57 (3H,s), 2.46 (1H, dd, J=4.4, 9.9 Hz), 2.10-1.90 (1H, m), 1.75-1.55 (3H, m),0.99 (3H, t, J=7.3 Hz)

Example 28

[0512] Preparation of4-{N-[2-(3-(S)-Hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-3-methoxy-N′-propylbenzamide

[0513] This was prepared from3-methoxy-4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-propylbenzamidein 77% yield according to a procedure similar to that described inExample 2.

[0514]¹H NMR (270 MHz, free amine, CDCl₃) δ7.48 (1H, d, J=2.2 Hz),7.37-7.22 (5H, m) 7.12 (1H, dd, J=2.2, 8.4 Hz), 6.72 (1H, d, J=8.4 Hz),6.15-6.05 (1H, m), 5.16 (1H, dd, J=6.6, 8.8 Hz), 4.15-4.05 (1H, m), 3.97(3H, s), 3.45-3.35 (2H, m), 3.23 (2H, dd, J=8.8, 12.5 Hz), 2.99 (1H, dd,J=6.4, 12.3 Hz), 2.80-2.70 (1H, m), 2.59 (3H, s), 2.45 (1H, dd, J=4.4,9.9 Hz), 2.20-1.90 (2H, m), 1.75-1.40 (4H, m), 0.99 (3H, t, J=7.3 Hz)

[0515] HCl salt: amorphous solid.

[0516] 1 R(KBr): 3350, 1630 cm⁻¹.

Example 29

[0517] Preparation of3-chloro-4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-propylbenzamide

[0518] (i) 3-chloro-4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}benzonitrile

[0519] To a stirred solution of the mixture of2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethanol and2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-2-(R)-phenylethanol (251 mg,1.00 mmol) and triethylamine (0.167 ml, 1.20 mmol) in CH₂Cl₂ (4 ml) wasadded methanesulfonyl chloride (0.093 ml, 1.20 mmol) dropwise at 0° C.(ice bath). After 15.5 h stirring at room temperature, the reactionmixture was washed with saturated NaHCO₃ aqueous solution, brine, dried(Na₂SO₄), and concentrated to give 238 mg of brown viscous oil-(i). To asuspension of NaH (48 mg, 1.20 mmol) in N,N-dimethylformamide (2 ml) wasadded a solution of 3-chloro-4-methylaminobenzonitrile (200 mg, 1.20mmol) at room temperature. After stirring for 45 min, to this mixturewas added a solution of the above brown viscous oil-(i) inN,N-dimethylformamide (2 ml) at room temperature and the mixture wasstirred at room temperature for 4.5 h. H₂O was added to this mixture,basified with 25%-NH₄OH and extracted with CH₂Cl₂. The extract waswashed with water, brine, dried (Na₂SO₄), and concentrated to give brownoil, which was purified by column chromatography (silica gel 20 g,CH₂Cl₂/MeOH 100/1-50/1) to afford 244 mg (61%) of brown oil.

[0520]¹H NMR (270 MHz, CDCl₃) δ7.61 (1H, d, J=2.2 Hz), 7.43-7.25 (6H,m), 6.98 (1H, d, J=8.4 Hz), 5.03 (1H, dd, J=7.3, 7.7 Hz), 4.58 (1H, d,J=6.6 Hz), 4.54 (1H, d, J=6.6 Hz), 4.10-3.97 (1H, m), 3.31 (3H, s), 3.10(2H, dd, J=1.5, 7.7 Hz), 2.75-2.65 (1H, m), 2.69 (3H, s), 2.55-2.43 (3H,m), 2.03-1.85 (1H, m), 1.70-1.60 (1H, m)

[0521] (ii)3-Chloro-4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-propylbenzamide

[0522] To a suspension of t-BuOK (381 mg, 3.05 mmol) and H₂O (0.055 ml,3.05 mmol) in t-BuOH (1.0 ml) was added a solution of3-chloro-4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}benzonitrile(244 mg, 0.611 mmol) in t-BuOH (1.0 ml) at room temperature. Afterrefluxing for 0.5 h, the mixture was allowed to cool to roomtemperature. n-Propyliodide (0.298 ml, 3.05 mmol) was added to themixture, and the mixture was refluxed for 3 h. After cooling down toroom temperature, the solvent was evaporated. The residue was dissolvedin CH₂Cl₂ and washed with water and brine, dried (Na₂SO₄), andconcentrated to give pale brown oil, which was purified by columnchromatography (silice gel, 15 g, CH₂Cl₂/MeOH: 80/1-50/1) to give 206 mg(73%) of ivory amorphous.

[0523]¹H NMR (270 MHz, CDCl₃) δ7.77 (1H, d, J=2.2 Hz), 7.52 (1H, dd,J=2.2, 8.4 Hz). 7.36-7.20 (5H, m), 6.92 (1H, d, J=8.4 Hz), 6.15-6.00(1H,m), 4.91 (1H, dd, J=7.3 7.7 Hz), 4.57 (1H, d, J=7.0 Hz), 4.53 (1H,d, J=7.0 Hz), 4.10-3.98 (1H, m), 3.45-3.35 (2H, m), 3.29 (3H, s), 3.14(1H, dd, J=7.7, 12.5 Hz), 3.05 (1H, dd, J=7.3, 12.5 Hz), 2.73 (1H, dd,J=6.2, 9.9 Hz), 2.64 (3H, s), 2.55-2.43 (3H, m), 2.01-1.88 (1H, m),1.75-1.55 (3H, m), 0.96 (3H, t, J=7.3 Hz)

Example 30

[0524] Preparation of3-Chloro-4-{N-[2-(3-(S)-Hydroxpyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-propylbenzamide

[0525] This was prepared from3-chloro-4-{-[2-(3-S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-propylbenzamidein 96% yield according to a procedure similar to that described inExample 2.

[0526]¹H NMR (270 MHz, free amine, CDCl₃) δ7.81 (1H, d, J=2.2 Hz), 7.51(1H, dd, J=2.2, 8.4 Hz), 7.42-7.22 (5H, m), 6.93 (1H, d, J=8.4 Hz),6.15-6.00 (1H, m), 4.99 (1H, dd, J=7.3, 7.9 Hz), 4.20-4.05 (1H, m),3.45-3.35 (2H, m), 3.16 (1H, dd, J=7.7, 12.5 Hz), 3.08 (1H, dd, J=7.3,12.5 Hz), 2.75-2.60 (2H, m), 2.65 (3H, s), 2.41 (1H, dd, J=4.4, 9.5 Hz),2.25-2.15 (1H, m), 2.08-1.93 (1H, m), 1.90-1.40 (4H, m), 0.99 (3H, t,J=7.3 Hz)

[0527] Fumaric acid salt: amorphous solid.

[0528] 1 R(KBr): 3350, 1630 cm⁻¹.

[0529] MS m/z: 416, 418 (M+H)⁺.

[0530] Anal. Calcd for C₂₃H₃₀N₃O₂Cl.C₄H₄O.H₂O: C, 58.96; H, 6.60; N,7.64

[0531] Found: C, 59.35, H,6.64; N, 7.55.

Example 31

[0532] Preparation of6-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-propylnicotinamide

[0533] (i) Methyl6-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}nicotinate

[0534] This was prepared from2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethanol and2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-2-(R)-phenylethanol and methyl6-methylaminonicotinate in 60% yield according to a procedure similar tothat described in Example 29 (i).

[0535]¹H NMR (270 MHz, CDCl₃) δ8.83 (1H, d, J=2.2 Hz), 8.01 (1H, dd,J=2.2, 9.2 Hz), 7.35-7.20 (5H, m), 6.48 (1H, d, J=9.2 Hz), 6.44-6.32(1H, m), 4.59 (1H, d, J=7.0 Hz),. 4.56 (1H, d, J=6.6 Hz), 4.22-4.12 (1H,m), 3.86 (3H, s), 3.30 (3H, s), 3.17-2.92 (3H, m), 2.83 (3H, s),2.80-2.70 (1H, m), 2.65-2.50 (2H, m), 2.12-1.95 (1H, m), 1.80-1.65 (1H,m),

[0536] (ii)6-{N-[2-(3-(S)-Methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}nicotinicacid

[0537] This was prepared from methyl6-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}nicotinatein 100% yield according to a procedure similar to that described inExample 1 (ii).

[0538]¹H NMR (270 MHz, CDCl₃) δ8.80-8.75 (1H, m), 7.95-7.87 (1H, m),7.35-7.15 (5H, m), 6.57 (1H, br, s), 6.42 (1H, d, J=9.2 Hz), 4.62 (1H,d, J=6.6 Hz), 4.59 (1H, d, J=7.0 Hz), 4.35-4.00 (2H, m), 3.50-3.25 (2H,m), 3.32 (3H, s), 3.18-3.08 (1H, m), 3.02-2.70 (3H, m), 2.79 (3H, s),2.20-2.05 (1H, m), 1.90-1.80 (1H, m),

[0539] (iii) 6-{N-[2-(3-(S)-Methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-propylnicotinamide

[0540] This was prepared from6-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}nicotinicacid and n-propylamine in 65% yield according to a procedure similar tothat described in Example 1 (iii).

[0541]¹H NMR (270 MHz, CDCl₃) δ8.57 (1H, d, J=2.6 Hz), 7.89 (1H, dd,J=2.6, 9.2 Hz), 7.35-7.20 (5H, m), 6.50 (1H, d, J=9.2 Hz), 6.40-6.35(1H, m), 6.00-5.90 (1H m), 4.59 (1H, d, J=7.0 Hz), 4.56 (1H, d, J=7.0Hz), 4.20-4.10 (1H, m), 3.45-3.35 (2H, m), 3.30 (3H, s), 3.17-2.92 (3H,m), 2.82 (3H, s) 2.80-2.70 (1H, m), 2.65-2.50 (2H, m), 2.12-1.95 (1H,m), 1.80-1.55 (3H, m), 0.99 (3H, t, J=7.3 Hz).

Example 32

[0542] Preparation of6-{N-[2-(3-(S)-Hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-propylnicotinamide

[0543] This was prepared from6-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-propylnicotinamidein 73% yield according to a procedure similar to that described inExample 2.

[0544]¹H NMR (270 MHz, free amine, CDCl₃) δ8.58 (1H, d, J=2.6 Hz), 7.89(1H, dd, J=2.6, 8.8 Hz), 7.35-7.20 (5H, m), 6.50 (1H, d, J=9.5 Hz), 6.36(1H, dd, J=5.9, 9.9 Hz), 6.00-5.92 (1H, m), 4.25-4.15 (1H, m), 3.45-3.35(2H, m), 3.17 (1H, dd, J=9.9, 12.5 Hz), 3.05-2.95 (2H, m), 2.81 (3H, s),2.72 (1H, d, J=9.5 Hz), 2.62 (1H, dd, J=4.8, 9.9 Hz), 2.40-2.25 (1H, m),2.17-2.02 (1H, m), 1.95-1.75 (2H, m), 1.70-1.55 (2H, m), 0.98 (3H, t,J=7.3 Hz).

[0545] Fumaric acid salt: amorphous solid.

[0546] 1 R(KBr): 3350, 1630 cm⁻¹.

[0547] MS m/z: 383(M+H)⁺.

[0548] Anal. Calcd for C₂₂H₃₀N₄O₂.C₄H₄O₄.1.5H₂O: C, 59.42; H, 7.10; N,10.66

[0549] Found: C, 59.50; H, 7.43; N, 10.73.

Example 33

[0550] Preparation of4-{N-[1-(S)-(3-Methoxymethoxyphenyl)-2-(3-(S)-Methoxymethoxypyrrolidin-1-yl)-ethyl]-N-methylamino}-N′-propylbenzamide

[0551] (i) Methyl4-{N-[1-(S)-(3-methoxymethoxyphenyl)-2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-ethyl]-N-methylamino}benzoate

[0552] This was prepared from the mixture of2-(R)-(3-methoxymethoxyphenyl)-2-(3-(S)-methoxymethoxypyrrolidin-1-yl)ethanoland1-(S)-(3-methoxymethoxyphenyl)-2-(3-(S)-methoxymethoxypyrrolidin-1-yl)ethanoland methyl 4-methylaminobenzoate in 60% yield according to a proceduresimilar to that described in Example 1 (i).

[0553]¹H NMR (270 MHz, CDCl₃) δ7.89 (2H, d, J=9.2 Hz), 7.27-7.19 (1H,m), 6.98-6.88 (3H, m), 6.77 (2H, d, J=9.2 Hz), 5.14 (2H, s), 5.14-5.08(1H, m), 4.59 (1H, d, J= 6.6 Hz), 4.55 (1H, d, J=7.0 Hz), 4.22-4.12 (1H,m), 3.85 (3H, s), 3.46 (3H, s), 3.30 (3H, s), 3.04 (2H, d, J=8.1 Hz),2.88 (3H, s), 2.85-2.53 (4H, m), 2.10-1.98 (1H, m), 1.83-1.70 (1H, m),

[0554] (ii)4-{N-[1-(S)-(3-Methoxymethoxyphenyl)-2-(3-(S)-methoxymethoxypyrrolidine-1-yl)-ethyl]-N-methylamino}benzoicacid

[0555] This was prepared from methyl4-{N-[1-(S)-(3-methoxymethoxyphenyl)-2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-ethyl]-N-methylamino}benzoatein 100% yield according to a procedure similar to that described inExample 1 (ii).

[0556]¹H NMR (270 MHz, CDCl₃) δ7.88 (2H, d, J=8.8 Hz), 7.30-7.12 (1H,m), 6.98-6.34 (3H, m), 6.68 (2H, d, J=8.8 Hz), 5.15-5.05 (1H, m), 5.10(2H, s), 4.55 (1H, d, J=6.6 Hz), 4.51 (1H, d, J=7.0 Hz), 4.18-4.08 (1H,m), 3.42 (3H, s), 3.25 (3H, s), 3.10-2.92 (2H, m), 2.85 (1H, dd, J=6.4,9.9 Hz), 2.74 (3H, s), 2.70-2.53 (3H, m), 2.10-1.93 (1H, m), 1.80-1.65(1H, m),

[0557] (iii) 4-{N-[1-(S)-(3-Methoxymethoxyphenyl)-2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-ethyl]-N-methylamino}-N′-propylbenzamide

[0558] This was prepared from4-{N-[1-(S)-(3-methoxymethoxyphenyl)-2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-ethyl]-N-methylamino}benzoicacid and n-propylamine in 80% yield according to a procedure similar tothat described in Example 1 (iii).

[0559]¹H NMR (270 MHz, CDCl₃) δ7.65 (2H, d, J=9.2 Hz), 7.28-7.18 (1H,m), 6.98-6.88 (3H, m), 6.76 (2H, d, J=8.8 Hz), 6.05-5.90 (1H, m), 5.14(2H, s), 5.08 (1H, dd, J=7.0, 7.7 Hz), 4.59 (1H, d, J=6.6 Hz), 4.55 (1H,d, J=7.0 Hz), 4.22-4.12 (1H, m), 3.46 (3H, s), 3.45-3.35 (2H, m), 3.30(3H, s), 3.03 (2H, d, J=7.7 Hz), 2.86 (3H, s), 2.85-2.80 (1H, m),2.75-2.50 (3H, m), 2.12-1.95 (1H, m), 1.85-1.52 (3H, m), 0.97 (3H, t,J=7.3 Hz)

Example 34

[0560] Preparation of4-{N-[1-(S)-(3-Hydroxyphenyl)-2-(3-(S)-hydroxypyrrolidin-1-yl)-ethyl]-N-methylamino}-N′-propylbenzamide

[0561] This was prepared from4-{N-[1-(S)-(3-methoxymethoxyphenyl)-2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-ethyl]-N-methylamino}-N′-propylbenzamidein 97% yield according to a procedure similar to that described inExample 2.

[0562]¹H NMR (270 MHz, free amine, CDCl₃-DMSO-d6) δ8.85 (1H, br, s),7.69 (2H, d, J=9.2 Hz), 7.11 (1H, t, J=7.7 Hz), 6.98-6.90 (1H, m),6.82-6.68 (5H, m), 5.06 (1H, dd, J=6.2, 8.4 Hz), 4.30-4.18 (1H, m), 3.67(1H, br, s), 3.40-3.30 (2H, m), 3.15-2.95 (2H, m), 2.86 (3H, s),2.85-2.67 (2H, m), 2.63-2.56 (1H, m), 2.55-2.43 (1H, m), 2.15-1.98 (1H,m), 1.70-1.52 (3H, m), 0.96 (3H, t, J=7.3 Hz).

[0563] HCl salt: amorphous solid.

[0564] 1 R(KBr): 3350, 1610 cm⁻¹

[0565] MS m/z: 397 (M⁺).

[0566] Anal. Calcd for C₂₃H₃₁N₃O₃.HCl.2.3H₂O C, 58.11 , H, 7.76, N, 8.84

[0567] Found : C,57.82 , H,8.06; N, 9.24

Example 35

[0568] Preparation of4-{N-[2-(3-(S)-Hydroxypyrrolidin-1-yl)-1-(S)-(3-methoxyphenyl)-ethyl]-N-methylamino}-N′-propylbenzamide

[0569] To a solution of4-{N-[1-(S)-(3-hydroxyphenyl)-2-(3-(S)-hydroxypyrrolidin-1-yl)-ethyl]-N-methylamino}-N′-propylbenzamide(100 mg, 0.252 mmol) in MeOH (0.1 ml)-CH₃CN (0.9 ml) was addedN,N-diisopropylethylamine (0.0641 ml, 0.353 mmol) and10%-trimethylsilyl-diazomethane in CH₂Cl₂ (0.6 ml) at room temperature.After stirring for 22 h at room temperature, 25%-NH₄OH was added to themixture and extracted with CH₂Cl₂. The extract was washed with brine,dried (Na₂SO₄) and concentrated to give brown oil, which was purified bycolumn chromato-graphy (silica gel 5 g, CH₂Cl_(2/)MeOH: 30/1-10/1) toafford 55.2 mg (53%) of white amorphous.

[0570]¹H NMR (270 MHz, free amine, CDCl₃) δ7.65 (2H, d, J=8.8 Hz), 7.24(1H, t, J=7.7 Hz) 6.90-6.77 (5H, m), 6.05-5.90 (1H, m), 5.10 (1H, dd,J=5.9, 8.8 Hz), 4.25-4.18 (1H, m) 3.77 (3H, s), 3.45-3.35 (2H, m), 3.11(1H, dd, J=9.2, 12.8 Hz), 3.01 (1H, dd, J=5.9, 12.8 Hz), 2.95-2.80 (1H,m), 2.84 (3H, s), 2.72 (1H, d, J=9.5 Hz), 2.56 (1H, dd, J=4.8, 9.5 Hz),2.38-2.25 (1H, m), 2.16-2.00 (1H, m), 1.85-1.55 (4H, m), 0.97 (3H, t,J=7.7 Hz).

[0571] HCl said: amorphous solid.

[0572] 1 R(neat, free amine): 3350, 1610 cm⁻¹.

[0573] MS m/z: 412 (M+H)⁺.

[0574] Anal. Calcd for C₂₄H₃₃N₃O ₃.HCl.0.5H₂O C, 63.08 , H, 7.72, N,9.19

[0575] Found :C,62.89 ; H,7.77 ;N, 9.25.

Example 36

[0576] Preparation of4-{N-[1-(S)-(3-t-Butoxycarbonylmethoxyphenyl)-2-(3-(S)-hydroxypyrrolidin-1-yl)-ethyl]-N-methylamino}-N′-propylbenzamide

[0577] A mixture of4-{N-[1-(S)-(3-hydroxyphenyl)-2-(3-(S)-hydroxypyrrolidin-1-yl)-ethyl]-N-methylamino}-N′-propylbenzamide(100 mg, 0.252 mmol), t-butyl bromoacetate (0.0409 ml, 0.277 mmol) andK₂CO₃ (38.3 mg, 0.277 mmol) in DMF (1.5 ml) was stirred at roomtemperature for 2 h. H₂O was added to the mixture and extracted withAcOEt/toluene=2/1. The extract was washed with water, brine, dried(Na₂SO₄) and concentrated to give pale brown amorphous, which waspurified by column chromato-graphy (silica gel 6 g, CH₂Cl₂/MeOH:30/1-10/1) to afford 80.1 mg (62%) of white amorphous.

[0578]¹H NMR (270 MHz, CDCl₃) δ7.65 (2H, d, J=9.2 Hz), 7.23 (1H, t,J=7.7Hz), 6.94-6.86 (2H, m), 6.82-6.72 (3H, m), 6.05-5.90 (1H, m), 5.09(1H, dd, J=6.2, 8.8 Hz), 4.48 (2H, s), 4.25-4.18 (1H, m), 3.45-3.35 (2H,m), 3.09 (1H, dd, J=9.2, 12.8 Hz), 3.00 (1H, dd, J=5.9, 12.8 Hz),2.95-2.80 (1H, m), 2.83 (3H, s), 2.71 (1H d, J=9.5 Hz), 2.54 (1H, dd,J=4.8, 9.5 Hz), 2.38-2.25 (1H, m), 2.16-2.00 (1H, m), 1.85-1.50 (4H, m),1.46 (9H, s), 0.98 (3H, t, J=7.3 Hz).

[0579] Example 37

[0580] Preparation of4-{N-[1-(S)-(3-Carboxymethoxyphenyl)-2-(3-(S)-Hydroxpyrrolidin-1-yl)-ethyl-N]-methylamino}-N′-propylbenzamide

[0581] A solution of4-{N-[1-(S-(3-t-butoxycarbonylmethoxyphenyl)-2-(3-(S)-hydroxypyrrolidin-1-yl)-ethyl]-N-methylamino}-N′-propylbenzamide(80.1 mg, 0.157 mmol) in trifluoroacetic acid (1 ml) and CH₂Cl₂ (0.5 ml)was stirred at room temperature for 1.5 h. The solvent was evaporated.The residue was dissolved in CH₂Cl₂ and 1.0 M hydrogen chloride solutionin diethyl ether (1 ml) was added. The white powder was collected andwashed with Et₂O and dried under reduced pressure for 6.5 h at 45° C. toafford 86.2 mg (quant) of white powder.

[0582] HCl salt: white powder.

[0583]¹H NMR (270 MHz, CDCl₃-DMSO-d6) δ12.49 (1H, br, s), 7.79 (2H, d,J=8.4 Hz), 7.42 (1H, br, s), 7.23 (1H, t, J=7.7 Hz), 7.07 (2H, d, J=8.4Hz), 6.85-6.76 (3H, m), 5.95-5.80 (1H, m), 4.53 (2H, s), 4.50-4.40 (1H,m), 4.00-3.70 (4H, m), 3.50-2.50 (3H, m), 2.80 (3H, s), 2.50-2.00 (2H,m), 1.75-1.55 (4H, m), 0.96 (3H, t, J=7.3 Hz).

[0584] 1 R(KBr): 3400, 1730, 1610 cm⁻¹.

[0585] MS m/z: 456 (M+H)⁺.

[0586] mp. 108-110° C.

[0587] Anal. Calcd for C₂₅H₃₃N₃O₅.HCl.3.5H₂O C, 54.10; H, 7.45; N, 7.57

[0588] Found: C, 54.07 ; H, 749 ; N, 7.39

Example 38

[0589] Preparation of4-{N-[1-(S)-Phenyl-2-(pyrrolidin-1-yl)ethyl]-N-methylamino}-N′-propylbenzamide

[0590] (i) Methyl4-{N-[1-(S)-phenyl-2-(pyrrolidin-1-yl)ethyl]-N-methylamino}benzoate

[0591] This was prepared from the mixture of2-(R)-phenyl-2-(pyrrolidin-1-yl)ethanol and1-(S)-phenyl-2-(pyrrolidin-1-yl)ethanol and methyl 4-methylaminobenzoatein 52% yield according to a procedure similar to that described inExample 1 (i).

[0592]¹H NMR (270 MHz, CDCl₃) δ7.88 (2H, d, J=9.2 Hz), 7.38-7.20 (5H,m), 6.78 (2H, d, J=9.2 Hz), 5.17 (1H, t, J=7.3 Hz), 3.84 (3H, s), 3.04(2H, d, J=7.3 Hz), 2.86 (3H s), 2.65-2.45 (4H, m), 1.80-1.65 (4H, m)

[0593] (ii)4-{N-[1-(S)-Phenyl-2-(pyrrolidin-1-yl)ethyl]-N-methylamino}benzoic acid

[0594] This was prepared from methyl4-{N-[1-(S)-phenyl-2-(pyrrolidin-1-yl),ethyl]-N-methylamino}benzoate in100% yield according to a procedure similar to that described in Example1 (ii).

[0595]¹H NMR (270 MHz, CDCl₃-DMSO-d6) δ7.92 (2H, d, J=8.8 Hz), 7.38-7.20(5H, m), 7.02 (2H, d, J=8.8 Hz), 5.80 (1H, br, s), 4.00-3.00 (7H, m),2.85 (3H, s), 2.20-1.90 (4H, m)

[0596] (iii)4-{N-[1-(S)-Phenyl-2-(pyrrolidin-1-yl)ethyl]-N-methylamino}-N′-propylbenzamide

[0597] This was prepared from4-{N-[1-(S)-phenyl-2-(pyrrolidin-1-yl)ethyl]-N-methylamino}benzoic acidand n-propylamine in 56% yield according to a procedure similar to thatdescribed in Example 1 (iii).

[0598]¹H NMR (270 MHz, free amine CDCl₃) δ7.65 (2H, d, J=8.8 Hz),7.36-7.20 (5H, m), 6.79 (2H, d, J=8.8 Hz), 6.05-5.90 (1H, m), 5.14 (1H,t, J=7.0 Hz), 3.45-3.35 (2H, m), 3.04 (2H, d, J=7.0 Hz), 2.84 (3H, s),2.65-2.45 (4H, m), 1.75-1.50 (6H, m), 0.97 (3H, t, J=7.3 Hz).

[0599] HCl salt: amorphous solid.

[0600] 1 R(KBr) : 1610 cm⁻¹.

[0601] MS m/z: 366 (M+H)⁺.

[0602] Anal. Calcd for C₂₃H₃₁N₃O.HCl.0.5H₂O: C, 67.22; H, 8.09; N,10.22

[0603] Found: C, 67 48; H, 3.37; N, 10.32.

Example 39

[0604] Preparation of4-{N-[2-(3-(S)-Hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-propylphthalimide

[0605] This was prepared from2-(R)-phenyl-2-(3-(S)-tetrahydropyran-2-yloxypyrrolidin-1-yl)ethanol and1-(S)-phenyl-2-(3-(S)-tetrahydropyran-2-yloxypyrrolidin-1-yl)ethanol and4-methylamino-N′-propylphthalimide in 16% over all yield according to aprocedure similar to that described in Example 1 (i) and 2.

[0606]¹H NMR (270 MHz, free amine, CDCl₃) δ7.63 (1H, d, J=8.4 Hz),7.38-7.22 (6H, m), 6.94 (1H, dd, J=2.6, 8.4 Hz), 5.19 (1H, dd, J=5.9,9.5 Hz), 4.30-4.20 (1H, m), 3.59 (2H, t, J=7.3 Hz), 3.18 (1H, dd, J=9.5,13.2 Hz), 3.03 (1H, dd, J=5.5, 12.8 Hz), 2.95 (3H, s), 2.95-2.85 (1H,m), 2.71 (1H, d, J=9.2 Hz), 2.61 (1H, dd, J=4.8, 9.5 Hz), 2.37 (1H, ddd,J=5.9, 8.8, 8.8 Hz), 2.20-2.05 (1H, m), 1.75-1.60 (4 H, m), 0.93 (3H, t,J=7.3 Hz)

[0607] HCl salt: amorphous solid.

[0608] 1 R(KBr) : 3400, 1760, 1700, 1620 cm¹.

[0609] Anal. Calcd for C₂₄H₂₉N₃O₃.HCl.0.5H₂O: C, 63.64; H,6.90; N, 9.28

[0610] Found: C,63.99; H, 7.18, N, 9.00.

Example 40

[0611] Preparation of5-{N-[2-(3-(S)-Methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-propyl-2-thiophenecarboxamide

[0612] This was prepared from2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethanol and2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-2-(R)-phenylethanol and5-methylamino-N′-propyl-2-thiophenecarboxamide in 49% yield according toa procedure similar to that described in Example 1 (i)

[0613]¹H NMR (270 MHz, CDCl₃) δ7.35-7.25 (5H, m), 7.18 (1H, d, J=4.4Hz), 5.83 (1H, d, J=4.0 Hz), 5.68-5.60 (1H, m), 4.86 (1H, dd, J=7.0, 7.7Hz), 4.62 (1H, d, J=7.0 Hz), 4.53 (1H, d, J=7.0 Hz), 4.25-4.15 (1H, m),3.40-3.30 (2H, m), 3.32 (3H, s), 3.13-3.00 (2H, m), 2.94 (1H, dd, J=6.2,9.9 Hz), 2.83 (3H, s), 2.80-2.70 (1H, m), 2.67-2.55 (2H, m), 2.15-2.00(1H, m), 1.87-1.73 (1H, m), 1.70-i.50 (2H, m), 0.95 (3H, t, J=7.7 Hz)

Example 41

[0614] Preparation of5-{N-[2-(3-(S)-Hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-propyl-2-thiophenecarboxamide

[0615] This was prepared from5-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-propyl-2-thiophenecarboxamidein 78% yield according to a procedure similar to that described inExample 2.

[0616]¹H NMR (270 MHz, free amine, CDCl₃) δ7.38-7.24 (5H, m), 7.18 (1H,d, J=4.0 Hz), 5.84 (1H, d, J=4.4 Hz), 5.70-5.60 (1H, m), 4.88 (1H, dd,J=6.0, 9.0 Hz), 4.30-4.22 (1H, m), 3.40-3.30 (2H, m), 3.15 (1H, dd,J=9.2, 12.8 Hz), 3.07-2.95 (2H, m), 2.81 (3H, s) 2.75 (1H, d, J=9.5 Hz),2.63 (1H, dd, J=4.8, 9.5 Hz), 2.42-2.30 (1H, m), 2.22-2.05 (1H, m),1.80-1.50 (4H, m), 0.96 (3H, t, J=7.7 Hz).

[0617] Fumaric acid salt: amorphous solid.

[0618] 1 R(KBr): 3300, 1610 cm⁻¹.

[0619] MS m/z=388 (M+H)⁺

[0620] Anal. Calcd for C21H29N₃O₂S.C₄H₄O₄.0.5H₂O: C, 57.34; H, 7.03; N,7.71

[0621] Found C,57.37; H,7.31 N, 7.79

Example 42

[0622] Preparation of4-{N-[2-3-(S)-Methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]amino}-N′-propylbenzamide

[0623] (i) Methyl4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]amino}benzoate

[0624] This was prepared from2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethanol and2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-2-(R)-phenylethanol and methyl4-aminobenzoate in 69% yield according to a procedure similar to thatdescribed in Example 1 (i).

[0625]¹H NMR (270 MHz, CDCl₃) δ7.75 (2H, d, J=8.8 Hz), 7.37-7.27 (5H,m), 6.47 (2H, d, J=8.8 Hz), 5.56 (1H, br, s), 4.65 (1H d, J=6.6 Hz),4.61 (1H, d, J=7.0 Hz), 4.35-4.28 (1H, m), 4.26-4.23 (1H, m), 3.80 (3H,s), 3.36 (3H, s), 2.90-2.76 (3H, m), 2.62-2.51 (2H, m), 2.48-2.42 (1H,m), 2.18-2.10 (1H, m), 1.84-1.82 (1H, m)

[0626] (ii)4-{N-[2-(3-(S)-Methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]amino}benzoicacid

[0627] This was prepared from methyl4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]amino}benzoatein 100% yield according to a procedure similar to that described inExample 1 (ii).

[0628]¹H NMR (270 MHz, CDCl₃) δ7.72 (2H, d, J=8.4 Hz), 7.36-7.23 (5H,m), 6.42 (2H, d, J=8.4 Hz), 5.80 (1H, br, s), 4.69-4.65 (1H, m), 4.63(1H, d, J=7.0 Hz), 4.60 (1H, d, J=7.0 Hz), 4.39-4.37 (1H, m), 4.32-4.22(1H,m), 3.34 (3H, s), 3.00-2.82 (3H, m), 2.66-2.48 (3H, m), 2.17-2.10(1H, m), 1.95-1.78 (1H, m)

[0629] (iii)4-{N-[2-(3-(S)-Methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]amino}-N′-propylbenzamide

[0630] This was prepared from4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]amino}benzoicacid and n-propylamine in 62% yield according to a procedure similar tothat described in Example 1 (iii).

[0631]¹H NMR (270 MHz, CDCl₃) δ7.49 (2H, d, J=8.5 Hz), 7.38-7.24 (5H,m), 6.48 (2H, d, J=8.8 Hz), 5.95-5.80 (1H, m), 5.46 (1H, br, s), 4.65(1H, d, J=7.0 Hz), 4.61 (1H, d, J=7.0 Hz), 4.32-4.23 (2H, m), 3.36 (3H,s), 3.38-3.31 (2H, m), 2.90-2.76 (3H, m), 2.59 (1H, dd, J=3.9, 10.8 Hz),2.53-2.42 (2H, m), 2.18-2.11 (1H, m), 1.83-1.82 (1H, m), 1.60-1.50 (2H,m), 0.93 (3H, t, J=7.3 Hz).

Example 43

[0632] Preparation of4-{N-[2-(3-(S)-Hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]amino}-N′-propylbenzamide

[0633] This was prepared from4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]amino}-N′-propylbenzamidein 67% yield according to a procedure similar to that described inExample 2.

[0634]¹H NMR (270 MHz free amine, CDCl₃) δ7.50 (2H, d, J=8.8 Hz),7.38-7.22 (5H, m), 6.48 (2H, d, J=8.8 Hz), 5.95-5.80 (1H, m), 5.39 (1H,br, s), 4.39-4.29 (2H, m), 3.40-3.28 (2H, m), 2.99-2.84 (2H, m),2.73-2.53 (3H, m), 2.40-2.31 (1H, m), 2.26-2.13 (1H, m), 1.90-1.67 (2H,m), 1.65-1.50 (2H, m), 0.94 (3H, t, J=7.3 Hz).

[0635] HCl salt: amorphous solid.

[0636] 1 R(KBr): 3350, 1610 cm⁻¹.

[0637] Anal. Calcd for C₂₂H₂₉N₃O₂.HCl.1.1H₂O : C, 62.44; H, 8.05; N,9.72

[0638] Found: C,62.36; H,7.66; N, 9.92.

Example 44

[0639] Preparation of4-{N-[1-(S)-(3-Chlorophenyl)-2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-ethyl]-N-methylamino}-N′-propylbenzamide

[0640] (i) Methyl4-{N-[1-(S)-(3-chlorophenyl)-2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-ethyl]-N-methylamino}benzoate

[0641] This was prepared from the mixture of2-(R)-(3-chlorophenyl)-2-(3-(S)-methoxymethoxypyrrolidin-1-yl)ethanoland1-(S)-(3-chlorophenyl)-2-(3-(S)-methoxymethoxypyrrolidin-1-yl)ethanoland methyl 4-methylaminobenzoate in 66% yield according to a proceduresimilar to that described in Example 1 (i):

[0642]¹H NMR (270 MHz, CDCl₃) δ7.90 (2H, d, J=8.8 Hz), 7.30-7.14 (4H,m), 6.77 (2H, d, J=9.2 Hz), 5.11 (1H, dd, J=7.0, 7.7 Hz), 4.60 (1H, d,J=7.0 Hz), 4.55 (1H, d, J=7.0 Hz), 4.22-4.13 (1H, m), 3.86 (3H, s), 3.30(3H, s), 3.12-2.94 (2H, m), 2.90-2.78 (1H, m), 2.87 (3H, s), 2.76-2.52(3H, m), 2.15-1.98 (1H, m), 1.85-1.70 (1H m),

[0643] (ii)4-{N-[1-(S)-(3-Chlorophenyl)-2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-ethyl]-N-methylamino}benzoicacid

[0644] This was prepared from methyl4-{N-[1-(S)-3-chlorophenyl)-2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-ethyl]-N-methylamino}benzoatein 96% yield according to a procedure similar to that described inExample 1 (ii).

[0645]¹H NMR (270 MHz CDCl₃) δ7.93 (2H, d, J=9.2 Hz), 7.32-7.10 (4H, m),6.82 (2H, d, J=9.2 Hz), 5.40-5.25 (1H, m), 4.62 (1H, d, J=7.0 Hz), 4.58(1H, d, J=7.0 Hz), 4.30-4.18 (1H, m), 3.40-3.00 (3H, m), 3.31 (3H, s),2.95-2.65(3H, m), 2.88 (3H, s), 2.20-2.00 (1H, m), 1.95-1.80 (1H, m),

[0646] (iii) 4-{N-[1-(S)-(3-Chlorophenyl)-2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-ethyl]-N-methylamino}-N′-propylbenzamide

[0647] This was prepared from4-{N-[1-(S)-(3-chlorophenyl)-2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-ethyl]-N-methylamino}benzoicacid and n-propylamine in 77% yield according to a procedure similar tothat described in Example 1 (iii).

[0648]¹H NMR (270 MHz, CDCl₃) δ7.66 (2H, d, J=9.2 Hz), 7.30-7.13 (4H,m), 6.78 (2H, d, J=9.2 Hz), 6.02-5.92 (1H, m), 5.07 (1H, dd, J=6.6, 7.7Hz), 4.60 (1H, d, J=7.0 Hz), 4.55 (1H, d, J=7.0 Hz), 4.25-4.12 (1H, m),3.45-3.35 (2H, m), 3.30 (3H, s), 3.12-2.93 (2H, m), 2.90-2.78 (1H, m),2.85 (3H, s), 2.75-2.52 (3H, m), 2.13-1.97 (1H, m), 1.85-1.70 (1H, m),1.69-1.54 (2H, m), 0.98(3H, t, J=7.3 Hz).

Example 45

[0649] Preparation of4-{N-[1-(S)-(3-Chlorophenyl)-2-(3-(S)-hydroxypyrrolidin-1-yl)-ethyl]-N-methylamino}-N′-propylbenzamide

[0650] This was prepared from4-{N-[1-(S)-(3-chlorophenyl)-2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-ethyl]-N-methylamino}-N′-propylbenzamidein 83% yield according to a procedure similar to that described inExample 2.

[0651]¹H NMR (270 MHz, free amine, CDCl₃) δ7.67 (2H, d, J=9.2 Hz),7.30-7.14 (4H, m), 6.79 (2H, d, J=8.8 Hz), 6.03-5.94 (1H, m), 5.09 (1H,dd, J=6.2, 8.8 Hz), 4.27-4.18 (1H, m), 3.45-3.35 (2H, m), 3.09 (1H, dd,J=8.8, 12.8 Hz), 3.01 (1H, dd, J=6.2, 12.8 Hz), 2.93-2.80 (1H, m), 2.84(3H, s), 2.72 (1H, d, J=9.9 Hz), 2.57 (1H, dd, J=5.0, 9.7 Hz), 2.38-2.27(1H, m), 2.11-2.02 (1H, m), 1.80-1.55 (4H, m), 0.98 (3H, t, J=7.3 Hz).

[0652] Fumaric acid salt: amorphous solid.

[0653] 1 R(KBr): 3350, 1610 cm⁻¹.

[0654] MS m/z: 416 (M+H)⁺

Example 46

[0655] Preparation of4-{N-[2-(3-(S)-Fluoropyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-propylbenzamide

[0656] (i) Methyl4-{N-[2-(3-(S)-fluoropyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}benzoate

[0657] This was prepared from2-(3-(S)-fluoropyrrolidin-1-yl)-1-(S)-phenylethanol and2-(3-(S)-fluoropyrrolidin-1-yl)-2-(R)-phenylethanol and methyl4-methylaminobenzoate in 54% yield according to a procedure similar tothat described in Example 1 (i).

[0658]¹H NMR (270 MHz, CDCl₃) δ7.89 (2H, d, J=9.2 Hz), 7.38-7.22 (5H,m), 6.78 (2H, d, J=9.2 Hz), 5.25-4.95 (1H, m), 5.14 (1H, dd, J=6.6, 8.8Hz), 3.84 (3H, s), 3.18-3.00 (2H, m), 2.95-2.75 (3H, m), 2.89 (3H, s),2.60-2.50 (1H, m), 2.15-1.85 (2H, m),

[0659] (ii)4-{N-[2-(3-(S)-Fluoropyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}benzoicacid

[0660] This was prepared from methyl4-{N-[2-(3-(S)-fluoropyrrolidin-1-yl)-1-S)-phenylethyl]-N-methylamino}benzoatein 100% yield according to a procedure similar to that described inExample 1 (ii).

[0661]¹H NMR (270 MHz, CDCl₃) δ7.92 (2H, d, J=8.8 Hz), 7.40-7.10 (5H,m), 6.83 (2H, d, J=8.8 Hz), 5.40-5.00 (2H, m), 3.40-3.15 (2H, m),3.10-2.70 (4H, m), 2.90 (3H, s), 2.30-1.90 (2H, m),

[0662] (iii)4-{N-[2-(3-(S)-Fluoropyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-propylbenzamide

[0663] This was prepared from4-{N-[2-(3-(S)-fluoropyrrolidin-1-yl)-1-(S)-phenylethyl}-N-methylamino)benzoicacid and n-propylamine in 73% yield according to a procedure similar tothat described in Example 1 (iii).

[0664]¹H NMR (270 MHz, free amine, CDCl₃) δ7.65 (2H, d, J=8.8 Hz),7.37-7.22 (5H, m), 6.79 (2H, d, J=8.8 Hz), 6.03-5.92 (1H, m), 5.25-4.95(1H, m), 5.11 (1H, dd, J=6.2, 8.4 Hz), 3.45-3.35 (2H, m), 3.18-3.02 (2H,m), 2.95-2.72 (3H, m), 2.87 (3H, s),2.63-2.50 (1H, m), 2.18-1.85 (2H,m), 1.72-1.54 (2H, m), 0.97 (3H, t, J=7.3 Hz)

[0665] HCl salt: amorphous solid.

[0666] 1 R(KBr) : 1605 cm⁻¹.

[0667] MS m/z 384 (M+H)⁺

[0668] Anal. Calcd for C₂₃H₃₀N₃OF.HCl.0.3H₂O.CH₄O: C, 63.02; H, 7.84; N,9.19

[0669] Found: C, 62.69 H, 8.17; N, 9.57.

Example 47

[0670] Preparation of4-{N-[2-(3-(S)-Methoxymethoxypyrrolidin-1-yl)-1-(R)-phenylethyl]-N-methylamino}-N′-propylbenzamide

[0671] (i) Methyl4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(R)-phenylethyl]-N-methylamino}benzoate

[0672] This was prepared from2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(R)-phenylethanol and2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-2-(S)-phenylethanol and methyl4-methylaminobenzoate in 49% yield according to a procedure similar tothat described in Example 1 (i).

[0673]¹H NMR (270 MHz, CDCl₃) δ7.88 (2H, d, J=8.8 Hz), 7.34-7.23 (5H,m), 6.78 (2H, d, J=9.2 Hz), 5.17 (1H, dd, J=7.0, 7.7 Hz), 4.58 (1H, d,J=7.0 Hz), 4.53 (1H, d, J=6.6 Hz), 4.22-4.15 (1H, m), 3.85 (3H, s),3.68-3.52 (1H, m), 3.28 (3H, s), 3.08-3.04 (2H, m), 2.86 (3H, s),2.76-2.67 (1H, m), 2.62-2.51 (2H, m), 2.08-1.97 (1H, m), 1.83-1.72 (1H,m),

[0674] (ii)4-{N-[2-(3-(S)-Methoxymethoxypyrrolidin-1-yl)-1-(R)-phenylethyl]-N-methylamino}benzoicacid

[0675] This was prepared from methyl4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(R)-phenylethyl]-N-methylamino}benzoatein 100% yield according to a procedure similar to that described inExample 1 (ii).

[0676]¹H NMR (270 MHz, CDCl₃), δ7.89 (2H d, J=9.2 Hz), 7.33-7.18 (5H,m), 6.75(2H, d, J=9.2 Hz), 5.15 (1H, dd, J=7.0, 7.3 Hz), 4.57 (1H, d,J=7.0 Hz), 4.52 (1H, d, J=7.0 Hz), 4.25-4.15 (1H, m), 3.33 (3H s), 3.05(1H, d, J=6.6 Hz), 2.88-2.84 (1H, m), 2.85 (3H, s), 2.76-2.62 (1H, m),2.50-2.61 (3H, m), 2.07-2.02 (1H, m), 1.78-1.73 (1H, m),

[0677] (iii)4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(R)-phenylethyl]-N-methylamino}-N′-propylbenzamide

[0678] This was prepared from4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(R)-phenylethyl]-N-methylamino}benzoicacid and n-propylamine in 60% yield according to a procedure similar tothat described in Example 1 (iii).

[0679]¹H NMR (270 MHz, CDCl₃) δ7.63 (2H, d, J=9.2 Hz), 7.34-7.24 (5H,m), 6.79 (2H, d, J=9.2 Hz), 5.98-5.82 (1H, m), 5.13 (1H, t, J=7.3 Hz),4.58 (1H, d, J=6.6 Hz), 4.54 (1H, d, J=7.0 Hz), 4.26-4.13 (1H, m),3.43-3.34 (2H, m), 3.29 (3H, s), 3.06 (2H, d, J=7.3 Hz), 2.91-2.88 (1H,m), 2.85 (3H, s), 2.73-2.67 (1H, m), 2.61-2.54 (2H, m), 2.11-1.98 (1H,m), 1.84-1.72 (1H, m), 1.65-1.57 (2H, m), 0.97 (3H, t, J=7.3 Hz).

Example 48

[0680] Preparation of4-{N-[2-(3-(S)-Hydroxypyrrolidin-1-yl)-1-(R)-phenylethyl]-N-methylamino}-N′-propylbenzamide

[0681] This was prepared from4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(R)-phenylethyl]-N-methylamino}-N′-propylbenzamidein 15% yield according to a procedure similar to that described inExample 2.

[0682]¹H NMR (270 MHz, free amine, CDCl₃) δ7.59 (2H, d, J=9.2 Hz),7.28-7.16 (5H, m), 6.75 (2H, d, J=8.8 Hz), 6.07-5.94 (1H, m), 5.12 (1H,t, J=7.3 Hz), 4.18-4.13 (1H, m), 3.35-3.27 (2H, m), 3.03 (2H, d, J=7.8Hz), 2.92-2.86 (1H, m), 2.73 (3H, s), 2.66 (1H, d, J=9.9 Hz), 2.50 (1H,dd, J=4.8, 9.7 Hz), 2.38-2.33 (1H, m), 2.09-1.96 (2H, m), 1.67-1.46 (3H,m), 0.90 (3H, t, J=7.3 Hz)

[0683] 1 R(neat): 3350, 1610 cm⁻¹.

[0684] HCl salt: amorphous solid.

[0685] Anal. Calcd for C₂₃H₃₁N₃O₂.HCl.1.9H₂O: C, 61.52; H, 8.37; N,9.20.

[0686] Found: C, 61.33 ; H, 7.97 ; N, 9.33

Example 49

[0687] Preparation of4-{N-[2-(3-)-Methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-pyrrolidinebenzamide

[0688] This was prepared from4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}benzoicacid and pyrrolidine in 77% yield according to a procedure similar tothat described in Example 1 (iii).

[0689]¹H NMR (270 MHz, CDCl₃) δ7.47 (2H, d, J=8.8 Hz), 7.33-7.21 (5H,m), 6.77 (2H, d, J=8.8 Hz), 5.11 (1H, dd, J=6.6, 7.3 Hz), 4.60 (1H, d,J=7.0 Hz), 4.56 (1H, dd, J=7.5 Hz), 4.21-4.15 (1H, m), 3.62-3.52 (4H,m), 3.30 (3H, s), 3.12-2.97 (2H, m), 2.82 (3H, s). 2.75-2.54 (4H, m),2.09-1.74 (6H, m)

Example 50

[0690] Preparation of4-{N-[2-(3-(S)-Hydroxypyrrolidin-1yl)-1-(S)-phenylethyl]-N-methylamino}-pyrrolidinebenzamide

[0691] This was prepared from4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-pyrrolidinebenzamidein 51% yield according to a procedure similar to that described inExample 2.

[0692]¹H NMR (270 MHz, free amine, CDCl₃) δ7.49 (2H, d, J=9.2 Hz),7.46-7.23 (5H, m), 6.79 (2H, d, J=8.8 Hz), 5.14 (1, dd, J=6.2, 8.8 Hz),4.24-4.20 (1H, m), 3.68-3.52 (4H, m), 3.12 (1H, dd, J=8.8, 12.6 Hz),3.03 (1H, dd, J=6.2, 12.8 Hz), 2.95-2.87 (1H, m), 2.81 (3H, s), 2.75(1H, d, J=10.3 Hz), 2.55 (1H, dd, J=4.8, 9.5 Hz), 2.35-2.27 (1H, m),2.17-2.03 (1H, m), 1.98-1.82 (6H, m)

[0693] 1 R(neat): 3400, 1610 cm⁻¹.

[0694] HCl salt: amorphous solid.

[0695] Anal. Calcd for C₂₄H₃₁N₃O₂.HCl.2H₂O: C, 61.65; H, 8.08, N. 8.83

[0696] Found: C,61.86; H, 7.79 N,9.02.

Example 51

[0697] Preparation of4-{N-[2-(3-(S)-tert-Butyldimethylsilyloxypyrrolidin-1-yl)-1-1-(S-phenylethyl]-N-methylamino}-N′-ethoxybenzamide

[0698] (i) Methyl4-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1(S)-phenylethyl]-N-methylamino}benzoate

[0699] This was prepared from methyl 4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}benzoatein 100% yield according to the procedures similar to those described inExample 2.

[0700]¹H NMR (270 MHz, CDCl₃) δ7.90(2H, d, J=9.2 Hz), 7.36-7.23(5H, m),6.80 (2H, d, J=9.2 Hz), 5.18 (1H, dd, J=5.9, 9.0 Hz), 4.24-4.20 (1H, m),3.85 (3H, s), 3.13 (1H, dd, J=5.9, 12.8 Hz), 2.94-2.88 (2H, m), 2.85(3H, s), 2.73 (1H, d, J=9.9 Hz), 2.56 (1H, dd, J=4.8, 9.5 Hz), 2.36-2.30(1H, m), 2.27-2.05 (1H, m), 1.80-1.50 (2H, m)

[0701] (ii) Methyl4-{N-[2-(3-(S)-tert-butyldimethylsilyloxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}benzoate

[0702] To a stirred solution of methyl4-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-(S)-phenylethyl]-N-methylamino}benzoate(865 mg, 2.44 mmol) in DMF (10 ml) was added imidazole (1.54 g, 24.4mmol) and tert-butyldimethylsilylchloride (1.83 g, 12.2 mmol) at 0° C.After 3 hr stirring, saturated NaHCO₃ aqueous solution was added to thereaction mixture and extracted with CH₂Cl₂. The extract was washed withwater and brine, dried (Na₂SO₄), and concentrated to give brown oil,which was purified by column chromatography (silica gel; 40 g,CH₂C₂/MeOH: 100/1-50/1) to give 760 mg (66%) of title compound.

[0703]¹H NMR (270 MHz, CDCl₃) δ7.79 (2H, d, J=9.2 Hz), 7.24-7.14 (5H,m), 6.68 (2H , d, J=9.2 Hz), 5.05 (1H, dd, J=6.2, 7.3 Hz), 4.21-4.12(1H, m), 3.75 (3H, s), 2.97-2.92 (2H, m), 2.82-2.76 (1H, m), 2.75 (3H,s), 2.58-2.53 (2H, m), 2.27 (1H, dd, J=4, 9.2 Hz), 1.93-1.86 (1H, m),1.58-1.47 (1H, m), 0.74(9H, s), 0.01 (6H, s).

[0704] (iii)4-{N-[2-(3-(S)-tert-Butyldimethylsilyloxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}benzoicacid

[0705] This was prepared from methyl4-{N-[2-(3-(S)-tert-butyldimethylsilyloxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}benzoatein 32% yield according to the procedures similar to those described inExample 1 (ii)

[0706]¹H NMR (270 MHz, CDCl₃) δ7.90 (2H, d, J=9.2 Hz), 7.32-7.23 (5H,m), 6.80 (2H, d, J=9.2 Hz), 5.29-5.26 (1H, m), 4.32-4.25 (1H, m),3.26-3.12 (2H, m), 3.12-3.06 (1H, m), 2.85 (3H, s), 2.73-2.65 (2H, m),2.46-2.41 (1H, m), 2.07-2.00 (1H, m), 1.71-1.62 (1H, m), 0.84 (9H, s),0.01 (6H, s).

[0707] (iv)4-{N-[2-(3-(S)-tert-Butyldimethylsilyloxypyrrolidin-1-yl)-1-(S)-phenylethyl]-methylamino}-N′-ethoxybenzamide

[0708] This was prepared from4-{N-[2-(3-(S)-tert-butyldimethylsilyloxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}benzoicacid and O-ethylhydroxylamine in 41% yield according to the proceduressimilar to those described in Example 1-(iii)

[0709]¹H NMR (270 MHz, CDCl₃) δ8.39 (1H, br, s), 7.62 (2H, d, J=8.8 Hz),7.34-7.24 (5H, m), 6.78 (2H, d, J=9.2 Hz), 5.11-5.09 (1H, m), 4.32-4.23(1H, m), 4.07 (2H, q, J=7.0 Hz), 3.06-3.02 (1H, m), 2.92-2.86 (1H, m),2.84 (3H s), 2.68-2.63 (2H, m), 2.38 (1H, dd, J=4.4, 9.2 Hz), 2.03-1.96(1H, m), 1.68-1.62 (2H, m), 1.32 (3H, t, J=7.0 Hz), 0.84 (9H, S), 0.01(6H, s).

Example 52

[0710] Preparation of4-{N-[2-(3-(S)-Hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N′-methylamino}-N′-ethoxybenzamide

[0711] To a stirred solution of4-{N-[2-(3-(S)-tert-butyldimethylsilyloxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-ethoxybenzamide(44.7 mg, 0.0901 mmol) in THF(1 ml) was added 1.0 M solution oftetrabutylammonium fluoride in THF (0.273 ml, 0.273 mmol) at roomtemperature. After 18 hr stirring, saturated NaHCO₃ aqueous solution wasadded to the reaction mixture and extracted with CH₂Cl₂. The extract waswashed with water and brine, dried (Na₂SO₄), and concentrated to givebrown oil, which was purified by column chromatography (silica gel, 20g, CH₂Cl₂/MeOH: 25/1-10/1) to give 28.4 mg(82%) of title compound.

[0712]¹H NMR (270 MHz, free amine, CDCl₃) δ8.60 (1H, br, s), 7.64 (2H,d, J=9.2 Hz), 7.36-7.24 (5H, m), 6.80 (2H, d, J=9.2 Hz), 5.16 (1H, dd,J=5.9, 9.2 Hz), 4.24-4.20 (1H, m), 4.06 (2H, q, J=7.0 Hz), 3.14 (1H, dd,J=9.2, 13.2 Hz), 3.04 (1H, dd, J=5.9, 12.0 Hz), 2.89-2.83 (1H, m), 2.83(3H, s), 2.76 (1H, d, J=9.5 Hz), 2.57 (1H, dd, J=4.8, 9.9 Hz), 2.38-2.29(1H, m), 2.16-2.03 (1H, m), 1.90-1.56 (2H, m), 1.32 (3H, t, J=7.0 Hz).

[0713] HCl salt: amorphous solid.

[0714] Anal. Calcd for C₂₂H₂₉N₃O₃.HCl.0.7H₂O C, 58.04, H, 8.00, N,3.46

[0715] Found: C,58.26; H, 8.40; N, 8.58.

Example 53

[0716] Preparation of4-{N-[2-(3-(S)-Methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-morpholinebenzamide

[0717] This was prepared from4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}benzoicacid and morpholine in 54% yield according to the procedures similar tothose described in Example 1 (iii).

[0718]¹H NMR (270 MHz, CDCl₃) δ7.32 (2H, d, J=8.8 Hz), 7.29-7.28 (5H,m), 6.78 (2H, d, J=8.8 Hz), 5.10(1H, dd, J=7.0, 7.7 Hz), 4.60 (1H, d,J=7.0 Hz), 4.55 (1H, d, J=6.6 Hz), 4.22-4.13 (1H, m), 3.68-3.67 (8H, m),3.30 (3H, s), 3.07-3.02 (2H, m), 2.90-2.80 (1H, m), 2.84 (3H, s),2.75-2.57 (3H, m), 2.07-2.02 (1H, m), 1.81-1.72 (1H, m)

Example 54

[0719] Preparation of4-{N-[2-(3-(S)-Hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-morpholinebenzamide

[0720] This was prepared from4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1yl)-1-(S)-phenylethyl]-N-methylamino}-morpholinebenzamidein 76% yield according to the procedures similar to those described inExample 2.

[0721]¹H NMR (270 MHz, free amine, CDCl₃) δ7.34 (2H, d, J=9.2 Hz),7.30-7.24 (5H, m), 6.80 (2H, d, J=8.8 Hz), 5.13 (1H, dd, J=6.6, 8.8 Hz),4.27-4.21 (1H, m), 3.81-3.58 (8H, m), 3.16-2.96 (2H, m), 2.92-2.87 (1H,m), 2.82 (3H, s), 2.75 (1H, d, J=9.2 Hz), 2.55 (1H, dd, J=4.4, 9.5 Hz),2.36-2.27 (1H, m), 2.12-2.09 (1H, m), 1.75-1.60 (2H, m)

[0722] 1 R(neat) 3400, 1610 cm⁻¹.

[0723] HCl salt: amorphous solid.

[0724] MS m/z:410 (M+H)⁺

Example 55

[0725] Preparation of4-{N-[2-(3-(S)-Methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-(3-hydroxypropyl)benzamide

[0726] This was prepared from4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}benzoicacid and 3-amino-1-propanol in 48% yield according to the proceduressimilar to those described in Example 1 (iii)

[0727]¹H NMR (270 MHz, CDCl₃) δ7.66 (2H, d, J=9.2 Hz), 7.40-7.20 (5H,m), 6.80 (2H, d, J=8.8 Hz), 6.40-6.30 (1H, m), 5.14 (1H, dd, J=7.0, 7.7Hz), 4.60 (1H, d, J=6.5 Hz), 4.55 (1H, d, J=6.6 Hz), 4.25-4.13 (1H, m),3.73-3.55 (4H, m), 3.30 (3H, s), 3.13-3.00 (2H, m), 2.90-2.80 (1H, m),2.86 (3H, s), 2.78-2.52 (3H, m), 2.13-1.98 (1H, m), 1.81-1.45 (4H, m)

Example 56

[0728] Preparation of 4-{N-[2-(3-(S)-Hydroxypyrrolidin-1yl)-1-(S)-phenylethyl]-N-methylamino}-N′-(3-hydroxypropyl)benzamide

[0729] This was prepared from4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-(3-hydroxypropyl)benzamidein 82% yield according to the procedures similar to those described inExample 2.

[0730]¹H NMR (270 MHz, free amine, CDCl₃) δ7.66 (2H, d, J=9.2 Hz),7.35-7.26 (5H, m), 6.81 (2H, d, J=9.2 Hz), 6.42-6.33 (1H m), 5.15 (1H,dd, J=5.9, 8.8 Hz), 4.27-4.17 (1H, m), 3.66 (2H, t, J=5.5 Hz), 3.59 (2H,t, J=5.9 Hz), 3.13 (1H, dd, J=9.2, 12.8 Hz), 3.03 (1H, dd, J=5.9, 12.8Hz), 2.94-2.86 (1H, m), 2.84 (3H, s), 2.72 (1H, d, J=9.5 Hz), 2.56 (1H,J=4.8, 9.9 Hz), 2.36-2.28 (1H, m), 2.13-2.03 (1H, m), 1.79-1.61 (5H, m)

[0731] 1 R(neat) 3350, 1610 cm⁻¹.

[0732] HCl salt: amorphous solid.

[0733] MS m/z:398 (M+H)⁺

Example 57

[0734] Preparation of4-{N-[2-(3-(S)-Methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-(2-(R)-hydroxypropyl)benzamide

[0735] This was prepared from4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}benzoicacid and (R)-(−)-1-amino-2-propanol in 83% yield according to theprocedures similar to those described in Example 1 (iii)

[0736]¹H NMR (270 MHz, CDCl₃) δ7.67 (2H, d, J=8.8 Hz), 7.40-7.20 (5H,m), 6.80 (2H, d, J=8.8 Hz), 6.50-6.40 (1H, m), 5.14 (1H, dd, J=7.0, 7.7Hz), 4.59 (1H, d, J=7.0 Hz), 4.55 (1H, d, J=7.0 Hz), 4.23-4.13 (1H, m),4.07-3.95 (1H, m), 3.66-3.55 (1H, m), 3.40-3.20 (1H, m), 3.30 (3H, s),3.13-3.00 (2H, m), 2.90-2.80 (1H, m), 2.85 (3H, s), 2.76-2.52 (3H, m),2.13-1.98 (1H, m), 1.85-1.45 (2H, m), 1.23 (3H, d, J=6.2 Hz).

Example 58

[0737] Preparation of4-{N-[2-(3-(S)-Hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-(2-(R)-hydroxypropyl)benzamide

[0738] This was prepared from4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-(2-(R)-hydroxypropyl)benzamidein 84% yield according to the procedures similar to those described inExample 2.

[0739]¹H NMR (270 MHz, free amine, CDCl₃) δ7.68 (2H, d, J=8.8 Hz),7.40-7.23 (5H, m), 6.82 (2H, d, J=8.8 Hz), 6.50-6.38 (1H, m), 5.16 (1H,dd, J=5.9, 8.8 Hz), 4.28-4.18 (1H, m), 4.10-3.95 (1H, m), 3.66-3.55 (1H,m), 3.40-3.35 (1H, m), 3.16-3.00 (2H, m), 2.95-2.80 (1H, m), 2.84 (3H,s), 2.74 (1H, d, J=9.2 Hz), 2.56 (1H, dd, J=4.4, 9.5 Hz), 2.40-2.25 (1H,m), 2.17-2.00 (1H, m), 1.90-1.40 (3H, m), 1.24 (3H, d, J=6.6 Hz) 1R(neat) 3350, 1610 cm⁻¹.

[0740] HCl salt: amorphous solid.

[0741] MS m/z:398 (M+H)⁺

[0742] Anal. Calcd for C₂₃H₃₁N₃O₃.HCl.0.85CH₄O, 62.11 H, 7.74, N, 9.11

[0743] Found: C,62.50; H, 8.13 , N,9.37

Example 59

[0744] Preparation of4-{N-[2-(3-(S)-Methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-isobutylbenzamide

[0745] This was prepared from4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}benzoicacid and isobutylamine in 72% yield according to the procedures similarto those described in Example 1 (iii).

[0746]¹H NMR (270 MHz, CDCl₃) δ7.65 (2H, d, J=8.8 Hz), 7.34-7.24(5H, m),6.80 (2H, d, J=8.8 Hz), 6.04-5.92 (1H, m), 5.18-5.08 (1H, m), 4.59 (1H,d, J=7.0 Hz), 4.55(1H, d, J=6.6 Hz), 4.22-4.13 (1H, m), 3.29 (3H, s),3.28-3.23 (2H, m), 3.10-3.02 (2H, m), 2.84-2.80 (1H, m), 2.84 (3H, s),2.72-2.57 (3H, m), 2.12-1.98 (1H, m), 1.89-1.79 (1H, m), 1.78-1.69 (1H,m), 0.96 (6H, d, J=6.6 Hz).

Example 60

[0747] Preparation of4-{N-[2-(3-(S)-Hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-isobutylbenzamide

[0748] This was prepared from4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-isobutylbenzamidein 86% yield according to the procedures similar to those described inExample 2.

[0749]¹H NMR (270 MHz, free amine, CDCl₃) δ7.66 (2H d, J=8.8 Hz),7.35-7.26(5H, m), 6.81 (2H, d, J=8.8 Hz), 6.06-5.96 (1H, m), 5.15 (1H,dd, J=5.9, 8.8 Hz), 4.26-4.18 (1H, m), 3.26 (2H, t, J=6.2 Hz), 3.13 (1H,dd, J=8.8, 12.8 Hz), 3.03 (1H, dd, J=5.9, 12.8 Hz), 2.92-2.85 (1H, m),2.84 (3H, s), 2.73 (1H, d, J=9.5 Hz), 2.56 (1H, dd, J=4.6, 9.7 Hz),2.36-2.28 (1H, m), 2.16-2.04 (1H, m), 1.96-1.58 (3H, m), 0.97 (6H, d,J=7.0 Hz)

[0750] 1 R(neat) :3350, 1610 cm⁻¹.

[0751] HCl salt: amorphous solid.

[0752] MS m/z:396 (M+H)⁺

[0753] Anal Calcd for C₂₄H₃₃N₃O₂.HCl.0.5H₂O C, 65.36 H, 8.00; N, 9.53

[0754] Found: C,65.58 ; H, 8.17; N,9.48.

Example 61

[0755] Preparation of4-{N-[2-(3-(S)-Methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-allylbenzamide

[0756] This was prepared from4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1yl)-1-(S)-phenylethyl]-N-methylamino}benzoicacid and allylamine in 33% yield according to the procedures similar tothose described in Example 1 (iii).

[0757]¹H NMR (270 MHz, CDCl₃) δ7.67 (2H, d, J=8.8 Hz), 7.31-7.26 (5H,m), 6.79 (2H, d, J=9.2 Hz), 6.01-5.88 (2H, m), 5.28-5.27 (1H, m),5.21-5.11 (2H, m), 4.59 (1H, d, J=7.0 Hz), 4.55 (1H, d, J=6.6 Hz),4.25-4.13 (1H, m), 4.09-4.04 (2H, ml), 3.29 (3H, s), 3.07-3.03 (2H, m),2.85-2.80 (1H, m), 2.85 (3H, s), 2.75-2.67 (1H, m), 2.64-2.56 (1H, m),2.06-2.01 (1H, m), 1.76-1.60 (1H, m), 1.60-1.52 (1H, m),

Example 62

[0758] Preparation of4-{N-[2-(3-(S)-Hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-allylbenzamide

[0759] This was prepared from4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-allylbenzamidein 52% yield according to the procedures similar to those described inExample 2.

[0760]¹H NMR (270 MHz, free amine, CDCl₃) δ7.68 (2H, d, J=8.8 Hz),7.35-7.26 (5H, m) 6.81 (2H, d, J=8.8 Hz), 6.01-5.89 (2H, m), 5.28-5.12(3H, m), 4.27-4.19 (1H, m), 4.09-4.05 (2H, m), 3.13 (1H, dd, J=9.2, 12.8Hz), 3.03 (1H, dd, J=5.9, 12.8 Hz), 2.92-2.86 (1H, m), 2.84 (3H, s),2.73 (1H, d, J=9.2 Hz), 2.56 (1H, dd, J=4.8, 9.5 Hz), 2.33-2.30 (1H, m),2.27-2.08 (1H, m), 1.67-1.48 (2H, m),

[0761] 1 R(neat): 3350, 1610 cm⁻¹.

[0762] HCl salt: amorphous solid.

[0763] MS m/z:380 (M+H)⁺

[0764] Anal. Calcd for C₂₃H₂₉N₃O₂.HCl.0.1H₂O.CH₄O. C, 64.09; H, 7.66, N,9.34

[0765] Found: C,63.86; H, 7.85 N,9.32.

Example 63

[0766] Preparation of4-{N-[2-(3-(S)-Methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-cyclopropylbenzamide

[0767] This was prepared from4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}benzoicacid and cyclopropylamine in 48% yield according to the proceduressimilar to those described in Example 1 (iii).

[0768]¹H NMR (270 MHz, CDCl₃) δ7.61 (2H, d, J=8.8 Hz), 7.33-7.22 (5H,m), 6.78 (7H, d J=8.8 Hz), 6.11-6.02 (1H, m), 5.15-5.11 (1H, m), 4.59(1H, d, J=6.6 Hz), 4.55 (1H, d, J=6.6 Hz), 4.19-4.14 (1H, m), 3.29 (3H,s), 3.07-3.03 (2H, m), 2.90-2.80 (1H, m), 2.84 (3H, s), 2.72-2.66 (1H,m), 2.64-2.56 (2H, m), 2.08-2.01 (1H, m), 1.79-1.73 (1H, m), 1.37-1.25(1H, m), 0.94-0.80 (2H, m), 0.60-0.54 (2H, m)

Example 64

[0769] Preparation of4-{N-[2-(3-(S)-Hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-cyclopropylbenzamide

[0770] This was prepared from4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-cyclopropylbenzamidein 76% yield according the procedures similar to those described inExample 2.

[0771]¹H NMR (270 MHz, free amine, CDCl₃) δ7.63 (2H, d, J=9.2 Hz),7.35-7.23 (5H, m), 6.79 (2H, d, J=8.8 Hz), 6.12-6.04 (1H, m), 5.15 (1H,dd, J=5.9, 8.8 Hz), 4.24-4.19 (1H, m), 3.13 (1H, dd, J=9.2, 12.8 Hz),3.03 (1H, dd, J=5.9, 10.3 Hz), 2.94-2.84 (2H, m), 2.83 (3H, s), 2.78(1H, d, J=9.5 Hz), 2.58-2.53 (1H,m), 2.33-2.31 (1H, m), 2.11-2.08 (1H,m), 1.68-1.61 (2H, m), 0.87-0.80 (2H, m), 0.60-0.54 (2H, m),

[0772] 1 R(neat): 3350, 1610 cm⁻¹.

[0773] HCl salt: amorphous solid.

[0774] MS m/z:380 (M+H)⁺

[0775] Anal. Calcd for C₂₃H₂₉N₃O₂.HCl.0.8H₂O C, 64.19 H, 7.40 N. 9.76

[0776] Found C,64.04 H, 7.50 , N,9.83

Example 65

[0777] Preparation of4-{N-[2-(3-(S)-Methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-(S)-sec-butylbenzamide

[0778] This was prepared from4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}benzoicacid and (S)-sec-butylamine in 18% yield according to the proceduressimilar to those described in Example 1 (iii).

[0779]¹H NMR (270 MHz, CDCl₃) δ7.65 (2H, d, J=8.8 Hz), 7.40-7.20 (5H, m)6.79 (2H, d, J=8.8 Hz), 5.74 (1H, d, J=8.4 Hz), 5.13 (1H, dd, J=6.6, 8.1Hz), 4.59 (1H, d, J=7.0 Hz), 4.55 (1H, d, J=7.0 Hz), 4.25-4.05 (2H, m),3.30 (3H, s), 3.15-2.95 (2H, m), 2.90-2.80 (1H, m), 2.85 (3H, s),2.76-2.55 (3H, m), 2.13-1.98 (1H, m), 1.85-1.70 (1H, m), 1.65-1.50 (2H,m), 1.20 (3H, d, J=6.6 Hz), 0.95 (3H, t, J=7.7 Hz).

Example 66

[0780] Preparation of4-{N-[2-(3-(S)-Hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-(S)-sec-butylbenzamide

[0781] This was prepared from4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-(S)-sec-butylbenzamidein 100% yield according to the procedures similar to those described inExample 2.

[0782]¹H NMR (270 MHz, free amine, CDCl₃) δ7.65 (2H, d, J=9.2 Hz),7.40-7.20 (5H, m), 6.80 (2H, d, J=9.2 Hz), 5.76 (1H, d, J=8.4 Hz), 5.14(1H, dd, J=6.2, 8.8 Hz), 4.25-4.05 (2H, m), 3.17-2.98 (2H, m), 2.95-2.78(1H, m), 2.83 (3H, s), 2.72 (1H, d, J=9.5 Hz), 2.57 (1H, dd, J=4.8, 9.5Hz), 2.40-2.28 (1H, m), 2.20-1.95 (2H, m), 1.70-1.50 (3H, m), 1.20 (3H,d, J=6.6 Hz), 0.95 (3H, t, J=7.3 Hz)

[0783] HCl salt: amorphous solid.

[0784] MS m/z:396 (M+H)⁺

[0785] Anal. Calcd for C₂₄H₃₃N₃O₂.HCl.0.3H₂O.CH₄O C, 63.96 , H, 8.29, N,8.95

[0786] Found C,64.14, H, 8.01, N,8.70

Example 67

[0787] Preparation of4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-(R)-sec-butylbenzamide

[0788] This was prepared from4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}benzoicacid and (R)-sec-butylamine in 18% yield according to the proceduressimilar to those described in Example 1 (iii).

[0789]¹H NMR (270 MHz, CDCl₃) δ7.65 (2H, d, J=8.8 Hz), 7.33-7.23 (5H,m), 6.79 (2H, d, J=9.2 Hz), 5.74 (1H, d, J=8.1 Hz), 5.13 (1H, dd, J=6.6,7.7 Hz), 4.59 (1H, d, J=6.6 Hz), 4.55 (1H, d, J=6.6 Hz), 4.19-4.08 (2H,m), 3.29 (3H, s), 3.09-2.98 (2H, m), 2.90-2.80 (1H, m), 2.84 (3H, s),2.72-2.57 (3H, m), 2.13-1.98 (1H, m), 1.78-1.75 (1H, m), 1.60-1.49 (2H,m), 1.20 (3H, d, J=6.6 Hz), 0.94 (3H, t, J=7.7 Hz).

Example 68

[0790] Preparation of4-{N-[2-(3-(S)-Hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-(R)-sec-butylbenzamide

[0791] This was prepared from4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-(R)-sec-butylbenzamidein 95% yield according to the procedures similar to those described inExample 2.

[0792]¹H NMR (270 MHz, free amine, CDCl₃) δ7.65 (2H, d, J=8.8 Hz),7.40-7.20 (5H, m), 6.80 (2H, d, J=8.8 Hz), 5.78 (1H, d, J=8.3 Hz), 5.14(1H, dd, J=5.9, 8.8 Hz), 4.25-4.03(2H, m), 3.17-2.98 (2H, m), 2.95-2.78(1H, m), 2.83 (3H, s), 2.71 (1H, d, J=9.5 Hz), 2.58 (1H, dd, J=4.8, 9.5Hz), 2.42-2.30 (1H, m), 2.23 (1H, br, s), 2.15-2.00 (1H, m), 1.70-1.50(3H, m), 1.20 (3H, d, J=6.6 Hz), 0.95 (3H, t, J=7.3 Hz).

[0793] HCl salt: amorphous solid.

[0794] MS m/z:396 (M+H)⁺

[0795] Anal. Calcd for C₂₄H₃₃N₃O₂.HCl.0.4H₂.CH₄O: C, 63.72; H, 8.30, N,8.92

[0796] Found: C,63.96, H; 8.08 N,9.08.

Example 69

[0797] Preparation of4-{N-[2-(3-(S)-Methoxymethoxypyrrolidin-1yl)-1-(S)-phenylethyl]-N-methylamino}-N′-propargylbenzamide

[0798] This was prepared from4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}benzoicacid and propargylamine in 18% yield according to the procedures similarto those described in Example 1 (iii).

[0799]¹H NMR (270 MHz, CDCl₃) δ7.65 (2H, d, J=8.8 Hz), 7.34-7.24 (5H,m), 6.80 (2H, d, J=9.2 Hz), 6.12-6.03 (1H, m), 5.14 (1H, dd, J=6.6, 7.3Hz), 4.59 (1H, d, J=73 Hz), 4.55 (1H, d, J=7.0 Hz), 4.23 (2H, q, J=2.6Hz), 4.19-4.14(1H, m), 3.29 (3H, s), 3.07-3.03 (2H, m), 2.85-2.80 (1H,m), 2.85 (3H, s), 2.75-2.70 (1H, m), 2.67-2.56 (2H, m), 2.25 (1H, t,J=2.6 Hz), 2.08-2.01 (1H, m), 1.87-1.70 (1H, m)

Example 70

[0800] Preparation of4-{N-[2-(3-(S)-Hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-propargylbenzamide

[0801] This was prepared from4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-propargylbenzamidein 77% yield according the procedures similar to those described inExample 2.

[0802]¹H NMR (270 MHz, free amine, CDCl₃) δ7.67 (2H, d, J=8.8 Hz),7.35-7.24 (5H, m), 6.81 (2H, d, J=8.8 Hz), 6.13-6.03 (1H, m), 5.16 (1H,dd, J=5.9, 9.0 Hz), 4.24-4.21 (3H, m), 3.13 (1H, dd, J=9.5, 12.8 Hz),3.03 (1H, dd, J=5.9, 12.8 Hz), 2.93-2.86 (1H, m), 2.84 (3H, s), 2.73(1H, d, J=8.3 Hz), 2.58-2.53 (1H, m), 2.32-2.24 (2H, m), 2.11-2.05 (1H,m), 1.76-1.58 (2H, m),

[0803] 1 R(neat): 3300, 1610 cm⁻¹.

[0804] HCl salt: amorphous solid.

[0805] MS n/z:378 (M+H)⁺

[0806] Anal. Calcd for C23H₂₇N₃O₂.HCl.0.8H₂O.CH₄O. C, 62.61 H, 7.36, N,9.13

[0807] Found C,62.23; H, 7.26; N,9.50.

Example 71

[0808] Preparation of4-{N-[2-(3-(S)-Methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-(3,3,3,-trifluoropropyl)benzamide

[0809] This was prepared from4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}benzoicacid and 3,3,3,-trifluoropropylamine in 39% yield according to theprocedures similar to those described in Example 1 (iii)

[0810]¹H NMR (270 MHz, CDCl₃) δ7.63 (2H, d, J=8.8 Hz), 7.31-7.24 (5H,m), 6.80 (2H, d, J=9.2 Hz), 6.21-6.12 (1H, m), 5.14 (1H, dd, J=7.0, 8.1Hz), 4.59 (1H, d, J=7.0 Hz), 4.55 (1H, d, J=7.0 Hz), 4.21-4.12 (1H, m),3.69 (2H, q, J=6.2 Hz), 3.29 (3H, s), 3.07-3.03 (2H, m), 2.85 (3H, s),2.84-2.80 (1H, m), 2.72-2.67 (1H, m), 2.64-2.56 (2H, m), 2.50-2.38 (2H,m), 2.08-2.01 (1H, m), 1.77-1.76 (1H, m).

Example 72

[0811] Preparation of4-{N-[2-(3-(S)-Hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-(3,3,3,-trifluoropropyl)benzamide

[0812] This was prepared from4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-(3,3,3,-trifluoropropyl)benzamidein 69% yield according to the procedures similar to those described inExample 2.

[0813]¹H NMR (270 M, free amine, CDCl₃) δ7.65 (2H, d, J=8.8 Hz),7.36-7.26 (5H, m), 6.81 (2H, d, J=9.2 Hz), 6.26-6.20 (1H, m), 5.16 (1H,dd, J=5.9, 9.2 Hz), 4.25-4.19 (1H, m), 3.69 (2H, q, J=6.2 Hz), 3.17-3.02(2H, m), 2.99-2.88 (1H, m), 2.84 (3H, s), 2.83-2.72 (1H, m), 2.59-2.53(1H, m), 2.52-2.38 (2H, m), 2.37-2.28 (1H, m), 2.16-2.05 (1H, m),1.80-1.75 (2H, m).

[0814] 1 R(neat): 3350, 1610 cm⁻¹.

[0815] HCl salt: amorphous solid.

[0816] MS m/z:436 (M+H)⁺

[0817] Anal. Calcd for C₂₃H₂₈N₃O₂F₃.HCl.0.4H₂O C, 57.65, H, 6.27, N,8.77

[0818] Found C,57.60, H, 6.26 , N,8.50

Example 73

[0819] Preparation of4-{N-[2-(3-(S)-Methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-(2-(S)-hydroxypropyl)benzamide

[0820] This was prepared from4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}benzoicacid and (S)-(−)-1amino-2-propanol in 55% yield according to theprocedures similar to those described in Example 1 (iii)

[0821]¹H NMR (270 MHz, CDCl₃) δ7.67 (2H, d, J=9.2 Hz), 7.40-7.20 (5H,m), 6.80 (2H, d, J=8.8 Hz), 6.50-6.40 (1H, m), 5.14 (1H, dd, J=7.0, 7.7Hz), 4.60 (1H, d, J=6.6 Hz), 4.55 (1H, d, J=7.0 Hz), 4.23-4.13 (1H, m),4.07-3.95 ( 1H, m), 3.66-3.55 (1H, ml), 3.40-3.25 (1H, m), 3.30 (3H, s),3.13-3.00 (2H, m), 2.90-2.80 (1H, m), 2.86 (3H, s), 2.76-2.52 (3H m),2.13-1.98 (1H, m), 1.85-1.45 (2H, m), 1.23 (3H, d, J=6.2 Hz).

Example 74

[0822] Preparation of4-{N-[2-(3-(S)-Hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino]-N′-(2-(S)-hydroxypropyl)benzamide

[0823] This was prepared from4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-(2-(S)-hydroxypropyl)benzamidein 81% yield according to the procedures similar to those described inExample 2.

[0824]¹H NMR (270 MHz, free amine, CDCl₃) δ7.68 (2H, d, J=8.8 Hz),7.40-7.20 (5H, m), 6.80 (2H, d, J=8.8 Hz), 6.60-6.50 (1H, m), 5.15 (1H,dd, J=5.9, 9.2 Hz), 4.28-4.18 (1H, m), 4.07-3.93 (1H, m), 3.66-3.55 (1H,m), 3.35-3.23 (1H, m), 3.13 (1H, dd, J=9.2. 12.5 Hz), 3.03 (1H, dd,J=5.9, 12.8 Hz), 2.95-2.80 (1H, m), 2.83 (3H, s), 2.72 (1H, d, J=9.5Hz), 2.56 (1H, dd, J=4.8, 9.9 Hz), 2.40-2.25 (1H, m), 2.20-1.75 (3H, m),1.70-1.55 (1H, m), 1.22 (3H, d, J=6.2 Hz).

[0825] 1 R(neat) 3350, 1610 cm⁻¹.

[0826] Maleic acid salt: amorphous solid

[0827] MS m/z:396 (M−H)⁺

[0828] Anal. Calcd for C₂₃H₃₁N₃O₃.C₄H₄O₄.0.3H₂O C, 62.49; H, 6.91 1 N,8.10

[0829] Found: C,62.65 , H, 7.24 , N,7.90

Example 75

[0830] Preparation of4-{N-[1-(R)-(3-Methoxymethoxyphenyl)-2-(3-(S)-methoxymethoxypyrrolidin-1yl)-ethyl]-N-methylamino}-N′-propylbenzamide

[0831] (i) Methyl4-{N-[1-(R)-(3-methoxymethoxyphenyl)-2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-ethyl]-N-methylamino}benzoate

[0832]2-(S)-(3-Methoxymethoxyphenyl)-2-(3-(S)-methoxymethoxypyrrolidin-1-yl)ethanoland1-(R)-(3-methoxymethoxyphenyl)-2-(3-(S)-methoxymethoxypyrrolidin-1-yl)ethanolwere prepared from(R)-1-(3-methoxymethoxyphenyl)-1,2-ethanediol-2-tosylate in 58% yield asa mixture according to the procedures similar to those described inPreparation 3. Title compound was prepared by reacting the mixture of2-(S)-(3-methoxymethoxyphenyl)-2-(3-(S)-methoxymethoxypyrrolidin-1-yl)ethanoland1-(R)-(3-methoxymethoxyphenyl)-2-(3-(S)-methoxymethoxypyrrolidin-1-yl)ethanolwith methyl 4-methylaminobenzoate in 54% yield according to theprocedures similar to those described in Example 1 (i).

[0833]¹H NMR (270 MHz, CDCl₃) δ7.88 (2H, d, J=8.8 Hz), 7.23-7.19 (1H,m), 6.95-6.90 (3H, m), 6.77 (2H, d, J=8.8 Hz), 5.13 (2H, s), 5.12-5.08(1H, m), 4.58 (1H, d, J=6.6 Hz) 4.53 (1H, d, J=6.6 Hz), 4.22-4.15 (1H,m), 3.84 (3H, s), 3.45 (3H, s), 3.28 (3H, s), 3.13-2.92 (2H, m), 2.88(3H, s), 2.90-2.84 (1H, m), 2.75-2.66 (1H, m), 2.61-2.50 (2H, 2.06-1.99(1H, m), 1.83-1.74 (1H, m).

[0834] (ii) 4-{N-[1-(R)-(3-Methoxymethoxyphenyl)-2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-ethyl]-N-methylamino}benzoic acid

[0835] This was prepared from methyl4-{N-[1-(R)-(3-methoxymethoxyphenyl)-2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-ethyl]-N-methylaminobenzoate in 91% yield according to the procedures similar to thosedescribed in Example 1 (ii)

[0836]¹H NMR (270 MHz, CDCl₃) δ7.91 (1H, d, J=3.8 Hz), 7.30-7.12 (1H,m), 6.98-6.84 (3H, m), 6.82 (2H, d, J=9.2 Hz), 5.35-5.25 (1H, m), 5.14(2H, s), 4.60 (1H, d, J=7.0 Hz). 4.55 (1H, d, J=7.0 Hz), 4.30-4.20 (1H,m), 3.45 (3H, s), 3.30 (3H, s), 3.25-3.05 (2H, m), 2.90 (3H, s),2.90-2.60 (4H, m), 2.20-2.00 (1H, m), 1.90-1.80 (1H, m).

[0837] (iii)4-{N-[1-(R)-(3-Methoxymethoxyphenyl)-2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-ethyl]-N-methylamino}-N′-propylbenzamide

[0838] This was prepared from4-{N-[1-(R)-(3-methoxymethoxyphenyl)-2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-ethyl]-N-methylamino}benzoicacid and n-propylamine in 71% yield according to the procedures similarto those described in Example 1 (iii)

[0839]¹H NMR (270 MHz, CDCl₃) δ7.64 (2H, d, J=8.8 Hz), 7.28-7.18 (1H,m), 6.98-6.88 (3H, m), 6.78 (2H, d, J=9.2 Hz), 6.00-5.90 (1H, m), 5.14(2H, s), 5.09 (1H, t, J=7.7 Hz), 4.58 (1H, d, J=7.0 Hz), 4.54 (1H, d,J=7.0 Hz), 4.25-4.12 (1H, m), 3.46 (3H, s), 3.45-3.35 (2H, m), 3.29 (3H,s), 3.08-2.96 (2H, m), 2.92-2.80 (1H, m), 2.86 (3H, s), 2.75-2.50 (3H,m), 2.12-1.95 (1H, m), 1.85-1.52 (3H, m), 0.97 (3H, t, J=7.3 Hz)

Example 76

[0840] Preparation of4-{N-[1-(R)-(3-t-Butoxycarbonylmethoxyphenyl)-2-(3-(S)-hydroxypyrrolidin-1-yl)-ethyl]-N-methylamino}-N′-propylbenzamide

[0841] This was prepared from4-{N-[1-(R)-(3-methoxymethoxyphenyl)-2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-ethyl]-N-methylamino}-N′-propylbenzamidein 11% over all yield according to the procedures similar to thosedescribed in Example 2 and Example 36.

[0842]¹H NMR (270 MHz, CDCl₃) δ7.65 (2H, d, J=8.8 Hz), 7.26-7.20 (1H,m), 6.92-6.89 (2H, m), 6.79 (2H, d, J=9.2 Hz), 6.79-6.75 (1H, m),6.01-5.92 (1H, m), 5.11 (1H, dd, J=7.0, 7.2 Hz), 4.47 (2H, s), 4 26-4.17(1H, m), 3.45-3.35 (2H, m), 3.04 (2H, d, J=7.3 Hz), 2.98-2.91 (1H, m),2.81 (3H, s), 2.69 (1H, d, J=9.2 Hz), 2.49 (1H, dd, J=4.8, 9.9 Hz),2.10-2.25 (1H, m), 2.17-2.06 (1H, m), 1.75-1.52 (4H, m), 1.45 (9H, s),0.98 (3H, t, J=7.3 Hz,

Example 77

[0843] Preparation of4-{N-[1-(R)-(3-Carboxymethoxyphenyl)-2-(3-(S)-hydroxypyrrolidine-1-yl)-ethyl]-N-methylamino}-N′-propylbenzamide

[0844] This was prepared from4-{N-[1-(R)-(3-t-butoxycarbonylmethoxyphenyl)-2-(3-(S)-hydroxypyrrolidin-1-yl)-ethyl]-N-methylamino}-N′-propylbenzamidein 86% yield according to the procedures similar to those described inExample 3.

[0845] HCl salt: light brown solid.

[0846]¹H NMR (270 MHz, DMSO-d6) δ10.55-10.15 (1H, m), 8.32-8.24 (1H, m),7.91-7.80 (2H, m), 7.34 (1H, t, J=7.7 Hz), 7.21-7.09 (2H, m), 6.98-6.84(3H, m), 5.95-5.80 (1H, m), 4.72 (2H, s), 4.60-4.40 (1H, m), 4.40-3.20(7H, m), 2.82 (1.2H, s), 2.81 (1.8H, s), 2.50-2.30 (2H, m), 2.15-1.85(2H, m), 1.70-1.50 (2H, m), 0.96 (3H, t, J=7.3 Hz)

[0847] 1 R(KBr): 3400, 1730, 1610 cm⁻¹.

[0848] MS m/z: 456 (M+H)⁺.

[0849] Anal. Calcd for C₂₅H₃₃N₃O₅.HCl.3.5H₂O: C, 54.10 , H, 7.45, N,7.57

[0850] Found : C, 54.49 ; H, 7.85; N, 7.76

Example 78

[0851] Preparation of3-Fluoro-4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-propylbenzamide

[0852] (i) Methyl3-fluoro-4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}benzoate

[0853] This was prepared from2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-2-(S)-phenylethanol and2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-2-(R)-phenylethanol and methyl3-fluoro-4-methylaminobenzoate in 52% yield according to the proceduressimilar to those described in Example 29 (i).

[0854]¹H NMR (270 MHz, CDCl₃) δ7.72-7.62 (2H, m), 7.38-7.22 (5H, m),6.81 (1H, t, J=8.8 Hz), 5.12-5.02 (1H, m), 4.58 (1H, d, J=7.0 Hz), 4.55(1H, d, J=7.0 Hz), 4.15-4.03 (1H, m), 3.88 (3H, s), 3.30 (3H, s),3.13-2.95 (2H, m), 2.88-2.78 (1H, m), 2.71(3H, d, J=0.7 Hz), 2.67-2.45(3H m), 2.05-1.90 (1H, m), 1.75-1.60(1H, m)

[0855] (ii)3-Fluoro-4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}benzoicacid

[0856] This was prepared from methyl3-fluoro-4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1yl)-1-(S)-phenylethyl]-N-methylamino}benzoatein 100% yield according to the procedures similar to those described inExample 1 (ii)

[0857]¹H NMR (270 MHz, CDCl₃) δ7.63-7.54 (2H, m), 7.38-7.22 (5H, m),6.76 (1H, t, J=8.4 Hz), 5.27-5.17 (1H, m), 4.61 (1H, d, J=7.0 Hz), 4.58(1H, d, J=7.0 Hz), 4.33-4.20 (1H, m), 3.55-3.43 (1H, m), 3.40-3.15 (3H,m), 3.31 (3H, s), 2.95-2.73 (2H, 2.74 (3H, s), 2.22-2.05 (1H, m),1.95-1.80 (1H, m)

[0858] (iii) 3-Fluoro-4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-propylbenzamide

[0859] This was prepared from3-fluoro-4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}benzoicacid and n-propylamine in 80% according to the procedures similar tothose described in Example 1 (iii)

[0860]¹H NMR (270 MHz, CDCl₃) δ7.48 (1H, dd, J=1.8, 14.3 Hz), 7.41-7.20(6H, m, 6.80 (1H, t, J=8.8 Hz), 6.08-6.00 (1H, m), 5.03-4.92 (1H, m),4.58 (1H, d, J=7.0 Hz), 4.54 (1H, d, J=6.6 Hz), 4.13-4.03 (1H, m),3.45-3.35 (2H, m), 3.30 (3H, s), 3.18-3.07 (1H, m), 3.02 (1H, dd, J=6.6,12.8 Hz), 2.83 (1H, dd, J=6.2, 9.9 Hz), 2.68 (3H, s), 2.65-2.45 ((3H,m), 2.07-1.93 (1H, m), 1.75-1.55 (3H, m), 0.99 (3H, t, J=7.3 Hz)

Example 79

[0861] Preparation of3-Fluoro-4-{N-[2-(3-(S)-Hydroxpyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-propylbenzamide

[0862] This was prepared from3-fluoro-4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-propylbenzamidein 40% yield according to the procedures similar to those described inExample 2

[0863]¹H NMR (270 MHz, free amine, CDCl₃) δ7.53 (1H, dd, J=2.2, 14.3Hz), 7.41-7.24 (6H, m), 6.83 (1H, t, J=8.8 Hz), 6.11-6.02 (1H, m),5.12-5.02 (1H, m), 4.22-4.13 (1H, m), 3.45-3.35 (2H, m), 3.35-3.23 (1H,m), 3.00 (1H, dd, J=5.5, 12.5 Hz), 2.92-2.73 (2H, m), 2.68 (3H, s),2.60-2.50 (1H, m), 2.33-2.18 (1H, m), 2.13-1.95 (1H, m), 1.90 (1H, br,s), 1.70-1.48 (3H, m), 0.99 (3H, t, J=7.3 Hz)

[0864] Maleic acid salt: amorphous solid.

[0865] 1 R(KBr): 3350, 1620 cm⁻¹.

[0866] MS .400 (M+H)⁺

[0867] Anal. Calcd for C₂₃H₃₀N₃O₂F.C₄H₄O₄.0.5H₂O C, 61.82; H, 6.72, N,8.01

[0868] Found . C, 61.52 , H,6.70 , N, 8.02.

Example 80

[0869] Preparation of 4-{N-[2-(3-(S)-Methoxymethoxypyrrolidin-1yl)-1-(S)-phenylethyl]-N-methylamino}-N′-(2,2,3,3,3,-pentafluoropropyl)benzamide

[0870] This was prepared from2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethanol and2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-2-(R)-phenylethanol and4-methylamino-N′-2,2,3,3,3,-pentafluoropropyl)benzamide in 32% yieldaccording to the procedures similar to those described in Example 1 (i).

[0871]¹H NMR (270 MHz, CDCl₃) δ7.67 (2H, d, J=8.8 Hz), 7.34-7.25 (5H,m), 6.81 (2H, d, J=9.2 Hz), 6.30-6.13 (1H, m), 5.15 (1H, t, J=7.7 Hz),4.59 (1H, d, J=6.6 Hz), 4.55 (1H, d, J=6.6 Hz), 4.23-4.10 (3H, m), 3.30(3H, s), 3.07-3.04 (2H, m), 2.87 (3H, s), 2.84-2.80 (1H, m), 2.76-2.67(1H, m), 2.64-2.53 (2H, m), 2.09-2.01 (1H, m), 1.77-1.70 (1H, m)

Example 81

[0872] Preparation of4-{N-[2-(3-(S)-Hydroxypyrrolidin-1yl)-1-(S)-phenylethyl]-N-methylamino}-N′-(2-2,3,3,3,-pentafluoropropyl)benzamide

[0873] This was prepared from4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-(2,2,3,3,3,-pentafluoropropyl)benzamidein 97% yield according to the procedures similar to those described inExample 2.

[0874]¹H NMR (270 MHz, free amine, CDCl₃) δ7.69 (2H, d, J=8.8 Hz),7.36-7.26 (5H, m), 6.82 (2H, d, J=8.8 Hz), 6.20-6.16 (1H, m), 5.16 (1H,dd, J=5.5, 8.8 Hz), 4.2-4.21 (1H, m), 4.14 (2H, dd, J=6.2, 14.7 Hz),3.14 (1H, dd, J=9.2, 12.8 Hz), 3.04 (1H, dd, J=5.9, 12.3 Hz), 2.95-2.88(1H, m), 2.86 (3H, s), 2.73 (1H, d, J=9.5 Hz), 2.57 (1H, dd, J=4.8, 9.5Hz), 2.37-2.29 (1H, m), 2.16-2.05 (1H, m), 1.80-1.60 (2H, m)

[0875] 1 R(neat) : 3350, 1610 cm⁻¹

[0876] HCl salt amorphous solid.

[0877] MS m/z:470 (M−H)⁻

[0878] Anal. Calcd for C₂₃H₂₆N₃O₂F₅.HCl.0.4CH₄O: C, 53.63 H, 5.44 N,8.16

[0879] Found: C,53.90; H, 5.33 ; N,7.79.

Example 82

[0880] Preparation of4-{N-[2-(3-(S)-Methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-tert-amylbenzamide

[0881] This was prepared from2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethanol and2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-2-(R)-phenylethanol and4-methylamino-N′-tert-amylbenzamide in 36% yield according to theprocedures similar to those described in Example 1 (i).

[0882]¹H NMR (270 MHz, CDCl₃) δ7.60 (2H, d, J=8.8 Hz), 7.34-7.23 (5H,m), 6.78 (H, d, J=8.8 Hz), 5.73-5.62 (1H, m), 5.13 (1H, dd, J=6.2, 8.4Hz), 4.60 (1H, d, J=7.0 Hz), 4.55 (1H, d, J=7.0 Hz), 4.17-4.15 (1H, m),3.30 (3H, s), 3.07-3.02 (2H, m), 2.33 (3 H, s), 2.86-2.80 (1H, m),2.72-2.64 (1H, m), 2.63-2.57 (2H, m), 2.09-2.01 (1H, m), 1.87-1.79 (1H,m), 1.83 (2H, q, J=7.3 Hz), 1.39 (6H, s), 0.88 (3H, t, J=7.3 Hz).

Example 83

[0883] Preparation of4-{N-[2-(3-(S)-Hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-tert-amylbenzamide

[0884] This was prepared from4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-tert-amylbenzamidein 88% yield according to the procedures similar to those described inExample 2.

[0885]¹H NMR (270 MHz, free amine, CDCl₃) δ7.62 (2H, d, J=8.8 Hz),7.35-7.22 (5H, m), 6.79 (2H, d, J=8.8 Hz), 5.73-5.63 (1H, m), 5.14 (1H,dd, J=5.9, 9.2 Hz), 4.24-4.20 (1H, m), 3.12 (1H, dd, J=8.8, 12.8 Hz),3.03 (1H, dd, J=5.9, 12.8 Hz), 2.93-2.86 (1H, m), 2.83 (3H, s), 2.73(1H, d, J=9.9 Hz), 2.56 (1H, dd, J=4.8, 9.5 Hz), 2.36-2.27 (1H, m),2.14-2.04 (1H, m), 1.83 (2H, q, J=7.3 Hz), 1.80-1.60 (2H, m), 1.40 (6H,s), 0.88 (3H, t, J=7.3 Hz)

[0886] 1 R(neat) 3350, 1610 cm⁻¹

[0887] HCl salt amorphous solid.

[0888] MS m/z:410 (M+H)⁺

[0889] Anal. Calcd for C₂₅H₃₅N₃O₂.HCl.0.2CH₄O C, 66.78 , H, 8.16; N,9.35

[0890] Found: C,66.67 ; H, 8.43; N,9.33.

Example 84

[0891] Preparation of4-{N-[2-(3-(S)-Methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-tert-butylbenzamide

[0892] This was prepared from2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethanol and2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-2-(R)-phenylethanol and4-methylamino-N′-tert-butylbenzamide in 66% yield according to theprocedures similar to those described in Example 1 (i).

[0893]¹H NMR (270 MHz, CDCl₃) δ7.61 (2H, d, J=8.8 Hz), 7.40-7.20 (5H,m), 6.78 (2H, d, J=9.2 Hz), 5.90-5.65 (1H, m), 5.18-5.10 (1H, m), 4.60(1H, d, J=6.6 Hz), 4.56 (1H, d, J=7.0 Hz), 4 24-4.14 (1H, m), 3.30 (3H,s), 3.10-2.98 (2H, m), 2.90-2.78 (1H, m), 2.84 (3H, s), 2.76-2.54 (3H,m), 2.15-1.95 (1H, m), 1.80-1.60 (1H, m), 1.45 (9H, s).

Example 85

[0894] Preparation of4-{N-[2-(3-(S)-Hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-tert-butylbenzamide

[0895] This was prepared from4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-tert-butylbenzamidein 52% yield according to the procedures similar to those described inExample 2.

[0896]¹H NMR (270 MHz, free amine, CDCl₃) δ7.62 (2H, d, J=8.8 Hz),7.35-7.24 (5H, m), 6.79 (2H, d, J=9.2 Hz), 5.83-5.77 (1H, m), 5.14 (1H,dd, J=5.5, 8.8 Hz), 4.26-4.18 (1H, m), 3.13 (1H, dd, J=9.2, 12.8 Hz),3.03 (1H, dd, J=5.9, 12.8 Hz), 2.92-2.86 (1H, m), 2.83 (3H, s), 2.74(1H, d, J=9.9 Hz), 2.55 (1H, dd, J=4.8, 9.9 Hz), 2.36-2.27 (H, m),2.11-2.08 (1H, m), 1.72-1.54 (2H, m), 1.45 (9H, s).

[0897] 1 R(neat) 3350, 1610 cm⁻¹.

[0898] HCl salt: amorphous solid.

[0899] MS m/z:396 (M+H)⁺

[0900] Anal. Calcd for C₂₄H₃₃N₃O₂.HCl.1.2H₂O C, 63.55; H, 8.09, N, 9.26

[0901] Found: C,63.34, H,7.93; N,9.01.

Example 86

[0902] Preparation of5-{N-[2-(3-(S)-Hydroxypyrrolidin-1yl)-1(S)-phenylethyl]-N-methylamino}-N′-propylpicolinamide

[0903] This was prepared from2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethanol and2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-2-(R)-phenylethanol and5-methylamino-N′-propylpicolinamide in 24% over all yield according tothe procedures similar to those described in Example 1 (i) and Example2.

[0904]¹H NMR (270 MHz, free amine, CDCl₃) δ3.12 (1H, d, J=3.3 Hz), 8.02(1H, d, J=8.8 Hz), 7.82-7.74 (1H, m), 7.38-7.24 (5H, m), 7.13 (1H dd,J=3.3, 8.8 Hz), 5.10 (1H, dd, J=5.5, 9.5 Hz), 4.30-4.20 (1H, m),3.45-3.35 (2H, m), 3.17 (1H, dd, J=9.5, 12.8 Hz), 3.01 (1H, dd. J=5.5,12.8 Hz), 2.95-2.84 (1H, m), 2.91 (3H, s), 2.70 (1H, d, J=9.2 Hz), 2.61(1H, dd, J=4.8, 9.5 Hz), 2.42-2.30 (1H, m), 2.18-2.02 (1H, m), 1.80-1.55(4H, m), 0.98 (3H, t, J=7.3 Hz).

[0905] Fumaric acid salt: amorphous solid.

[0906] 1 R(KBr): 3400, 1650 cm⁻¹.

[0907] MS m/z:383 (M+H)⁺

[0908] Anal. Calcd for C₂₂H₃₀N₄O₂.C₄H₄O₄. 0.5H₂O: C, 61.52; H, 6.95 N,11.04

[0909] Found C,61.75 H,7.09,N,10.95

Example 87

[0910] Preparation of4-{N-Hydroxy-N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]amino}-N′-propylbenzamide

[0911] This was prepared from2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethanol and2-(3-(S)-methoxymethoxypyrrolidin-1yl)-2-(R)-phenylethanol and methyl4-hydroxyaminobenzoate in 33% over all yield according to the proceduressimilar to those described in Example 1 (i),(ii) and (iii).

[0912]¹H NMR (270 MHz, CDCl₃) δ7.55 (2H, d, J=8.8 Hz), 7.43-7.18 (5H,m), 6.90 (2H, d, J=8.8 Hz), 6.05-5.95 (1H, m), 4.87 (1H, dd, J=5.1, 10.3Hz), 4.63 (1H, d, J=7.0 Hz), 4.60 (1H, d, J=7.0 Hz), 4.30-4.20 (1H, m),3.58-3.46 (2H, m), 3.43-3.25 (2H, m), 3.35 (3H, s), 2.95-2.50 (4H, m),2.20-1.80 (2H, m), 1.70-1.50 (2H, m), 0.96 (3H, t, J=7.3 Hz).

Example 88

[0913] Preparation of4[}N-Hydroxy-N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]amino}-N′-propylbenzamide

[0914] This was prepared from4-{N-hydroxy-N-[2-(3-(S)-methoxymethoxypyrrolidin-1yl)-1-(S)-phenylethyl]amino}-N′-propylbenzamidein 63% yield according to the procedures similar to those described inExample 2.

[0915]¹H NMR (270 MHz, free amine, CDCl₃) δ8.86 (1H, s), 8.18-8.08 (1H,m), 7.64 (2H, d, J=8.8 Hz), 7.42 (2H, d, J=6.6 Hz), 7.27-7.12 (3H, m),7.07 (2H, d, J=8.8 Hz), 4.96 (1H, dd, J=6.6, 7.3 Hz), 4.62 (1H, d, J=4.8Hz), 4.15-4.05 (1H, m), 3.20-3.10 (2H, m), 3.07-2.92 (2H, m), 2.74 (1H,dd, J=6.2, 9.5 Hz), 2.56 (2H, t, J=7.3 Hz), 2.36 (1H, ddd, J=4.3, 9.5Hz), 2.00-1.80 (1H, m), 1.55-1.40 (3H, m), 0.86 (3H, t, J=7.3 Hz).

[0916] Fumaric acid salt: amorphous solid.

[0917] 1 R(KBr): 3300, 1630 cm⁻¹.

[0918] MS m/z:384 (M+H)⁺

[0919] Anal. Calcd for C₂₂H₂₉N₃O₃.C₄H₄O₄.0.5H₂O C, 61.40; H, 6.74, N,8.26

[0920] Found: C, 61.40; H,6.78; N, 8.08.

Example 89

[0921] Preparation of4-{N-[2-(3-(S)-Fluoropyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-(2-(S)-hydroxypropyl)benzamide

[0922] This was prepared from4-{N-[2-(3-(S)-fluoropyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}benzoicacid and (S)-(+)-1-amino-2-propanol in 38% yield according to theprocedures similar to those described in Example 1 (iii).

[0923]¹H NMR (270 MHz, free amine, CDCl₃) δ7.67 (2H, d, J=8.8 Hz),7.35-7.23 (5H, m, 6.78 (2H, d, J=8.8 Hz), 6.47-6.42 (1H, m), 5.21-4.94(1H, m), 5.11 (1H, dd, J=6.2, 8.4 Hz), 4.03-3.97 (1H, m), 3.64-3.56 (1H,m), 3.35-3.25 (1H, m), 3.16-3.01 (2H, m, 2.89 -2.76 (3H, m), 2.87 (3H,s), 2.58-2.50 (1H, m), 2.11-1.90 (1H, m), 1.76-1.55 (2H, m), 1.22 (3H,d, J=6.6 Hz)

[0924] Fumaric acid salt: amorphous solid.

[0925] MS m/z: 400 (M+H)⁺

[0926] Anal. Calcd for C₂₃H30N₃O₂F.C₄H₄O₄.0.8CH₄O C, 61.70; H, 6.93; N,7.76.

[0927] Found: C, 61.52; H, 6.59; N,7.64.

Example 90

[0928] Preparation of2-Chloro-4-{N-[2-(3-(S)-fluoropyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-propylbenzamide

[0929] This was prepared from2-(3-(S)-fluoropyrrolidin-1-yl)-]-(S)-phenylethanol and2-(3-(S)-fluoropyrrolidin-1-yl)-2-(R)-phenylethanol and2-chloro-4-methylamino-N′-propylbenzamide in 13% yield according to theprocedures similar to those described in Example 1 (i).

[0930]¹H NMR (270 MHz, free amine, CDCl₃) δ7.75 (1H, d, J=8.4 Hz),7.38-7.20 (5H, m) 6.78-6.70 (2H, m), 6.58-6.50 (1H, m), 5.25-4.95 (1H,m), 5.04(1H, dd, J=6.2, 8.4 Hz), 3.50-3.37 (2H, m), 3.12 (1H, dd, J=9.2,12.8 Hz), 3.03 (1H, dd, J=5.9, 12.8 Hz), 2.95-2.75 (2H, m), 2.85 (3H,s), 2.60-2.50 (1H, m), 2.17-1.85 (2H, m), 1.70-1.55 (3H, m), 0.99 (3H t,J=7.3 Hz).

[0931] Fumaric acid salt: amorphous solid.

[0932] MS m/z: 418 (M+H)⁺

[0933] Anal. Calcd for C₂₃H₂₉N₃OFCl.C₄H₄O₄.0.1H₂O: C, 60.52; H, 6.25; N,7.84

[0934] Found: C, 60.16; H 6.61; N,7.64.

Example 91

[0935] Preparation of4-{N-[2-(3-(S)-Fluoropyrrolidin-1-yl)-1-(S)-phenylethyl]-N-hydroxyamino}-N′-propylbenzamide

[0936] This was prepared from2-(3-(S)-fluoropyrrolidin-1-yl)-1-(S)-phenylethanol and2-(3-(S)-fluoropyrrolidin-1yl)-2-(R)-phenylethanol and4-hydroxyamino-N′propylbenzamide in 56% yield according to theprocedures similar to those described in Example 1 (i).

[0937] HCl salt:

[0938] mp: 195-200° C.

[0939]¹H NMR (270 MHz, DMSO) δ10.67 (1H, br, s), 9.35-9.20 (1H, m),8.30-8.20 (1H, m), 7.70 (2H, d, J=8.4 Hz), 7.50-7.15 (7H, m), 5.70-5.35(2H, m), 4.25-3.30 (6H, m), 3.25-3.10 (2H, m), 2.70-2.10 (2H, m),1.60-1.40 (2H, m), 0.86 (3H, t, J=7.3 Hz)

[0940] 1 R(KBr): 1600 cm⁻¹

[0941] MS m/z: 384 (M−H)⁻

[0942] Anal. Calcd for C₂₂H₂₈N₃O₂F.HCl C, 62.63 H, 6.93; N, 9.96

[0943] Found C, 62.23, H, 7.10 , N,9.79

Example 92

[0944] Preparation of5-{N-[2-(3-(S)-Fluoropyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-propylpicolinamide

[0945] This was prepared from2-(3-(S)-fluoropyrrolidin-1-yl)-1-(S)-phenylethanol and2-(3-(S)-fluoropyrrolidin-1-yl)-2-(R)-phenylethanol and5-methylamino-N′-propylpicolinamide in 26% yield according to theprocedures similar to those described in Example 1 (i).

[0946]¹H NMR (270 MHz, free amine, CDCl₃) δ8.10 (1H, d, J=2.9 Hz), 8.01(1H, d, J=8.8 Hz), 7.82-7.74 (1H, m), 7.38-7.24 (5H, m), 7.11 (1H, dd,J=2.9, 8.8 Hz), 5.23-4.95 (1H, m) 5.07 (1H, dd, J=5.9, 9.5 Hz),3.45-3.35 (2H, m), 3.18 (1H, dd, J=9.5, 12.8 Hz), 3.03 (1H, dd, J=5.9,12.8 Hz), 2.95-2.75 (2H, m), 2.93 (3H, s), 2.60-2.50 (1H, m), 2.18-1.90(2H, m), 1.70-1.55 (3H, m), 0.98 (3H, t, J=7.3 Hz).

[0947] Fumaric acid salt: amorphous solid.

[0948] 1 R(KBr) 1650 cm⁻¹.

[0949] MS m/z:385 (M+H)⁺

[0950] Anal. Calcd for C₂₂H₂₉N₄OF.C₄H₄O₄.0.6H₂O C, 61.07; H, 6.74; N,10.96

[0951] Found: C, 60.87; H, 6.35; N, 10.89.

Example 93

[0952] Preparation of4-{N-Methylamino-N-[2-(3-pyrrolidin-1-yl)-1-(S)-phenylethyl]-N′-propylbenzamide

[0953] This was prepared from 2-(R)-phenyl-2-(3-pyrrolin-1-yl)ethanoland 4-methylamino-N′-propylbenzamide in 12% yield according to theprocedures similar to those described in Example 1 (i).

[0954]¹H NMR (270 MHz, free amine, CDCl₃) δ7.65 (2H, d, J=9.2 Hz),7.35-7.24 (5H, m), 6.80 (2H, d, J=9.2 Hz), 5.97 (1H, br s), 5.72 (2H,s), 5.12 (1H, dd, J=7.0, 7.7 Hz), 3.58-3.49 (4H, m), 3.38 (2H, dd,J=5.9, 7.3 Hz), 3.25-3.21 (2H, m), 2.86 (3H, s), 1.61 (2H, dd, J=7.3,14.7 Hz), 0.97 (3H, t, J=7.3 Hz)

[0955] 1 R(neat): 2950, 1650 cm⁻¹.

[0956] HCl salt: amorphous solid.

[0957] MS m/z: 363 (M⁺)

[0958] Anal. Calcd for C₂₃H₂₉N₃O.HCl.0.1CH₄O.0.9H₂O: C, 66.16 H, 7.74;N, 10.02.

[0959] Found: C, 66.56; H7.64; N,9.65

Example 94

[0960] Preparation of4-{N-[2-(3-(R)-fluoropyrrolidine-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-propylbenzamide

[0961] This was prepared from2-(3-(R)-fluoropyrrolidin-1-yl)-1-(S)-phenylethanol and2-(3-(R)-fluoropyrrolidin-1-yl)-2-(R)-phenylethanol and4-methylamino-N-propylbenzamide in 47% yield according to the proceduressimilar to those described in Example 1 (i).

[0962]¹H NMR (270 MHz, free amine, CDCl₃) δ7.67 (2H, d, J=8.8 Hz),7.34-7.24 (5H, m), 6.79 (2H, d, J=8.8 Hz), 6.13 (1H, br, s), 5.25-4.95(1H, m), 5.13 (1H, dd, J=6.2, 8.4 Hz), 3.41-3.34 (2H, m), 3.17-3.05 (2H,m), 3.02-2.77 (3H, m), 2.82 (3H, s), 2.59-2.51 (1H, m), 2.09-1.91 (2H,m), 1.72-1.54 (2H, m), 0.95 (3H, t, J=7.3 Hz)

[0963] HCl salt: amorphous solid.

[0964] MS m/z: 383 (M⁺)

[0965] Anal. Calcd for C₂₃H₃₀N₃OF.HCl.0.5H₂O C, 64.40; H, 7.52; N, 9.80

[0966] Found C, 64.51; H, 7.74 ; N, 9.46

Example 95

[0967] Preparation of4-{N-[2-(3-(S)-fluoropyrrolidin-1-yl)-1-(R)-phenylethyl]-N-methylamino}-N′-propylbenzamide

[0968] This was prepared from2-(3-(S)-fluoropyrrolidin-1-yl)-1-(R)-phenylethanol and2-(3-(S)-fluoropyrrolidin-1-yl)-2-(S)-phenylethanol and4methylamino-N′-propylbenzamide in 28% yield according to the proceduressimilar to those described in Example 1 (i).

[0969]¹H NMR (270 MHz, free amine, CDCl₃) δ7.65 (2H, d, J=8.4 Hz),7.30-7.24 (5H, m), 6.80 (2H, d, J=8.4 Hz), 6.00 (1H, br, s), 5.25-4.95(2H, m), 3.43-3.36 (2H, m), 3.13-3.07 (2H, m), 3.01-2.89 (2H, m), 2.83(3H, s), 2.58-2.55 (1H, m), 2.10-2.00 (1H, m), 2.00-1.92 (1H, m),1.73-1.55 (3H, m), 0.97 (3H, t, J=7.3 Hz)

[0970] HCl salt: amorphous solid.

[0971] MS m/z: 383 (M⁺)

[0972] Anal. Calcd for C₂₃H₃₀N₃OF.HCl.2H₂O: C, 60.58; H, 7.74, N, 9.21

[0973] Found: C, 60,59;H, 7.36; N, 9.23.

Example 96

[0974] Preparation of4-{N-[2-(3-(S)-Chloropyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-propylbenzamide

[0975] This was prepared from2-(3-(S)-chloropyrrolidin-1-yl)-1-(S)-phenylethanol and2-(3-(S)-chloropyrrolidin-1-yl)-2-(R)-phenylethanol and4-methylamino-N′-propylbenzamide in 40% yield according to theprocedures similar to those described in Example 1 (i).

[0976]¹H NMR (270 MHz, free amine, CDCl₃) δ7.68 (2H, d, J=8.8 Hz),7.33-7.27 (5H, m), 6.78 (2H, d, J=8.8 Hz), 6.23 (1H, br, s), 5.08 (1H,dd, J=7.3, 7.7 Hz), 4.30-4.25 (1H, m), 3.40-3.33 (2H, m), 3.13-3.08 (3H,m), 2.84 (3H, s), 2.81-2.65 (3H, m), 2.36-2.22 (1H, m), 2.02-1.95 (1H,m), 1.63-1.53 (2H, m), 0.94 (3H, t, J=7.3 Hz)

[0977] HCl salt: amorphous solid.

[0978] MS m/z: 399 (M⁺)

[0979] Anal. Calcd for C₂₃H₃₀N₃OCl.HCl.2.5H₂O: C, 57.38; H, 7.54;N,8.73.

[0980] Found C,57.10, H, 7.42, N,8.48

Example 97

[0981] Preparation of4-{N-[2-(3-(S)-Chloropyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-(2-(S)-hydroxypropyl)benzamide

[0982] This was prepared from2-(3-(S)-chloropyrrolidin-1-yl)-1-(S)-phenylethanol and2-(3-(S)-chloropyrrolidin-1-yl)-2-(R)-phenylethanol and4-methylamino-N′-(2-(S)-hydroxypropyl)benzamide in 45% yield accordingto the procedures similar to those described in Example 1 (i).

[0983]¹H NMR (270 MHz, free amine, CDCl₃) δ7.68 (2H, d, J=9.2 Hz),7.35-7.28 (5H, m), 6.79 (2H, d, J=8.8 Hz), 6.52 (1H, br, s), 5.10 (1H,t, J=7.3 Hz), 4.32-4.27 (1H, m), 4.02-3.97 (1H, m), 3.64-3.56 (1H, m),3.35-3.24 (1H, m), 3.14-3.10 (3H, m), 2.85 (3H, s), 2.82-2.76 (2H, m),2.74-2.69 (1H, m), 2.38-2.27 (1H, m), 2.05-1.80 (2H, m), 1.22 (3H, d,J=6.2 Hz)

[0984] HCl salt: amorphous solid.

[0985] MS m/z: 415 (M⁺)

Example 98

[0986] Preparation of4-{N-[2-(3-(S)-Chloropyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-(2-(R)-hydroxypropyl)benzamide

[0987] This was prepared from2-(3-(S)-chloropyrrolidin-1-yl)-1-(S)-phenylethanol and2-(3-(S)-chloropyrrolidin-1-yl)-2-(R)-phenylethanol and4-methylamino-N′-(2-(R)-hydroxypropyl)benzamide in 44% yield accordingto the procedures similar to those described in Example 1 (i).

[0988]¹H NMR (270 MHz, free amine, CDCl₁) δ7.68 (2H, d, J=9.2 Hz),7.35-7.23 (5H, m), 6.79 (2H, d, J=9.2 Hz), 6.53 (1H, br s), 5.11 (1H, t,J=7.3 Hz), 4.33-4.27 (1H, m), 4.03-3.98 (1H, m), 3.64-3.56 (1H, m),3.35-3.25 (1H, m), 3.16-3.12 (1H, m), 3.12 (2H, d, J=7.3 Hz), 2.85 (3H,s), 2.83-2.71 (3H, m), 2.36-2.27 (1H, m), 2.04-1.98 (1H, m), 1.22 (3H,d, J=6.2 Hz)

[0989] HCl salt: amorphous solid.

[0990] MS m/z: 416 (M+H)⁺

[0991] Anal. Calcd for C₂₃H₃₀N₃O₂Cl.HCl.H₂O: C, 58.72; H,7.07; N,8.93

[0992] Found C, 58.56; H 7.00; N,8.76

Example 99

[0993] Preparation of4-{N-[2-(3-Oxopyrrolidin-1-yl)-1-(S)-phenylethyl-N-methylamino}-N′-propylbenzamide

[0994] To a stirred solution of oxalylcloride (0.26 ml, 3.0 mmol) inCH₂Cl₂ (15 ml) was added a solution of DMSO (0.29 ml, 4.0 mmol) inCH₂Cl₂ (1ml) at −78° C. The reaction mixture was stirred for 10 min anda solution of4-{N-[2-(3-(S)-hydroxypyrrolidin-1yl)-1-(S)-phenylethyl]-N-methylamino}-N′-propylbenzamide(5.73 mg, 1.5 mmol) in CH₂Cl₂ (5 ml) was added and stirring wascontinued for an additional 15 min at −78° C. 60 min at −45° C.Triethylamine (1.6 ml, 110 mmol) was added and then the reaction mixturewas allowed to warm to room temperature. Saturated NC₄Cl aqueoussolution was added and extracted with AcOEt. The extract was washed withwater and brine, dried Na₂SO₄), and concentrated to give brown oil,which was purified by column chromatography (silica gel. 70 g,CH₂Cl₂/MeOH: 50/1-40/1) to give 195 mg(34%) of pale yellow oil.

[0995]¹H NMR (270 MHz, free amine, CDCl₃) δ7.66 (2H, d, J=9.2 Hz),7.36-7.25 (5H, m), 6.30 (2H, d, J=9.2 Hz), 6.01 (1H, br, s), 5.17 (1H,t, J=7.3 Hz), 3.43-3.36 (2H, m), 3.17-3.13 (2H, m), 3.07-2.92 (4H, m),2.85 (3H, s), 2.35 (2H, t, J=7.0 Hz), 1.6-1.53 (2H, m), 0.97 (3H, t,J=7.7 Hz).

[0996] HCl salt amorphous solid.

[0997] MS m/z: 379 (M⁺)

Example 100

[0998] Preparation of4-{N-[2-(3-(S)-Hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-propylbenzamide

[0999] 4-{N-[2-(3-(S)-Methoxymethoxypyrrolidin-1yl)-1-(S)-phenylethyl]-N-methylamino}-N′-propylbenzamidewas prepared from2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethanol and2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-2-(R)-phenylethanol and4-methylamino-N′-propylbenzamide according to the procedures similar tothose described in Example 1 (i). Title compound was prepared from4-{N-[2-(3-(S)-methoxymethoxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-N-propylbenzamidein 65% over all yield according to the procedures similar to thosedescribed in Example 2. The title compound was the same as one obtainedin Example 2

[1000]¹H NMR (270 MHz, free amine, CDCl₃) δ7.66 (2H, d, J=8.8 Hz),7.40-7.20 (5H, m), 6.80 (2H, d, J=9.2 Hz), 6.05-5.90 (1H, m), 5.14 (1H,dd, J=5.9, 9.2 Hz), 4.28-4.16 (1H, m), 3.46-3.32 (2H, m), 3.12 (1H, dd,J=9.2, 12.8 Hz), 3.03 (1H, dd, J=5.9, 12.8 Hz). 2.95-2.80 (1H, m), 2.83(3H, s), 2.72 (1H, d, J=9.5 Hz), 2.56 (1H, dd, J=4.8, 9.9 Hz), 2.33 (1H,ddd, J=6.2, 8.8, 8.8 Hz), 2.18-2.00 (1H, m), 1.89 (1H, br, s), 1.70-1.50(3H, m), 0.97 (3H, t, J=7.3 Hz)

[1001] HCl salt: amorphous solid.

[1002] MS m/z-382 (M+H)⁺

[1003] Anal. Calcd for C₂₃H₃₁N₃O₂.HCl.1.5H₂O.CH₄O: C, 60.43, H, 8.24, N,8.81

[1004] Found : C,60.23; H,8.62 ; N,9.03.

[1005] The chemical structures of the compounds prepared in Examples 1to 100 are summarized in the following tables. In the tables, H-represents hydrogen, Me-, Et-, Pr-, Bu-, Pe- and Am- represent methyl,ethyl, propyl, butyl, pentyl and amyl respectively; F- and Cl- representfluorine and chlorine respectively; All- and Prp- represent allyl andpropargyl respectively; MeO-and EtO- represent methoxy and ethoxyrespectively; HO- represents hydroxy; Car- represents carboxy; Ph-, Py-,Th- and Bn- represent phenyl, pyridyl, thienyl and benzyl respectively;MOM-, t-Boc-, 2-THP- and TBDMS- represent methoxymethyl,t-butoxycarbonyl, tetrahydropyran-2-yl and t-butyldimethysilylrespectively; tri-F-Pr-, penta-F-Pr- and 2-HO-Pr-represent3,3,3-trifluoropropyl, 2,2,3,3,3-pentafluoropropyl and 2-hydroxypropylrespectively, O=represents oxo; and cyc represents cyclic. TABLE 1 (I)

Ex.-# A Ar¹ Ar² R¹ R² R³  1 (S)-MOM-O— (S)-Ph- 1,4-Ph- Me- Pr— H—  2(S)-HO— (S)-Ph- 1,4-Ph- Me- Pr— H—  3 (S)-MOM-O— (S)-Ph- 1,4-Ph- Me- Me-H—  4 (S)-HO— (S)-Ph- 1,4-Ph- Me- Me- H—  5 (S)-MOM-O— (S)-Ph- 1,4-Ph-Me- Er— H—  6 (S)-HO— (S)-Ph- 1,4-Ph- Me- Er— H—  7 (S)-MOM-O— (S)-Ph-1,4-Ph- Me- Bu- H—  8 (S)-HO— (S)-Ph- 1,4-Ph- Me- Bu- H—  9 (S)-2-THP-O—(S)-Ph- 1,4-Ph- Me- Pe- H—  10 (S)-HO— (S)-Ph- 1,4-Ph- Me- Pe- H—  11(S)-MOM-O— (S)-Ph- 1,4-Ph- Me- i-Pr— H—  12 (S)-HO— (S)-Ph- 1,4-Ph- Me-i-Pr— H—  13 (S)-MOM-O— (S)-Ph- 1,4-Ph- Me- Ph- H—  14 (S)-HO— (S)-Ph-1,4-Ph- Me- Ph- H—  15 (S)-MOM-O— (S)-Ph- 1,4-Ph- Me- 2-Cl-Bn- H—  16(S)-HO— (S)-Ph- 1,4-Ph- Me- 2-Cl-Bn- H—  17 (S)-MOM-O— (S)-Ph- 1,4-Ph-Me- Me- Me-  18 (S)-HO— (S)-Ph- 1,4-Ph- Me- Me- Me-  19 (S)-2-THP-O—(S)-Ph- 1,4-Ph- Me- Pr— Me-  20 (S)-HO— (S)-Ph- 1,4-Ph- Me- Pr— Me-  21(S)-MOM-O— (S)-Ph- 1,3-Ph- Me- Pr— H—  22 (S)-HO— (S)-Ph- 1,3-Ph- Me-Pr— H—  33 (S)-MOM-O— (S)-3-MOM— 1,4-Ph- Me- Pr— H— O-Ph-  34 (S)-HO—(S-3-HO-Ph- 1,4-Ph- Me- Pr— H—  35 (S)-HO— (S)-3-MeO— 1,4-Ph- Me- Pr— H—Ph-  36 (S)-HO— (S)-3-t-Boc- 1,4-Ph- Me- Pr— H— MeO—  37 (S)-HO—(S)-3-Car- 1,4-Ph- Me- Pr— H— MeO-Ph-  38 H— (S)-Ph- 1,4-Ph- Me- Pr— H— 40 (S)-MOM-O— (S)-Ph- 2,5-Th- Me- Pr— H—  41 (S)-HO— (S)-Ph- 2,S-Th-Me- Pr— H—  42 (S)-MOM-O— (S)-Ph- 1,4-Ph- H— Pr— H—  43 (S)-HO— (S)-Ph-1,4-Ph- H— Pr— H—  44 (S)-MOM-O— (S)-3-Cl-Ph- 1,4-Ph- Me- Pr— H—  45(S)-HO— (S)-3-Cl-Ph- 1,4-Ph- Me- Pr— H—  46 (S)-F— (S)-Ph- 1,4-Ph- Me-Pr— H—  47 (S)-MOM-O— (R)-Ph- 1,4-Ph- Me- Pr— H—  48 (S)-HO— (R)-Ph-1,4-Ph- Me- Pr— H—  51 (S)-TBDMS- (S)-Ph- 1,4-Ph- Me- EtO— H— O—  52(S)-HO— (S)-Ph- 1,4-Ph- Me- EtO— H—  55 (S)-MOM-O— (S)-Ph- 1,4-Ph- Me-3-HO-Pr— H—  56 (S)-HO— (S)-Ph 1,4-Ph- Me- 3-HO-Pr— H—  57 (S)-MOM-O—(S)-Ph 1,4-Ph- Me- 2-(R)-HO— H— Pr—  58 (S)-HO— (S)-Ph- 1,4-Ph- Me-2-(R)-HO— H— Pr—  59 (S)-MOM-O— (S)-Ph- 1,4-Ph- Me- i-Bu- H—  60 (S)-HO—(S)-Ph- 1,4-Ph- Me- i-Bu- H—  61 (S)-MOM-O— (S)-Ph- 1,4-Ph- Me- All- H— 62 (S)-HO— (S)-Ph- 1,4-Ph- Me- All-  63 (S)-MOM-O— (S)-Ph- 1,4-Ph- Me-cyc-Pr— H—  64 (S)-HO— (S)-Ph- 1,4-Ph- Me- cyc-Pr— H—  65 (S)-MOM-O—(S)-Ph- 1,4-Ph- Me- (S)-sec- H— Bu-  66 (S)-HO— (S)-Ph- 1,4-Ph- Me-(S)-sec- H— Bu-  67 (S)-MOM-O— (S)-Ph- 1,4-Ph- Me- (R)-sec- H— Bu-  68(S)-HO— (S)-Ph- 1,4-Ph- Me- (R)-sec- H— Bu-  69 (S)-MOM-O— (S)-Ph-1,4-Ph- Me- Prp- H—  70 (S)-HO— (S)-Ph- 1,4-Ph- Me- Prp- H—  71(S)-MOM-O— (S)-Ph- 1,4-Ph- Me- tri-F—Pr— H—  72 (S)-HO— (S)-Ph- 1,4-Ph-Me- tri-F—Pr— H—  73 (S)-MOM-O— (S)-Ph 1,4-Ph Me 2-(S)-HO— H Pr  74(S)-OH (S)-Ph- 1,4-Ph- Me- 2-(S)-HO— H— Pr—  75 (S)-MOM-O— (R)-3-1,4-Ph- Me- Pr— H— MOM-O—Ph-  76 (S)-HO— (R)-3-t-Boc- 1,4-Ph- Me- Pr— H—MeO-Ph-  77 (S)-HO— (R)-3-Car- 1,4-Ph- Me- Pr— H— MeO-Ph-  80 (S)-MOM-O—(S)-Ph- 1,4-Ph- Me- penta-F— H— Pr—  81 (S)-HO— (S)-Ph- 1,4-Ph- Me-penta-F— H— Pr—  82 (S)-MOM-O— (S)-Ph- 1,4-Ph- Me- t-Am- H—  83 (S)-HO—(S)-Ph- 1,4-Ph- Me- t-Am- H—  84 (S)-MOM-O— (S)-Ph- 1,4-Ph- Me- t-Bu- H— 85 (S)-HO— (S)-Ph- 1,4-Ph- Me- t-Bu- H—  87 (S)-MOM-O— (S)-Ph- 1,4-Ph-HO— Pr— H—  88 (S)-HO— (S)-Ph- 1,4-Ph- HO— Pr— H—  89 (S)-F— (S)-Ph-1,4-Ph- Me- 2-(S)-HO— H— Pr—  91 (S)-F— (S)-Ph- 1,4-Ph- HO— Pr— H—  94(R)-F— (S)-Ph- 1,4-Ph- Me- Pr— H—  95 (S)-F— (R)-Ph- 1,4-Ph- Me- Pr— H— 96 (S)-Cl- (S)-Ph- 1,4-Ph- Me- Pr— H—  97 (5)-Cl- (S)-Ph- 1,4-Ph- Me-2-(S)-HO— H— Pr  98 (S)-Cl- (S)-Ph- 1,4-Ph- Me- 2-(R)-HO— H— Pr—  99 O═(S)-Ph- 1,4-Ph- Me- Pr— H— 100 (S)-HO— (S)-Ph- 1,4-Ph- Me- Pr— H—

[1006] TABLE 2 Example 23 Example 28

Example 24 Example 29

Example 25 Example 30

Example 26 Example 31

Example 27 Example 32

Example 39 Example 79

Example 49 Example 86

Example 50 Example 90

Example 53 Example 92

Example 54 Example 93

Example 78

1. A compound of the following formula:

and the salts thereof, wherein A is hydrogen, halo, hydroxy, C₁-C₆alkyl, halo C₁-C₆ alkyl, C₁-C₆ alkoxy, halo C₁-C₆ alkoxy, oxo, OYwherein Y is a hydroxy protecting group, or absent; the broken linerepresents an optional double bond with proviso that if the broken lineis a double bond, then A is absent; Ar¹ is phenyl optionally substitutedby one or more substituents selected from halo, hydroxy, C₁-C₄ alkyl,C₁-C₄ alkoxy, C₁-C₄ alkoxy-C₁-C₄ alkoxy, CF₃, carboxy-C₁-C₄ alkoxy andC₁-C₄ alkoxy-carbonyl-C₁-C₄ alkoxy; Ar² is aryl or heteroaryl selectedfrom phenyl, naphthyl, pyridyl, thienyl, furyl, pyrrolyl and pyrimidyl,the aryl or heteroaryl being optionally substituted bygone or moresubstituents selected from halo, hydroxy, amino, nitro, carboxy, C₁-C₄alkyl, C₁-C₄ alkoxy, C₁-C₄ alkylamino, di C₁-C₄ alkylamino, halo C₁-C₄alkyl, C₁-C₄ alkylthio and sulfonyl methyl, R¹ is hydrogen, hydroxy,C₁-C₄ alkyl, C₁-C₄ alkoxy or OY wherein Y is a hydroxy protecting group;and R² and R³ are independently selected from hydrogen, hydroxy, C₁-C₇alkyl optionally substituted by one or more hydroxy or halo, C₃-C₆cycloalkyl, C₂-C₆ alkenyl C₂-C₆ alkynyl, C₁-C₇ alkoxy, phenyl optionallysubstituted by halo, phenyl C₁-C₇ alkyl, halo substituted phenyl C₁-C₇alkyl, and (CH₂)nX-R⁴ wherein n is one or two; X is O, NH or S and R⁴ isC₁-C₃ alkyl, or when Ar² is phenyl, —Ar²—C(═O)—N(R²)— is a phthalimidegroup and R³ is C₁-C₇ alkyl, or R² and R³, together with the nitrogenatom to which they are attached, form a pyrrolidine, piperidine ormorpholine ring, optionally substituted by C₁-C₃ alkyl or halo.
 2. Acompound according to claim 1 , wherein A is hydrogen, halo, hydroxy,oxo or OY; or if the broken line is a double bond, then A is absent; Ar¹is phenyl optionally substituted by one to three substituents selectedfrom halo, hydroxy, C₁-C₄ alkoxy, carboxy C₁-C₄ alkoxy and C₁-C₄alkoxy-carbonyl-C₁-C₄ alkoxy; Ar² is phenyl, pyridyl or thienyl,optionally substituted by one to two halo or C₁-C₄ alkoxy; R¹ ishydrogen, hydroxy or C₁-C₄ alkyl; and R² and R³ are independentlyselected from hydrogen, C₁-C₇ alkyl optionally substituted by one ormore hydroxy or halo, C₃-C₆ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl,C₁-C₄ alkoxy phenyl and halo substituted phenyl C₁-C₇ alkyl, when Ar² isphenyl, —Ar²—C(═O)—N(R²)— is a phthalimide group and R³ is C₁-C₇ alkyl,or R² and R³, together with the nitrogen atom to which they areattached, form a pyrrolidine or morpholine ring.
 3. A compound accordingto claim 2 , wherein A is hydrogen, fluorine, chlorine, hydroxy or OYwherein Y is methoxymethyl or tetrahydropyranyl; or if the broken lineis a double bond, then A is absent; Ar¹ is phenyl optionally substitutedby chlorine, hydroxy, methoxy or carboxymethoxy; Ar² is phenyl, pyridylor thienyl, optionally substituted by chlorine, fluorine or methoxy; R¹is C₁-C₄ alkyl; R² is C₁-C₇ alkyl optionally substituted by hydroxy orfluorine, C₂-C₆ alkenyl, halo substituted phenylmethyl or phenyl; and R³is hydrogen or methyl; or R² and R³, together with the nitrogen atom towhich they are attached, form a pyrrolidine or morpholine ring.
 4. Acompound according to claim 3 , wherein A is hydroxy, fluorine orchlorine; or if the broken line is a double bond, then A is absent; Ar¹is phenyl optionally substituted by carboxymethoxy; Ar² is phenyloptionally substituted by methoxy or pyridyl; R¹ is C₁-C₄ alkyl; R² isC₁-C₇ alkyl optionally substitute by hydroxy; and R³ is hydrogen.
 5. Acompound according to claim 4 selected from4-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1(S)-phenylethyl]-N-methylamino}-N′-propylbenzamide,4-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-2-methoxy-N′-propylbenzamide;6-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-propylnicotinamide;4-{N-[1-(S)-(3-carboxymethoxyphenyl)-2-(3-(S)-hydroxypyrrolidin-1-yl)-ethyl]-N-methylamino}-N′-propylbenzamide,4-{N-[2-(3-(S)-fluoropyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-propylbenzamide;4-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-(2-(S)-hydroxypropyl)benzamide;5-(N-(2-(3-(S)-fluoropyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-propylpicolinamide;4-{N-methylamino-N-[2-(3-pyrrolin-1-yl)-1-(S)-phenylethyl]}-N′-propylbenzamide;and4-{N-[2-(3-(S)-chloropyrrolidin-1yl)-1-(S)-phenylethyl]-N-methylamino}-N′-(2-(S)-hydroxypropyl)benzamide.6. A compound according to claim 3 selected from4-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-isopropylbenzamide;3-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-propylbenzamide;2-chloro-4-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-propylbenzamide;4-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-3-methoxy-N′-propylbenzamide;3-chloro-4-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-propylbenzamide;4-{N-[1-(S)-(3-hydroxyphenyl)-2-(3-(S)-hydroxypyrrolidin-1-yl)-ethyl]-N-methylamino}-N′-propylbenzamide;4-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-(3-methoxyphenyl)-ethyl]-N-methylamino}-N′-propylbenzamide;4-{N-[1-(S)-phenyl-2-(pyrrolidin-1-yl)ethyl]-N-methylamino}-N′-propylbenzamide,4-{N-[1-(S)-(3-chlorophenyl)-2-(3-(S)-hydroxypyrrolidin-1-yl)-ethyl]-N-methylamino}-N′-propylbenzamide;4-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(R)-phenylethyl]-N-methylamino}-N′-propylbenzamide;4-{N-[2-(3-S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-pyrrolidinebenzamide;4-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-morpholinebenzamide;4-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-(2-(R)-hydroxypropyl)benzamide;4-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-isobutylbenzamide;4-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-allylbenzamide;4-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-(3,3,3,-trifluoropropyl)benzamide;3-fluoro-4-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-propylbenzamide;4-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-(2,2,3,3,3,-pentafluoropropyl)benzamide;4-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-tert-amylbenzamide;5-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-propylpicolinamide;4-{N-[2-(3-(S)-fluoropyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-(2-(S)-hydroxypropyl)benzamide;2-chloro-4-{N-[2-(3-(S)-fluoropyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-propylbenzamide;and4-{N-[2-(3-(S)-chloropyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-propylbenzamide.7. A compound according to claim 2 selected from4-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-methylbenzamide;4-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N-ethylbenzamide;4-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-butylbenzamide;4-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-pentylbenzamide;4-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N-phenylbenzamide;4-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-(2-chlorobenzyl)benzamide;4-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′,N′-dimethylbenzamide;4-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-methyl-N′-propylbenzamide;5-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N-propyl-2-thiophenecarboxamide;4-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-amino}-N′-propylbenzamide;4-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-propylphthalimide;4-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-ethoxybenzamide;4-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-(3-hydroxypropyl)benzamide,4-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-cyclopropylbenzamide;4-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-(S)-sec-butylbenzamide;4-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-(R)-sec-butylbenzamide,4-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-propargylbenzamide;4-{N-[1-(R)-(3-carboxymethoxyphenyl)-2-(3-(S)-hydroxypyrrolidin-1-yl)-ethyl]-N-methylamino}-N′-propylbenzamide;4-{N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-tert-butylbenzamide;4-{N-hydroxy-N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1(S)-phenylethyl]amino}-N′-propylbenzamide;4-{N-[2-(3-(S)-fluoropyrrolidin-1-yl)-1-(S)-phenylethyl]-N-hydroxyamino}-N′-propylbenzamide;4-{N-[2-(3-(R)-fluoropyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-propylbenzamide;4-{N-[2-(3-(S)-fluoropyrrolidin-1-yl)-1-(R)-phenylethyl]-N-methylamino}-N′-propylbenzamide;4-{N-[2-(3-(S)-chloropyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-(2-(R)-hydroxypropyl)benzamide;and4-{N-[2-(3-oxopyrrolidin-1-yl)-1-(S)-phenylethyl]-N-methylamino}-N′-propylbenzamide.8. A pharmaceutical composition for the prevention or treatment of amedical condition for which agonist activity toward opioid kappareceptor is needed, in a mammalian subject, which comprises atherapeutically effective amount of a compound according to claim 1 ,and a pharmaceutically inert carrier.
 9. A pharmaceutical compositionaccording to claim 8 , which is useful as an analgesic, anesthetic,anti-inflammatory or neuroprotective agent, or useful in the treatmentof arthritis, stroke or functional bowel disease.
 10. A method for thetreatment of a medical condition for which agonist activity towardopioid kappa receptor is needed, in a mammalian subject, when comprisesadministering to said subject a therapeutically effective amount of acompound according to claim 1 .
 11. A compound of the following formula.

wherein Ar^(2a) is phenyl, pyridyl or thienyl; X is hydrogen, halo orC₁-C₇ alkoxy; R¹ is hydrogen, optionally protected hydroxy or C₁-C₄alkyl; and R² and R³ are independently hydrogen or C₁-C₇ alkyloptionally substituted by hydroxy or halo.
 12. A compound according toclaim 11 selected from 4-methylamino-N′ -propylbenzamide; 5-N-methylamino-N′-propylpicolinamide; 2-chloro-4-methylamino-N′-propylbenzamide;4-methylamino-N′-(2-(S)-hydroxypropyl)benzamide;4-methylamino-N′-(2-(R)-hydroxypropyl)benzamide,4-methylamino-N′-(2,2,3,3,3-pentafluoropropyl)benzamide; and4-methylamino-N′ -tert-amylbenzamide.
 13. A compound selected from2-(3-(S)-fluoropyrrolidin-1-yl)-1-(S)-phenylethanol; 2-(3-(S)-fluoropyrrolidin-1-yl)-2-(R)-phenylethanol;2-(R)-phenyl-2-(3-pyrroline-1yl)ethanol,2-(3-(R)-fluoropyrrolidin-1-yl)-1-(S)phenylethanol;2-(3-(R)-fluoropyrrolidin-1-yl)-2-(S)-phenylethanol;2-(3-(S)-fluoropyrrolidin-1-yl)-1-(R)-phenylethanol,2-(3-(S)-fluoropyrrolidin-1-yl)-2-(S)-phenylethanol2-(3-(S)-chloropyrrolidin-1-yl)-1-(S)-phenylethanol; and2-(3-(S)-chloropyrrolidin-1-yl)-2-(R)-phenylethanol.
 14. A process forproducing a compound of formula (I), which comprises reacting an amidecompound of the formula (VId):

with an ethanol compound selected from compounds (Va), (Vb) and (Vc),and a mixture of compounds (Va) and (Vb):

in the absence or presence of a base in a reaction inert solvent.